




REPORT
2007



Biotechnology in Bavaria 2007

Imprint

Editorial staff: Dr. Georg Kääb, Dr. Stephanie Wehnelt

Data collection: Dr. Petra Burgstaller, Sabine Jordan

Company Profiles: Ivonne Wagner, Johanna Büchel

Layout-Design: aimcom, Munich, www.aimcom.de

Photos Co-authors: private

Illustration: inspired by Sarah Illenberger,
manufactured by Georg Kääb

Wool-Photography: Thorsten Naeser, www.geo-foto.de

Contact

Prof. Dr. Horst Domdey, Managing Director
Spokesman of the Bavarian Biotechnology Cluster
Nicola Schumacher, Cluster Manager

Bio^M Biotech Cluster Development GmbH
Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0)89-89 96 79-0
Fax: +49 (0)89-89 96 79-79
E-Mail: info@bio-m.org
Internet: www.bio-m.org

The layout, graphics and other contents of this brochure
of the Bavarian Biotechnology Cluster are protected by
copyright law.

Content

Welcome notes	06-07
■ Emilia Müller – Bavarian Minister of Economic Affairs, Infrastructure, Transport and Technology	06-07
■ Prof. Dr. Horst Domdey – Managing Director, Bavarian Biotechnology Cluster	06-07
<hr/>	
Preface	09
<hr/>	
The Companies in the Bavarian Biotechnology Cluster	11
■ Current status	11
■ Company foundations	11
<hr/>	
Employment	12-13
■ Jobs in the biotechnology companies	12
■ Employees in Bavaria's Life Science industry	13
<hr/>	
Products and Pipeline	14
■ Product Pipeline	14
<hr/>	
M&A Activities, Cooperations and Big Deals	16-19
■ Mergers and Acquisitions	16
■ Big Deals	16
■ Cooperations and alliances	17
■ More about the Finance Climate	18
■ Revenues	19
<hr/>	
Guest Authors & Portraits of the Bio Regions	20-35
■ Dr. Viola Bronsema – BIO Deutschland, Berlin	20-21
■ The BioTech Region Munich-Martinsried	22-23
■ Prof. Dr. Günther Wess (scientific director) – German Research Center for Environmental Health, Munich	24
■ Regensburg – Biotech on the Danube	26-27
■ Dr. Rudolf Staudigl – Member of the Managing Board of Wacker Chemie AG	28-29
■ BioCampus Straubing-Sand	30-31
■ Erich R. Reinhardt – Member of the Managing Board of Siemens AG, CEO Healthcare Sector	32-33
■ The Innovation and Start-up Center IGZ BioMed/ZmK in Würzburg	34-35
<hr/>	
Company profiles	37-113
in alphabetical order	

Welcome notes



Bavaria's technology policy is an important component of our forward looking economic policy. Sustainably increasing technological productivity is one of the top priorities of the Bavarian State Government. This also and especially applies to the field of modern biotechnology. For us, it is a key industry of central importance. In Bavaria, the biotech industry can build on an excellent research landscape of universities, clinics and research institutions. Already today the Greater Munich area is Germany's leading biotechnology and venture-capital location. Our long-term investments in research capacities are proving to be worthwhile.

Our efforts to continue this commitment, which recently led to the outstanding results in the Federal Government's Excellence Initiative, will remain undiminished in future as well. Along with a deliberate strengthening of applied research, the aim of our future programme "Bavaria 2020" is also to achieve clear improvements for start-up businesses in the field of state-of-the-art technologies.

We have set ourselves an ambitious goal: the plan is to reach for expenditure on research and development in Bavaria 3.6 % of the gross domestic product by 2020. Only in this way will Bavaria remain at the forefront of progress.



Since almost two years, the cluster initiative Allianz Bayern Innovativ has been funding 19 defined industry and competence clusters in order to activate the innovation and productivity potential in these selected clusters.

With an initial timeline of five years, 50 million Euros will be spent to support this unprecedented Bavarian cluster initiative. The purpose of all cluster platforms is to function as service providers for firms within their specific sectors.

The immediate goal is to promote contacts between companies, universities, research facilities, chambers of commerce, associations, capital investors, funding institutions, consultants and other major players within each cluster.

Especially biotechnology has to rely on innovation-friendly framework conditions, for example when it comes to tax regulations governing equity capital, and as regards the Genetic Engineering Act or the German Medicines Act.

What is now needed to enable the Bavarian biotechnology region to really get going are committed investors who recognise the great potential of existing companies as well as promising start-up businesses, and contribute their capital along with their knowledge. The limitation imposed on forward carried losses and the absence of attractive tax legislation for VC funds in Germany is the wrong signal to

potential investors. The distortions resulting from the Corporate Tax Reform Act 2008 should be corrected as soon as possible.

The Bavarian State Government will continue its commitment to biotechnology and at the same time work towards improving the framework conditions for technology oriented companies. Our goal will always be the permanent establishment of Bavaria as a leading biotechnology location in Europe.

Emilia Müller
Bavarian Minister of Economic Affairs, Infrastructure,
Transport and Technology

The Bavarian hightech cluster Biotechnology connects the well developed biotech regions Munich-Martinsried and Regensburg with the growing locations in Würzburg, Erlangen, Bayreuth and Straubing.

All of these locations have developed their own core competencies and have thus established different profiles. Location characteristics and their companies' profiles will be found within this brochure. Facts and figures for the year 2007 of the well established commercial biotechnology scene in Bavaria are being provided on the next pages.

Within the Bavarian Biotechnology Cluster four cutting edge areas will be the main focus in the near future:

- technology scouting
- establishing a network of clinical study centers
- establishing a science-business network
- industrial ("white") biotechnology.

Within the area of white biotechnology, a major success has already been achieved by recently securing governmental funding of 5 Mio Euro. This has lead to the establishment of a particular white biotechnology network organisation within the Bavarian Biotechnology Cluster, enabling various specific

projects in collaboration with industrial network partners. The next step is to focus on the three remaining goals, a task which will certainly keep us busy for a while.

The figures for the year 2007 reveal that the Bavarian biotechnology industry has shown an impressive robustness despite some severe set-backs caused by the misfortunes of a couple of companies. And even the decrease of staff numbers in some Bavarian pharma companies could easily be compensated by an increasing demand of skilled employees in the small and medium sized Biotech companies.

This in itself is marvellous news!

In addition, the number of Biotech companies settling impressive "big deals" is still growing and, in 2008, more products will be finally approved, maintaining Bavaria's drug pipeline as number one in Germany. Therefore, although one should always be cautious, I am absolutely confident that the seeds of the past years will soon bear rich fruits in the Bavarian Biotechnology Cluster.

Prof. Dr. Horst Domdey
Managing Director, Bavarian Biotechnology Cluster



Preface

Which year symbolizes best the beginning of a modern biotechnology industry in Bavaria?

Probably you will have to go back to the 70s of the last century and recall the pioneering foundation of the Max Planck Institute of Biochemistry in Martinsried near Munich with its emphasis on molecular biology.

Or perhaps the foundation of the Gene Center Munich at the beginning of the 80s, one of three centres in Germany devoting themselves quite exclusively to genetic research?

It was also around this time that the subject of genetic engineering got included in Bavarian biology textbooks, thus familiarising teachers and pupils for the first time with the basics, possibilities and risks of the use of genetic engineering and biotechnology. Parallel to this, an application-oriented programme of teacher training was already being developed to transport the completely new laboratory techniques required for molecular biology work into education and training. After a while these were even literally transported, for example, with the first biotech lab on wheels, the Biotech-Mobil, which from 1996 onwards visited all Bavarian schools. From very early on, this helped to create a basic understanding of molecular biology among the population at large, and it also helped to promote an objective discussion about the chances and risks involved.

By the end of the 80s, this ambience of progressive research institutions and a Bavarian population that was open to innovations resulted in the first companies being established in Southern Bavaria, a trend which by 1996 had already led to the foundation of around 30 biotechnology companies in the Munich region. Another major boost was certainly caused by Munich-Martinsried winning the federal BioRegio Competition in 1996. But also the Regensburg location profited with lasting effect from participating in the competition. In the following years Munich grew into one of the most important Biotech Clusters in Europe.

An evaluation study by the Kiel Institute for the World Economy (IfW) confirms that the Munich region has undergone an "exemplary development". But even if Bavaria's South is often the centre of attention of national and inter-

national observers, the Regensburg and Würzburg locations have nevertheless – or even because of this – also developed in a consistent and remarkable manner.

In this report we therefore quite deliberately consider development of Bavaria as a biotechnology location as a whole, based on a detailed survey of all companies in the region. We made a distinction between sector-specific parameters and therefore carried out separate surveys for pharmaceutical companies, contract research organisations (CROs) and small and medium-sized enterprises (SMEs) in the biotechnology sector.

The data forming the basis of this report are based on the evaluation of a written survey carried out by Bio^M Biotech Cluster Development GmbH at the beginning of 2008 of approx. 250 Life Science companies throughout Bavaria. Based on the questionnaires returned and intensive follow-up telephone calls it was possible to achieve a response rate of almost 80 %.

Additional information was obtained by further individual inquiries. Possible deviations from previously published figures are the result of additional data obtained in this survey that also refer to the previous year.

The period under review for this report is the year 2007. Sales figures, some of which were only published in March 2008, also relate exclusively to this period. Data used in this report that are not a result of the survey come from other sources that are mentioned separately on the respective pages.

Guest articles from research and industry as well as profiles of the locations Würzburg, Regensburg, Straubing and Munich-Martinsried supplement the overview of the Bavarian Biotechnology Cluster. A detailed description of Bavaria's Life Science companies provides the reader with all necessary information about the scope of business and contact data. We thank all authors and the companies for their contribution.

March 2008



The Companies in the Bavarian Biotechnology Cluster

Current status

The Bavarian Biotechnology sector has successfully consolidated in the past years.

At first glance there are no significant changes in 2007 compared with the previous year. The number of biotech SMEs, most of which continue to work in the field of drug or diagnostics development, add up to **146**, with virtually no change compared with 2006. 104 of these companies are domiciled in the Greater Munich area. Regensburg has the second-largest company cluster in Bavaria, with 26 biotech SMEs. There were eight newly established companies in total (seven in and around Munich, one in Regensburg) and seven liquidations.

The number of newly established companies has risen slightly compared with recent years but still remains at a


low level that can hardly compensate for the usual number of company closures.

Apart from this, a development already observable in recent years is becoming even more apparent: almost all companies established in recent years are providing services on the basis of platform technologies or specific know-how.


There are two new additions to the group of contract research organisations (CROs); on the other hand three of the pharmaceutical companies have withdrawn their business units from Bavaria.

The total number of companies in the Life Science sector of the Bavarian Biotech Cluster therefore adds up to **244**.

BIOTECH/PHARMA COMPANIES IN BAVARIA



BAVARIAN BIOTECH SME IN 2007



Company foundations

Eight newly founded biotech companies commenced business in Bavaria in 2007.

More detailed descriptions of these companies' profiles can be found in the detailed list of Bavarian Life Science companies in the Appendix.

Overall, the two most frequently represented fields of business of the Bavarian biotech SMEs are still "Therapeutics and Diagnostics" as well as "Devices and Reagents", which are far ahead of other specialisations (see chart).

COMPANY	CATEGORY	LOCATION
AntiProt	Devices & Reagents	Martinsried
bioregeneration	Therapeutics & Diagnostics	Garching
Cellasys	Devices & Reagents	Munich
CodonSense Biosystem	Therapeutics & Diagnostics	Germering
Diaferon	Therapeutics & Diagnostics	Munich
KM Bioservice	DNA-, Protein-Analysis	Munich
PolyQuant	DNA-, Protein-Analysis	Regensburg
QuoNova Europe	Therapeutics & Diagnostics	Martinsried

Employment

Jobs in the biotechnology companies


Compared with the previous year the number of employees has risen by 200. After the consolidation measures in the economically turbulent years 2001-2004 in the form of mergers, the utilization of synergies and focussing on core business, the number of SME employees stabilized in Bavaria as a whole.

Some greater difficulties faced by certain companies were more than offset in 2007 due to increased staff requirements elsewhere. As a result, the Bavarian Biotech SMEs currently employ 3470 people (previous year: 3240). 2400 of these employees continue to work at the biotech location Greater-Munich. Interestingly, the Regensburg location has the greatest increase in employment figures: there, the number of employees increased in 2007 to a current 896 (previous year: 685).


All biotech companies combined, i.e., including the subsidiaries of international corporations, the number of employees is almost 8700.

The high-tech biotechnology sector is still urgently seeking mainly highly qualified specialists, for example in the field of clinical development or for work on cell cultures. The demand for laboratory assistants has also risen once more. The rapid expansion of the production centre Penzberg (Roche Diagnostics) means that employees in this field are also very much in demand. In 2007, Bavaria's biotech companies advertised more than 500 vacancies via the job portal operated by Bio^M on the Internet.


NUMBER OF EMPLOYEES IN THE BAVARIAN BIOTECH CLUSTER



NUMBER OF EMPLOYEES IN THE BIOTECH SME IN BAVARIA (2007)



SIZE OF BIOTECH SME BY NUMBER OF EMPLOYEES IN 2007



Employees in Bavaria's Life Science industry

In addition to the 3470 employees in the small and medium-sized biotechnology companies there are almost about 5230 employees working in the branches and subsidiaries of international biotechnology companies; almost 4400 alone are working for Roche in Penzberg (an increase of 260 in 2007).

In addition, there are a good 5400 employees working for national and international pharmaceutical and health care companies. It was mainly the international pharmaceutical corporations that, by cutting the number of staff by around 600, stalled a more significant growth in the overall number of employees working for the Bavarian Life Science industry in 2007. Apart from this, a not inconsiderable percentage of local Life Science jobs are offered by CROs: Approximately another 1200 people are employed in this sector (an increase of 140).

The total number of employees in 2007 in the Life Science industry came to around 15,000. And this figure does not even include laboratory suppliers, other service providers and other professions, such as financial institutions, lawyers or consultants working for the biotech and pharma industries.

Along with these jobs in industry, there are almost 20.000 employees working in the Life Science field at Bavarian research institutes. Thus, the entire sector offers almost/approximately 35.000 jobs in science and industry in Bavaria.

Within the group of biotech SMEs, most of the people are employed in therapeutics and/or diagnostics companies and their corresponding platform-technology providers. 1670 people are employed in this sector, i.e. around 48 % of all employees in Bavarian biotech SMEs.

An overview of company sizes in Bavarian enterprises is shown above.

Products and Pipeline



Product Pipeline

All the media hype about the failure of GPC Biotech's product "Satraplatin" with regard to the indication tested (the treatment of prostate cancer) has not only smashed this company from the front rank of promising biotech SMEs, but has also diverted attention from many other positive developments in Bavarian biotech SMEs.

Bavaria continues to have the only location, Martinsried, that offers Germany's only approved biotech drugs, i.e. two drugs manufactured by the company Medigene. Towards the end of 2007 other Bavarian products had either already been approved in other countries (IDEA/Switzerland) or were already at a far advanced phase in the approval procedure, so that approval can be expected in 2008 (Fresenius/Trion; Medigene).

At present, clinical development work by Bavarian companies is concerned with the fields of indication listed in more detail below.

DRUG PIPELINE (CLINICAL TRIALS) IN BAVARIA



Further good news came not only from the approval institutions but also from the companies themselves: 2007 was a year of "Big Deals" for Bavarian Biotechnology as it is shown in the following section.



M&A Activities, Cooperations and Big Deals

Mergers and Acquisitions

The pharmaceutical and big biotech corporations have to continue – and want to continue – to augment and fill their product pipelines with external developments by means of acquisitions. The pharmaceutical industry is (also on an international scale) increasingly prepared to spend larger sums not only to acquire licences for individual products but also to take over entire companies.

This trend is also attractive to the VC sector: IPOs are still especially rare in Europe, and the sale of a company can therefore represent a more attractive possibility for an

alternative immediate exit to VC investors in the present environment than developing a company further in the long term by means of financing rounds. Some of the Bavarian biotechnology companies have reached a level of maturity that makes them interesting for the pharmaceutical and big biotech corporations.

Or, even as still relatively young companies, they play an important role in new technological fields themselves. In connection with the global trend in the M&A sector, this means that further interesting news can be expected in the near future.

Bavarian Company	Aquired Company, Acquisition/Merging-Partner	Announcement	Type of Deal
OncoMab GmbH	Patrys Pty Limited	Jan 07	Patrys acquires OncoMab GmbH
Therapeutic Human Polyclonals	Roche	Apr 07	Roche takes over THP
Ingenium Pharmaceuticals AG	ProBioDrug AG	Jun 07	ProBioDrug takes over Ingenium
Alnylam Pharmaceuticals	Roche	Jul 07	Roche agrees with Alnylam on a cooperation to develop RNA-Interference-Therapeutics; German branch is Roche Kulmbach GmbH
Epidauros Biotechnologie AG	Clinical Data Inc.	Aug 07	Clinical Data acquires Epidauros

Big Deals

The level of maturity of the Bavarian Biotech SMEs becomes particularly apparent when one considers the interest shown by the big international pharmaceutical corporations in concluding deals involving huge sums.

The financing volumes (effective over a period of several years) have become extremely large and meanwhile exceed by far the current possibilities of realising finance via the capital markets or VC companies.

Particularly striking was the agreement in 2007 between Morphosys (Martinsried) and Novartis with a volume amounting to at least \$ 600 million over the next 10 years.

The licence agreement between Munich based IDEA and Alpharma for around \$ 250 million is of a similar order of magnitude.

And, of all things, in the beginning of 2008 Scil Technology, Martinsried, was able to announce a big deal: Pharmaceutical giant Pfizer is prepared to pay them around \$ 250 million if future, now joint, product developments go according to plan.

Cooperations and alliances

At all stages of the research-intensive biotechnology sector, cooperations between companies and between companies and research institutes are indispensable for the establishment of a sustainable value added chain.

Thanks to the excellent research facilities and university institutes, the locations in the Bavarian Biotechnology Cluster therefore find themselves in a privileged position that is also recognised internationally.

A selection from the large number of cooperations among companies can be found in the following list:

COOPERATIONS AND DEALS 2007

Cooperation Partner	Announcement of Cooperation	Type of Cooperation
Cambridge Antibody Technology	Jan 07	License agreement to develop and commercialize the antibody SC-1 (first identified by Oncomab GMBH/Patrys Ltd. and in-licensed by The Debiopharm Group in 2003)
Johnson & Johnson	Jan 07	Kinaxo enters agreement to carry out selectivity analyses for selected J&J small molecule compounds
Bayer Schering Pharma AG	Jan 07	Bayer Schering Pharma AG selects CRELUX as structural biology service provider to deliver several complex structures on three different targets.
Palau Pharma (Barcelona, Spain)	Jan 07	Affectis in-licenses a clinical stage compound for the treatment of psychiatric disorders from Palau Pharma.
Molecular Connections (Bangalore, India)	Jan 07	Genomatix and Molecular Connections form strategic partnership.
Tracon Pharmaceuticals	Mar 07	Agreement granting TRACON exclusive worldwide rights to develop and commercialize Micromet's D93 antibody with a novel mode of action for the treatment of cancer.
Astellas	Mar 07	MorphoSys entered into a license agreement for the use of its HuCAL technology. It is the third therapeutic agreement of MorphoSys in Japan.
Nycomed	May 07	Micromet and Nycomed enter into exclusive worldwide collaboration to develop and commercialize anti-GM-CSF antibodies for the treatment of inflammatory and autoimmune diseases.
Boehringer Ingelheim Pharmaceuticals, Inc.	Jun 07	Proteros enters into a research collaboration with Boehringer Ingelheim in the field of protein crystallography.
Genfit (Lille, France)	Jul 07	Bicoll signs a partnership with Genfit and announces the partial financing of a 3.2 million euro joint EuroTrans-Bio project by ERA-Net/ European Commission.
Alpharma	Sep 07	IDEA signs major licensing agreement with Alpharma for Diractin®, a treatment of deep pain.
Boehringer Ingelheim Pharmaceuticals, Inc.	Oct 07	Biomax licenses the BioRS™ Integration and Retrieval System to Boehringer Ingelheim.
Dyax	Nov 07	MorphoSys and Dyax sign a licensing agreement covering a patent portfolio relating to antibodies and other proteins.
Novartis	Dec 07	MorphoSys and Novartis forge strategic alliance to establish an innovative therapeutic antibody pipeline.
Operon Biotechnologies	Dec 07	Operon and MWG (all part of the Eurofins Genomics network) agree to work together in order to create a new worldwide leader in the competitive custom oligonucleotide market.

More about the Finance Climate


VC investments in biotechnology companies

In 2007, around \$ 5.4 billion in venture capital was invested in young biotech companies in the USA, but only around \$ 1.5 billion in Europe. Of this sum, around € 440 million was invested in the German Life Science sector (i.e. around \$ 660 million, just about half of the VC finance volume invested in Europe as a whole). [Source: VC-facts; transkript] If one subjects these German finance volumes to closer scrutiny, it becomes apparent that only a fifth of them were first financing rounds, and that most of them, however, were third or even later rounds – proof of the difficulties that particularly young companies are still experiencing.

Investments in Bavaria

Following the ongoing trend over the last few years, the volume of external funding continues to decrease. In 2007, there were no IPOs of Bavarian biotech firms and the VC-rounds and follow-on financing of listed companies merely added up to 209 Mio. € (2006: 240 Mio. € plus an IPO-Volume of about 150 Mio. €). There is a fundamental change taking place with Bavarian biotech SMEs gaining massive financing values by "Big Deals" (a more than tenfold increase since 2006!).

EXTERNAL FINANCING



Company	Date	Raised Funds [Mio. €]	Type
GPC Biotech AG	Jan 07	33,6	Follow-on
MediGene AG	Feb 07	12,6	Follow-on
Schmack Biogas AG	Feb 07	27,20	Follow-on
4SC AG	Mai 07	3,40	Follow-on
MorphoSys AG	Mai 07	32,60	Follow-on
Kinaxo Biotechnologies GmbH	Mai 07	k.A.	VC
SpheroTec GmbH	Mai 07	0,68	VC (HTGF)*
Micromet Inc.	Jun 07	25,00	Follow-on
Biocam GmbH	Jul 07	2,00	VC + Silent Partnership
Diaferon GmbH	Jul 07	0,68	VC (HTGF)
Proteros biostructures GmbH	Aug 07	1,0	VC
4SC AG	Sep 07	16,78	Follow-on
MediGene AG	Sep 07	15,60	Follow-on
Sirion GmbH	Sep 07	k.A.	VC (HTGF)*
Antisense Pharma GmbH	Nov 07	27,00	VC
Sloning BioTechnology	Nov 07	4,70	VC

* HTGF = HighTech Gründer Fond


Revenues

To improve comparability, the following details focus on the published business data of listed Bavarian biotechnology companies. Their stated revenues for 2007 add up to 286 Mio. €.

In relation to the number of employees in those listed companies, the per-capita sales volume is 238.000 €.

Considering that in 2006, the revenues of the listed biotech SMEs in Munich alone comprised of about 150 Mio. €, which represents approx. 60% of the revenues achieved by all biotech companies in the area, one can assume that the revenues of all the Bavarian biotech SMEs in 2007 will have reached about 400 Mio. €.

REVENUES TOTAL IN MIO. €, LISTED COMPANIES



Summary

This shows that, all in all, Bavarian biotech companies are increasingly successful, thanks to their product developments, in securing partnerships or finance involving huge sums, thus making themselves more and more independent of volatile financial markets and capital-market instruments.

The Bavarian biotech industry can look back on a history that has developed over some decades, a history with more ups than downs.

Within a period of about 15 years, an industry employing around 25,000 people established itself, creating newly around 20,000 jobs. By gaining federal fundings of about 150 Mio. € the further privately investments of about 2.5 Billion € could be attracted.

The companies have reached a level of maturity that allows them increasingly to enter into cooperations involving huge sums: after a build-up phase that lasted many years, for many companies the harvest has now begun.

This holds out hope for the future!

Endurance and stamina:

Biotech entrepreneurs are creating a very special pool of talent and innovation

DR. VIOLA BRONSEMA
BIO Deutschland, Berlin



Small and medium-sized enterprises (SMEs) who invest in innovation also create high-quality jobs. An analysis conducted by the KfW (Kreditanstalt für Wiederaufbau) shows that investments in research and development are the mainspring for the creation of new jobs: young, innovative and research-oriented SMEs especially are the central force behind an active structural change that will secure a national economy's long-term competitiveness.

While employment figures, for example in the German pharmaceutical industry, are falling (minus 1% in 2007), the number of jobs created in the field of biotechnology is constantly increasing. In 2006, SMEs showed a growth of nine percent ¹. After increases in previous years, approximately three quarters (72%) of small and medium-sized biotechnology companies are once again planning to employ further staff in 2008 ². According to details provided by the pharmaceutical industry itself, it will slightly reduce the number of jobs, probably by -1.5% in 2008 ³.

A meta-analysis by the Institute for the Study of Labour (Institut für die Zukunft der Arbeit – IZA) revealed that innovative SMEs provide not only jobs, but also innovations that are superior, not in quantity, but in quality, to those of big industry. According to the findings of a survey conducted by the BIO Deutschland trade association, however, investments by this sector in research and development (R & D) will grow less strongly than in the previous year: For 2007 at least 56% of the companies planned to increase their invest-

ments in this field; in the current year of 2008 their number will amount to only 47% ⁴.

Even so, it is important not to ease up: the preconditions for innovation have never been better than they are today. Worldwide, around four million people work in research and development ⁵. Of these, more than 80 percent live in the "highly-developed" countries (40% USA, 26% EU, 15% Japan). The number of research workers in science-driven post-industrial societies lies between eight and nine per thousand active employees. In Germany, it is only around seven. This clearly shows the course that Germany, a country poor in resources, needs to take.

Innovative entrepreneurs in the biotechnology sector want to be part of this. They seem quite undaunted by the fact that they will need stamina and endurance to achieve this aim: the overwhelming majority of the biotech companies that took part in the survey said that their current business situation was "good" (61%). A third of the companies regarded their own situation as "satisfactory". A majority of the companies also saw their medium-term future in a positive light: 55% expect their own situation to develop well.

Even so, the assessment of the business climate, that is, of the political, economic and social conditions, is not as favourable as it was last year: most of the German companies regard it as "satisfactory" (56%), 16% as "bad" and only 28% as "good". This means that the number of dissatisfied companies doubled in comparison to last year. In the current survey, only 43% believe that the general conditions will improve, as compared with 54% last year. On the other hand, the percentage of those who expect that the business climate will not change in future increased by 10 percentage points to 50%.

The trade association of the biotechnology industry in Germany, BIO Deutschland, interprets this as a clear indication of the pressing need for further significant improvements in the framework conditions for SMEs in Germany. In its first report, published at the end of February, the Commission of Experts for Research and Innovation (Expertenkommission Forschung und Innovation) confirms this view. Federal Government experts make it clear that the

German tax system imposes considerable restrictions on the way in which finance is provided, especially for young, innovative companies ⁶. At the same time, so the report, there is too little focus on state-of-the-art technology. Germany's traditional strengths lie in the field of high-quality technology – mainly in the automotive industry, classical chemistry and mechanical engineering. The growth potentials are, however, far greater in the research-and-development-intensive high-tech sectors and knowledge-intensive services.

One of the primary objectives of the BIO Deutschland trade association is therefore to contribute actively to improving the framework conditions for innovative SMEs. The association works at different levels and with various committees to achieve this aim. The key instruments are statements and opinions currently being elaborated in eight working groups. One of the next aims the association is

One of the primary objectives of the BIO Deutschland trade association is therefore to contribute actively to improving the framework conditions for innovative SMEs.

seeking to accomplish will be the introduction of tax incentives for R & D, especially in innovative SMEs, already a common practice in other European countries. Additional measures are also planned for improving the legal framework conditions for the protection of intellectual property with respect to the needs of SMEs: some of the objectives

are to cut down bureaucracy relating to the law on employees' inventions, to reduce the fees for industrial property rights for small and medium-sized enterprises and to harmonize industrial-property legislation relating to biotechnological inventions in the European Union. Other objectives of BIO Deutschland are to support technology transfer and to make the professional image of the innovative entrepreneur better-known.

Important is that innovation no longer arises mainly within the fixed limits of a company or institution. A lively productive process calls for the integration of various innovation channels and external players. Today, the transformation, or 'translation', of inventions and discoveries into marketable offers needs to be given far more consideration far more quickly. This is the only way to ensure that new technologies are got ready for marketing fast and efficiently, and that the markets in question are capable of assessment and develop-

ment. SMEs, research-intensive and with proven experience in the field of cooperation, are playing an ever more important role in this context: They are creative, productive and agile. As independent innovation and talent pools, they are the part of the value added chain that links public research with Germany's big-industry sector.

- ¹ biotechnologie.de 2007
- ² BIO Deutschland and BIOCOM 2008
- ³ Wirtschaftswoche No. 52, 21.12.2007
- ⁴ BIO Deutschland and BIOCOM 2008
- ⁵ OECD Science, Technology and Industry Outlook OECD, Paris, 2002
- ⁶ Commission of Experts for Research and Innovation of the Federal Government, 27.02.2008

The BioTech Region Munich-Martinsried

Prompted by its victory in the 1996 Bio-Regio Competition organised by the Federal Ministry of Education and Research, the Munich BioTech Region has developed into one of the leading clusters within Europe. Today, Munich leads Germany as regards the number of companies, employees and, most of all, the number of drugs in clinical development. Especially in the field of therapeutics and diagnostics, the region has become Germany's most important location. The central network coordinator for this cluster is Bio^M Biotech Cluster Development GmbH.

The Munich BioTech Region: an international reputation, successful companies, a strong medical drugs pipeline

The well-functioning network of science, industry and politics provides the biotechnology companies with a decisive locational advantage that has enabled the Munich BioTech Region to develop into Germany's leading biotechnology cluster. With more than 190 companies and more than 13,000 employees in the Life Science sector, and with two universities (which just recently joined the ranks of Germany's elite universities), two universities of applied sciences, the Max Plank Institutes of Biochemistry, Neurobiology and Psychiatry, the Helmholtz Research Center for Environmental Health, as well as further renowned institutes and organizations, the region offers an outstanding environ-

ment for innovations. The small and medium-sized biotechnology companies focus on so-called "red biotechnology", especially on research and development in the field of diagnostics and therapeutics. Small and medium sized enterprises (SMEs) from Munich are at the very forefront of drug development throughout Germany – two products from MediGene have received marketing approval, further products have already been approved in other countries and are expected to receive approval in Germany in 2008. Eight companies are listed on the stock exchange, among them MorphoSys, one of the region's largest companies and one of those with the highest turnover.



Bio^M – the cluster's central coordinating body

Bio^M Biotech Cluster Development GmbH coordinates the activities of the Munich Biotech Region and is the central point of contact for biotech companies and start-ups.

As a service and consulting company, its aim is to promote the development of the Munich BioTech Region as one of the leading biotechnology centres in Europe. In September 2006, Bio^M Biotech Cluster Development GmbH became the successor to Bio^M AG Munich Biotech Development and took over the business segment of location promotion for Greater Munich.

As part of the Bavarian Cluster Initiative, Bio^M is also in charge of managing biotechnology throughout Bavaria. One of its current aims in this capacity is to develop a Bavarian network that will strengthen cooperation between research institutes and industry, make the location more interesting for clinical studies and promote "white" (industrial) biotechnology.

Bio^M Biotech Cluster Development GmbH represents the Munich BioTech Region and the Bavarian cluster at conferences and trade fairs in Germany and abroad, provides support

for the companies through marketing and public relations work and maintains an Internet information portal at www.bio-m.org. Along with a comprehensive database and up-to-date information, the portal also provides an exchange for jobs, office space and premises, as well as an events calendar.

CONTACT

Bio^M Biotech Cluster Development GmbH
Dr. Stephanie Wehnelt
Am Klopferspitz 19
82152 Martinsried
Phone: +49 (0)89-89 96 79 29
Internet: www.bio-m.org



Helmholtz Zentrum München

More than just a change of name

PROF. DR. GÜNTHER WESS

(scientific director)

German Research Center for
Environmental Health, Munich



As of 2007/2008, the former "GSF - National Research Center for Environment and Health" has changed its name to "Helmholtz Zentrum München – Deutsches Forschungszentrum für Gesundheit und Umwelt" – "German Research Center for Environmental Health".

The new name, on the one hand, emphasises the Center's affiliation with the Helmholtz Association, Germany's largest research organisation. On the other, the new name also reflects its strategic advancement to the field of "Environmental Health". This combination of health and environmental research and the focus on chronic and complex diseases is unique.

Thanks to the excellence of its research, the Helmholtz Zentrum München is helping to solve the great pressing questions of the 21st century in the field of human health and the environment in relation to global change.

The new name aims to make this clear both internally and externally. At the same time, it is meant to show just how firmly established the Center is in Munich's science and knowledge region. An integral part of European and international cooperations, it carries out numerous research projects at the highest scientific level together with the Munich partner universities, the Ludwig-Maximilians-Universität and the Technische Universität München, as well as with other research institutes in the region. The Center cooperates closely in the training of the next generation of scientists, thus investing in the future.

Environmental Health – The Research Center's new strategic orientation

With its strategic orientation, the Helmholtz Zentrum München investigates complex diseases at the interface of health and the environment. A comprehensive understanding of disease mechanisms is expected to contribute essential innovative diagnostic and therapeutic methods to a future of a society worth living in. In the years to come future medicine will concentrate increasingly on preventive measures as well as on causal therapy measures. Here, the centre places a specific emphasis on chronic diseases such as lung diseases, diabetes, neurodegenerative diseases, viral diseases and tumors. In future there will also be new emphases placed in the fields of systems biology, chemical and structural biology, scientific information processing as well as modern biophysical imaging. The Helmholtz Zentrum München combines excellent basic research with international experimental platforms, so-called clinical cooperation groups, and centres for translational medicine. The aim is a close link between research and clinical application. As a national competence center the Helmholtz Zentrum München will also continue to fulfil important tasks in the field of radiation research and radiation protection. Our aim is to prevent diseases caused by environmental factors by making knowledge-based recommendations to politicians, society and the individual citizen.

Cooperations with industry: technology transfer at the research-application interface

Thanks to the know-how derived from its research activities, the Helmholtz Zentrum München has a broad range of new, innovative and competitive technologies at its disposal, especially in the fields of biotechnology, pharmaceuticals and medical technology but also as regards the methods of environmental analysis. Also, a large number of networks and partnerships in the field of research and industry provide the basis for a rapid translation of the Center's research results into practical applications. The professional exploitation of scientific results, i.e. the protection of specific know-how and the identification of new technologies and their protection by means of patent law, etc., are carried out within the technology-transfer framework by means of cooperation and licensing agreements (Legal and Technology Transfer Department at the Center) as well as via an external marketing partner.



Regensburg – Biotech on the Danube

BioPark Regensburg GmbH is the administrative centre and management unit of the BioRegio Regensburg biotechnology cluster in Eastern Bavaria. There are 40 companies with more than 2400 employees currently working in the field of life sciences in the BioRegio Regensburg cluster. These include 26 companies with 900 employees working in the core area of biotechnology. After Munich, this makes Regensburg the second largest biotechnology region in Bavaria.

Research at the university location Regensburg

Regensburg University, the University of Applied Sciences and the Medical Centre currently employ a total of 7,000 people; altogether there are 24,000 students. Along with metabolic physiology and immunology (SFB – Collaborative Research Centres, DFG – German Research Foundation), research is concentrated especially on the neurosciences (BMBF – Federal Ministry of Education and Research). It has been possible to engage the José Carreras Foundation to support haematological therapy research using adult stem cells. The “Human Tissue & Cell Research” Foundation was founded on site with the aim of developing new therapeutic

methods for patients with liver diseases. The development of vaccines to combat the HIV virus (AIDS) receives substantial funding from the Bill & Melinda Gates Foundation. In the field of infection biology, the Medical Centre is a partner of the World Health Organisation (WHO). Since 2007, the Fraunhofer Project Group for the Diagnosis and Treatment of Tumors, Metabolic Diseases and Diseases associated with Aging has been located in the BioPark as an extra-mural research unit.

The BioPark at the business location Regensburg

The development of innovative technologies in and around the city is booming: During the last few years the region has become one of Bavaria's fastest growing economic regions. Through the foundation of BioPark Regensburg GmbH in 1998, the City created yet another catalyst for this aspiring future-oriented sector. With support from the State of Bavaria, the BioPark was built directly on the university campus at a cost of € 36 million in two phases, in 2001 and 2006. The multifunctional buildings offer 12,000 square metres of state of the art laboratory, office and storage space for companies and institutes working in the fields of biotechnology, medical technology and associated services. At present, the BioPark accommodates 22 leaseholders and a 500-strong workforce.



Successes “Made in Regensburg”

In 2006, BioRegio Regensburg celebrated its 10th anniversary. During this time more than € 100 million were invested in the development of Life Sciences. The return of investment is impressive; 27 companies have been founded since 1996 alone and the number of employees in the region has increased more than fivefold to 2400. BioPark companies regularly receive awards for their innovative business ideas. Antisense Pharma

GmbH was awarded the Bavarian Innovation Award (Bayerischer Innovationspreis) and the German Founders' Award (Deutscher Gründerpreis) for a new type of treatment for brain tumors. Geneart AG received the Bavarian Founders' Award (Bayerischer Gründerpreis) and was chosen by Financial Times Deutschland as one of the 10 most innovative high-tech companies in Germany and was the first BioPark company to go public at the Frankfurt Stock Exchange. The company Profos AG was awarded first place in the Northern Bavaria BusinessPlan Competition for its developments in the field of bacteriophage technology. AMGEN Research GmbH, founded in BioPark Regensburg in the year 2000, is the only research centre of one of the biggest American biotech companies in Europe. Every year 10 million compounds are analysed in Regensburg in order to identify new key structures for the development of innovative drugs. In May 2007, Bayer Innovation, a one-hundred-percent subsidiary of Bayer AG Leverkusen, started its pilot production plant for silicone skin replacement products. It is based on a technology developed by the Regensburg company Si4Health GmbH. In 2008, BioPark Regensburg received an award as Outstanding Site of the nationwide initiative "Germany – Land of Ideas" (Deutschland – Land der Ideen).

Interdisciplinary Projects

Together with the State of Bavaria, the City of Regensburg and the consultancy company Capgemini Deutschland GmbH, BioPark Regensburg GmbH has identified regional

interdisciplinary fields in the region since 2006. In the applied fields of molecular diagnostics and biochips, as well as biofunctional surfaces, regional companies from the glass, mechanical engineering, electrical engineering, textile and food industries were brought together through workshops with companies from BioRegio Regensburg.

This new network, which embraces all these technologies, made it possible to increase the cluster's dynamics by a further 11 regional companies. Another approach is the sensor-technology cluster platform of the Allianz Bayern Innovativ initiative, which is operated from Regensburg. The cluster management of the strategic sensor-technology partnership is domiciled in the BioPark, along with the successful company PreSens Precision Sensing GmbH (chemo- and biosensors).



Outlook

Innovation needs space, which is why BioPark III is currently being planned. In 2009, construction work will start on a further 6,000 square metres. For 2010/2011 the City of Regensburg is drawing up a plan for the development of the Technology Park Regensburg GmbH in the immediate vicinity of the University, the Medical Centre and the BioPark.

CONTACT

BioPark Regensburg GmbH
Dr. Thomas Diefenthal
Josef-Engert-Str. 9
D 93053 Regensburg
Phone: +49 (0)941 920 460
Fax: +49 (0)941 920 4624
Internet: www.bioregio-regensburg.de

“White Biotechnology”:

The major driving force for innovation in the chemical industry

DR. RUDOLF STAUDIGL

Member of the Managing board
of Wacker Chemie AG



White biotechnology describes the use of methods of modern biotechnology for industrial processes, mainly in the chemical industry. Possible products are chemicals produced using cells, microorganisms or enzymes, as well as the microorganisms or enzymes themselves.

In recent years, this form of industrial biotechnology has developed into one of the major driving forces for innovation in the chemical industry. According to a study by McKinsey from 2006, sales of white biotechnology products in 2005 amounted to approximately \$ 75 billion worldwide. Approximately 4-6% of the sales of the German chemical industry are generated by means of biotechnological products (DIB 2006). In the coming years, the growth rates for sales of biotechnological products will be definitely higher than those for products manufactured by traditional chemical means. The McKinsey study expects a growth rate of approximately 11% per year. Wacker Chemie AG has been quick to identify this trend. For more than 15 years, the Consortium for Electrochemical Industry, Wacker Chemie's central research division, has been developing biotechnological processes for new products.

Most of all the chemicals manufactured industrially today and practically all bulk basic chemicals are built up from simple chemical components produced from mineral oil during the refining process. Biotechnological methods are

mostly used when complex substances are involved, for example, chiral molecules or molecules with many functional chemical applications. The more complex the chemistry, the greater the chance that biotechnology will be used.

A few examples of the successes achieved by “today's” white biotechnology:

- More than two thirds of all commercial chiral synthesis is carried out using biotechnological means (Blaser & Schmidt, 2003).
- Of nine natural amino acids produced on a large industrial scale, only two (Glycine, D,L-Methionine) are manufactured by chemical means.
- Vitamin B2, only recently still synthesised from ribose using a four-stage chemical process is now almost exclusively produced by biotechnological means.
- To an increasing extent, biomaterials, in the form of performance chemicals with new properties, are conquering their market, for example, Bacteriorhodopsin, proteins from spider silk, or Wacker Chemie's cyclodextrins.
- The market launch of polylactide means that the entry into the plastics segment has been achieved on a larger scale.

Today, Wacker Chemie is successfully using biotechnological methods in the Fine Chemicals division to produce fine chemicals for the pharmaceutical, cosmetics and food industry. A production volume of more than 5000 tons p.a. makes it the world market leader in the production of cyclodextrins. A superior fermentative production method for the amino acid L-Cystein has enabled Wacker Chemie to hold its own even against strong Chinese competitors.

In recent years, it has become increasingly apparent that there are limits to the use of petrochemical bulk chemicals for synthesising materials as well as to their energetic use. Mineral oil is not available in unlimited amounts, the continuing growth in demand has led to a drastic increase in prices and the production of oil is limited to a few, in part politically unstable, producing regions and the unrestrained use of mineral oil has led to an alarming increase in global

CO₂ output. This is where white biotechnology can make an enormous contribution to the saving of resources and to the protection of the climate. Improved (bio) technology on the one hand and the increased price of oil on the other make the biogenic production of bulk chemicals economically competitive as well. One successful example is bioethanol, which is used not only as a fuel but also as a basic chemical for synthesising materials in the chemical industry. In certain regions (Brazil, USA) bioethanol costs less than comparable petrochemical bulk chemicals. In 2006 world production

and academe has established itself in the past months. Managed by Wacker Chemie and Süd-Chemie and in cooperation with the Ministry of Economic Affairs and Bio^M Cluster Management GmbH a concept has been developed for the promotion of white biotechnology entitled "Industrial processes using biogenic building blocks und performance proteins". As one of the award-winning concepts in the "BiolIndustrie 2021" competition, it received grants from the Federal Ministry of Education and Research and the Bavarian Ministry of Economic Affairs.

White biotechnology is one of the key technologies for innovative and sustainable new processes in the chemical industry.

amounted to more than 40 million tons, there are more than 100 biorefineries for the production of bioethanol in the USA alone and another 70 are currently being planned or built.

This "new" biotechnology, aiming at CO₂ neutral bulk chemicals that are not dependent on mineral oil for chemical production and energy, offers important fields of innovation and growth for the big chemical industry:

- Biotechnological production, in optimised "biorefineries", of important basic chemicals that are still manufactured today by petrochemical means.
- Use of secondary flows from bioethanol / biodiesel plants.
- New chemical products / processes with customer benefit for the "biorefinery" growth area.

In its central research division, Wacker Chemie is working on these subjects with a new strategic research focus on "White Biotechnology".

Bavaria and the Bavarian chemical industry have recognised the importance of white biotechnology. Stimulated by the "BiolIndustrie 2021" programme of the Federal Ministry of Education and Research, an interdisciplinary network consisting of almost 50 partners from the worlds of industry

Important contents of the concept are:

- Promotion of innovative projects for the production of bio-based bulk chemicals in "third-generation" bio-refineries.
- Promotion of small and medium-sized enterprises, focusing on the field of white biotechnology.
- Promotion of academic research and training in this field and development of a centre of excellence for white biotechnology at the TUM.
- Screening of ideas and deliberate encouragement of cooperation between industry and the academic world with the aim of translating technologies into marketable products.

White biotechnology is one of the key technologies for innovative and sustainable new processes in the chemical industry. White biotechnology will make significant contributions to the preservation of resources, the protection of the climate and the improvement of the quality of life by means of intermediate products, methods and high-quality end products. Those wanting to participate need to do research and development work and need to invest in production. With its big chemical companies, its innovative small and medium-sized enterprises, and its know-how infrastructure, Bavaria as a location is set to position itself for the future in the field of white biotechnology as well.

BioCampus Straubing-Sand

Straubing is the region of Renewable Raw Materials. In the immediate vicinity of the scientific and technical institutions of the Straubing Competence Center numerous companies are setting up at the river port and in the BioCubator (Business Incubator for Renewable Raw Materials) with the aim of using biogenic resources commercially.

Straubing in Lower Bavaria is the region for Renewable Raw Materials. This where the State of Bavaria bundles all activities relating to research on, and the development and marketing of renewable raw materials. The claim is an ambitious one: the Straubing-Bogen administrative district wants to become No. 1 in Europe in the fast-growing market of biomass utilisation.

The big advantage of Lower-Bavarian Straubing is that it does not take long at all to put scientific findings from the think tank of the internationally renowned Competence Center into practice.

Under the brand name BioCampus, the City of Straubing, the Straubing-Bogen administrative district and the community of Aiterhofen have specially made land available in the Straubing-Sand business park and river port area that have attracted impressive investments in the field of the energetic use of biomass. In 2005, the first leading industrial company, CompacTec, established itself in the Straubing-Sand river port area, where it operates a modern wood-pellet production plant with a capacity of 140,000 tons p.a.

The big advantage of Lower-Bavarian Straubing is that it does not take long at all to put scientific findings from the think tank of the internationally renowned Competence Center into practice.



CONTACT

BioCampus Straubing-Sand
Diplom-Ökonom (Master of Economics)
Andreas Löffert, Managing Director
Europaring 4
D-94315 Straubing
Phone: +49 (0)9421 785 150
Internet: www.straubing-sand.de

Directly opposite, one year later, Campa Süd invested € 60 million in building Bavaria's largest oil mill. The plant has the capacity to press 600,000 tons p.a. of rapeseed for the production of plant fuels.

Companies from this sector find an optimal mix of soft and hard locational advantages in Straubing. Along with synergies with institutions of the Competence Center what the companies appreciate most are the logistical possibilities for the transport and transhipment of biomass offered by the river port. A good deal of this biomass comes from the Lower-Bavarian Gauböden, Southern Germany's largest plant-cultivation region, and from the nearby Bavarian Forest. There is important innovative potential here not only in the energetic use of biogenic resources but especially also in their use for producing materials. The range of start-up businesses in the Straubing Technology Cluster covers wood processing as well as designing new textiles.

The State of Bavaria and the Straubing-Bogen administrative district are continuing to invest in the infrastructure for this promising sector. The foundation stone for a Business Incubator for Raw Renewable raw Materials was laid right next to the Innovation and Business Start-up Center Straubing-Sand. The so-called BioCubator provides highly attractive laboratory, office and storage space for companies from this sector, and, of course, in a building that is for the most part being constructed with Renewable Raw Materials. Anybody who wants to do business with Renewable Raw Materials will find an ideal network of science, technology, companies, finance instruments and other supporting institutions in Straubing.



Business Incubator for Renewable Raw Materials – ready to move into from October 2008 onwards



Campa Süd – Bavaria's largest oil mill for the production of biogenic fuels

Siemens Healthcare:

Looking at the Future

ERICH R. REINHARDT
Member of the Managing Board of
Siemens AG, CEO Healthcare Sector



In the past hundred years, medicine has progressed tremendously. Infectious diseases, for example, can be healed with antibiotics, and also the possibilities to diagnose and treat widespread illnesses like cardiovascular diseases or cancer have improved a great deal.

Yet, there are still great challenges that face our public health system today and will also do so in the coming decades:

The world population is growing and the proportion of older people is on the rise. At the same time, it is possible to observe an increase in illnesses caused by today's lifestyle such as cardiovascular disease, cancer, diabetes, and dementia. Despite great efforts, we have so far not been successful in putting a stop to the resulting increase in healthcare costs. However, society has the aspiration to ensure that everyone will have access to high-quality healthcare in future as well. Consequently, this calls for an increase in the efficiency of the healthcare system.

Improvement in procedures, for example by means of healthcare IT solutions, seems to be one possibility to immediately increase efficiency.

An even greater potential for improvement, however, offers early diagnosis. Even today, many diseases are still diagnosed relatively late, which reduces the chances of recovery and multiplies the costs of treatment. In the case of cancer of the colon, for example, only approximately 35 percent of

the patients are diagnosed at stage 0 to 1, when the tumour is still localized and therefore surgery has a good chance of success. If the tumour is diagnosed later, this reduces the chance of successful treatment and the probability of survival. For example, the probability of the patient surviving a further five years at stage 1 exceeds 90 percent, at stage IIIB it is still something more than 60 percent, at Stage IV, however, it is less than 10 percent.

An equally big challenge is the choice of therapy, but here is great potential for improvement. For lack of suitable test methods, it is currently scarcely possible to predict whether a patient will respond to a certain treatment or not. In many cases, doctors need to try out different treatments before they find the right one. This increases the patients' discomfort and stress and gives rise to additional costs.

So how can these potentials be tapped best in order to improve the quality of medical care?

A very promising approach is molecular medicine, i.e., an improved understanding of the causes of illnesses and the correlations between them at the molecular level. In conjunction with knowledge-based applications that bring together all information acquired by means of different diagnostic methods, it is possible to compare them with reference data of large populations. The aim of this is to help diagnose diseases at a very early stage and, ideally, to prevent them from breaking out at all or – if the disease has already broken out – to select therapies in a more targeted and personalized way.

What shape might such an approach assume in future? What effects would it have on the course and the treatment of an illness? Let us take coronary heart diseases (CHD) as an example:

Today, approximately 60 percent of patients at risk of a heart attack or stroke can be identified using classical diagnostic methods (Body Mass Index, diabetic yes/no, smoker yes/no, age, cholesterol levels and the ratio of HDL/LDL cholesterol). Even so, approximately 40 percent of all cases occur with patients who have a low risk according to classical diagnostic criteria.

With new laboratory tests (in vitro) in the field of molecular medicine and imaging methods (in vivo) supported by knowledge-based analytical methods, there is a very good chance of identifying a large proportion of the high-risk patients who would remain unidentified using today's diagnostic methods. At the same time, pharmaceutical companies are developing new drugs for treating illnesses in a more targeted way or for delaying or even completely preventing their outbreak. So, in a few years, preventive treatment and therapy of cardiovascular diseases might look as follows:

On a voluntary basis, and from a certain age (e.g. 40) onwards, every citizen is subjected to a routine check-up for CHD. A sample of the patient's blood is taken and examined for specific indicators of the disease (e.g. certain gene or protein patterns). Together with all the other data known about the patient and possible earlier findings, all is put into context with reference data using knowledge-based analytical methods, and results in quantifiable findings. If, for example, there is a high risk of the patient suffering a heart attack or a stroke within a few years, follow-up

A second very promising field of application for innovative methods based on molecular medicine as well as knowledge-based methods is cancer. Today, people are working ardently on methods for diagnosing tumours earlier and improving their characterization, for example, on the basis of genetic analyses. In many cases, this will make it possible in future to predict more precisely whether a patient will respond to a certain type of chemotherapy.

These were just two examples. There are many other illnesses, such as Alzheimer's disease, for example, where work is under way to find similar solutions for improving early detection, diagnosis, and therapy.

Summing up the view of Siemens, it may be said that, in the long term, medical treatment based more strongly on the methods of molecular medicine, as well as on knowledge-based methods, can contribute considerably to improving the quality and raising the efficiency of healthcare. We are convinced that an approach embracing all diagnostic methods is sensible and necessary to fully exploit the potential. This is why the Healthcare Sector of Siemens has

Medical treatment based more strongly on the methods of molecular medicine, as well as knowledge based methods, can make important contributions to improving the quality and raising the efficiency of healthcare.

examinations are recommended in order to determine the stage of the illness more precisely, for example, by means of PET-CT and a biomarker for vulnerable plaques. Using the information acquired, this is followed up by therapy, if necessary, with the appropriate drugs being selected on the basis of the acquired data (gene/protein patterns). The success of the treatment is monitored by laboratory tests and/or PET-CT examinations.

This combination of laboratory tests, imaging diagnostic methods, and knowledge-based applications would lead to a reduction in the number of heart attacks and strokes, ultimately improving the quality and efficiency of healthcare.

deliberately reoriented itself in the past few years so as to be able to provide solutions using laboratory diagnostics and molecular medicine along with imaging diagnostics and healthcare IT. In 2005, the company acquired CTI, forming a new Molecular Imaging Business Unit that focuses on the development of new molecular biomarkers for PET applications. The new Diagnostics Division was created through the acquisition of DPC, Bayer Diagnostics and Dade Behring in 2006 and 2007. The Division is developing, for example, new molecular in-vitro diagnostic methods.

Today, Siemens is the first integrated diagnostics company worldwide.

The Innovation and Start-up Center IGZ BioMed/ZmK in Würzburg

With its focus on the themes of biotechnology/biomedicine, medical technology, and information technology/ modern communication, Würzburg's Innovation and Start-up Center for Biotechnology and Biomedicine and Center for Modern Communication Technologies (IGZ BioMed/ZmK) is the largest entrepreneurship center in the administrative district of Lower Franconia.

The plan is to link up companies, service providers and investors with universities and research institutes in nineteen key sectors and fields of competence.

It was opened in December 2001 and since then has offered technology-oriented business start-ups around 2,000 m² of laboratory space together with a suitable technical infrastructure and 3,000 m² of office space. Additional services available are conference and seminar rooms, as well as comprehensive consultancy services.

The start-up center is operated by IGZ Betriebsgesellschaft mbH managed by Klaus Walther, head of the City's Business Development Department (Congress / Tourism / Industry). Partners in the IGZ Betriebsgesellschaft mbH are the City of Würzburg, the County of Würzburg, the Main-Franconia Savings Bank and the Würzburg-Schweinfurt Chamber of Commerce.

In autumn 2005, IGZ BioMed/ZmK launched the "Life Sciences in Würzburg" project aimed at better utilizing the high potential of the life sciences – especially at the renowned Würzburg University. The purpose of the project is to provide in-depth consultancy services and to promote business start-ups, company recruitments and existing companies at the location in cooperation with the Bavarian

Ministry of Economic Affairs, the Julius Maximilian University Würzburg and the Business Development Department of the City of Würzburg. The initiative fits in admirably with the Bavaria-wide efforts to improve technology transfer from universities to companies. One outstanding example is the "Cluster-Offensive Bayern" initiated by the Bavarian State Government.

The plan is to link up companies, service providers and investors with universities and research institutes in nineteen key sectors and fields of competence. The IGZ BioMed/ZmK is Lower Franconia's regional partner for BioM GmbH, which has taken over cluster management in the field of biotechnology throughout Bavaria.

In the field of medical engineering, the Bavarian cluster is managed by the MedTech Pharma Forum from Nuremberg. In this field, too, the IGZ BioMed/ZmK Innovation and Start-up Center is the partner for companies in the region of Lower Franconia.

Current measures for creating an attractive start-up climate in the Lower Franconia region are supported by the Federal Government with funds from the promotion scheme "Exist III – Existenzgründungen aus Hochschulen" (Business start-ups from universities). The University of Würzburg, in cooperation with IGZ BioMed/ZmK and netzwerk|nordbayern, has developed a comprehensive programme of measures for this purpose. The aim is to offer young academics high-quality lectures and seminars on business-administration and sector-specific themes. In addition, it is planned to have technology-scouts track down research results with business potential at the region's universities and research institutions. Once potential founders have been identified and motivated, they receive individual in-depth advice and support to help them on their way towards their own company.



Central tasks are:

- general coaching and consultancy for business start-ups regarding economic strategies, business models, scientific projects, market entrance strategies, patent and brand strategies, financial strategies, knowledge management, investor relations, corporate governance, corporate social responsibility, directives, data protection and IT security
- advice and support for business start-ups during negotiations with investors and financing rounds, also in the context of negotiations with strategic partners and licensing or cooperation partners
- analysis of potentials of regional business start-ups and of possible technology-oriented spin-offs
- support in the preparation and maintenance of business plans
- advice on matters of company management in business start-ups
- advice on the preparation of finance planning and liquidity planning
- advice on quality management and quality assurance as well as risk management in business start-ups
- advice on the qualification of company founders
- regional and supraregional formation of networks; networking of academic and industrial partners
- advice on activities to promote the recruitment of innovative companies, simultaneously strengthening cooperation between existing institutions and companies
- cooperation in creating and developing a constructive climate between regional companies and institutions

There are also successes to be reported with regard to the already established leaseholders of the Würzburg Innovation and Start-up Center. The pharmaceutical company vaso-

pharm GmbH, for example, has taken an important step forward in the development of a drug for the treatment of the consequences of traumatic brain injury; at the end of 2006, the substance VAS203 received the approval of the Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte; BfArM)) for a phase I clinical study in humans, enabling the start of a corresponding study in January 2007.

The Würzburg company Patrys GmbH, located on IGZ BioMed/ZmK premises, is the operative core of the Australian Patrys Ltd, whose stock exchange debut in 2007 was a remarkable one: owing to its noteworthy floatation on the Australian Stock Market Exchange, the company now has € 15 million available. The capital thus acquired could enable the company to carry out clinical studies for its first own special-type of antibody for tumour therapy.



In previous years IGZ BioMed/ZmK has done a great deal of promotional groundwork, also with long-term prospects of job-relevant success for the location. In the coming years, further business start-ups are expected from pre-seed promotion schemes that have already been launched. Another important aim is to further improve the networking of the regional technological companies from the health industry, medical technology, silicate research, plastics technology and medical imaging. The development of its own unmistakable and yet innovative profile in the life sciences sector will have a central role to play in this context. These and further measures will give further drive to the "Life Sciences in Würzburg" location project for many years to come.



An attractive location for high-tech business start-ups: the Innovation and Start-up Center for Biotechnology and Biomedicine/Center for Modern Communication Technologies (IGZ BioMed/ZmK) in Würzburg

CONTACT

IGZ BioMed/ZmK,
Dr. Gerald Böhm
Friedrich-Bergius-Ring 15
D-97076 Würzburg
Phone: +49 (0)931 270 62 94
Internet: www.igz.wuerzburg.de



Company profiles



Contact:
Bettina von Klitzing

Am Klopferspitz 19a
D-82152 Martinsried/München
Phone: +49 (0) 89 700763 0
Fax: +49 (0) 89 700763 29
E-Mail: Bettina.von.Klitzing@4sc.com
Internet: www.4sc.com

4SC AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Medicinal Chemistry, Molecular Modelling, Small Molecules, Infectious Diseases, Rheumatology, Autoimmune Diseases

4SC is a drug discovery and development company that uses its cheminformatics-based technology platform for the discovery and development of new drug candidates for the treatment of patients suffering from diseases with high medical needs.

The company has been generating a risk-balanced and continuously advancing pipeline of projects. 4SC's therapeutic focus centres on cancer and inflammatory diseases since these indications combine significant market potential and high medical needs with reasonable development time and cost in the early clinical stages. The first project on the treatment of rheumatoid arthritis is currently undergoing clinical phase IIa.

4SC has been listed in the Prime Standard Segment (regulated market) of the Frankfurt Stock Exchange since 15 December 2005.



Contact:
Dr. Peter H. Kalinka

Hammersbacher Fußweg 24
D-82467 Garmisch-Partenkirchen
Phone: +49 (0) 8821 9430 271
Fax: +49 (0) 8821 9430 272
E-Mail: accelsiors@t-online.de
Internet: www.accelsiors.com

Accelsiors Group International

CRO

Accelsiors International headquartered in Europe, is composed of an international CRO, drug development consulting and a biopharma development group. With offices in Germany, Hungary, the United States and a partnership in China, India and Latin America, Accelsiors conducts cost effective, time efficient large multi-centric international trials.

Accelsiors' comprehensive project experience developed for multinational and US companies, provides reliable data and regulatory support for the filing of products with EMEA and FDA, while counseling clients through all project phases, from planning to implementation, from cloning to filing.

Accelsiors intimate involvement with biologics (Peptides, EPO, Ifn-beta, Ifn-alpha, hGH, SR-Forms) and small molecules (GnRH) contributes proven experience to complicated drug development programs.



Contact:
Dr. Jörg Plümpe

Von-Heyden-Str. 12
D-93105 Tegernheim
Phone: +49 (0) 9403 95449-10
Fax: +49 (0) 9403 95449-15
E-Mail: chromeonsales@activemotif.com
Internet: www.chromeon.com

Active Motif Chromeon GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Fine Chemicals / Reagents, Nanobiotechnology, Microscopy

Active Motif Chromeon provides several different lines of fluorescent chromophores – the Chromeo™ Dyes, RuLabels and Py-Dyes. Chromeo Dye excitation and emission properties match common excitation sources and filter sets. But, several of the dyes have unique Stokes shift properties that make them ideal multiplex dye partners. RuLabels are phosphorescent ruthenium probes that emit strongly polarized light with a long decay time, which enhances sensitivity and reduces background. The Py-Dyes possess unique physical and spectral properties that make conjugation simple, while greatly reducing background.

Affectis Pharmaceuticals AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, RNAi & Antisense, Small Molecules, CNS

Affectis is a biopharmaceutical company implementing novel concepts for the treatment of psychiatric disorders, especially depression and schizophrenia. Affectis has unique capabilities to discover and develop drugs based on pioneering findings in the field of psychiatric disorders. The Company's drug discovery programme targets two interrelated pathways so far unknown in the context of depression and schizophrenia.

The Company started operations in November 2003 as spin-off of the Max-Planck-Institute of Psychiatry (MPI) in Munich, Germany.



Contact:
Sabina van den Brandt

Fraunhoferstr. 13 / 4. OG
D-82152 Martinsried
Phone: +49 (0) 89 8932811-0
Fax: +49 (0) 89 8932811-111
E-Mail: info@affectis.com
Internet: www.affectis.com

Agrobiogen GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: Agrobiotechnology, Transgenic Animals, Gene Transfer, Genomics, Xenotransplantation, Automation

Agrobiogen focuses on and is experienced in the application of molecular-genetic techniques in livestock animals (especially moleculargenetic diagnosis and gene transfer). Many transgenic rabbit lines and several cattle clones have been established. As a service for other biotech companies transgenic farm animals are generated using conventional microinjection procedures and nucleus transfer. Gene diagnosis of microorganisms toxic to livestock like BVD, as well as parentage control of animals, scrapie resistance genotyping and analysis of DNA markers are offered as a service for breeders, veterinarians and companies. Agrobiogen has developed a simple labour-saving system for collection of tissue samples and extraction of DNA from millions of animals for automatically controlled analyses.



Contact:
Prof. Dr. Gottfried Brem

Thalmannsdorf 25, Larezhauen
D-86567 Hilgertshausen
Phone: +49 (0) 8250 928234
Fax: +49 (0) 8250 928236
E-Mail: monika.gutscher@agrobiogen.de
Internet: www.agrobiogen.de

ALGORA Gesellschaft für Medizinstatistik und Vertriebssysteme mbH

CRO

Keywords: Clinical Research, Monitoring, Analysis, Oncology, Infectious Diseases

Algora is a niche CRO successfully operating on clinical trials in Germany. Services include phase II-IV trials as well as large observational studies and range from protocol development to final study reports. Algora manages complete study projects or delivers individual services, such as clinical monitoring, data management or statistical analysis. Experienced in oncology since the first days of the company in 1989, Algora always had a focus on innovative therapies, leading to close relationships to university hospitals and medical societies. Since 1995 another focus developed in large pediatric studies. Customers are pharmaceutical and medical device companies, independent research groups, and other CROs.



Contact:
Dr. Karl Fehnle

Münchner Str. 11
D-85540 Haar
Phone: +49 (0) 89 6137270
Fax: +49 (0) 89 61372720
E-Mail: cro@algora.de
Internet: www.algora.de



Contact:
Silvia Schmidt

Hanauerstr. 1
D-80992 München
Phone: +49 (0) 89 149096 1600
Fax: +49 (0) 89 149096 2000
E-Mail: silvia.schmidt@amgen.com
Internet: www.onkologie.de

AMGEN GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development

Amgen's corporate mission is to be the world leader in developing and delivering important, cost-effective therapeutics based on cellular and molecular biology. The company's first product, EPOGEN® (Epoetin alfa), stimulates and regulates the production of red blood cells. Amgen's second product, NEUPOGEN® (Filgrastim), is a recombinant granulocyte colony-stimulating factor (G-CSF) that selectively stimulates growth of infection-fighting white blood cells known as neutrophils. In 2001 Amgen launched a new drug, called Aranesp®, which also stimulates the production of red blood cells. Aranesp® was created by rational drug design and has a threefold longer halflife time compared to Epogen®. In 2002 AMGEN launched a second generation G-CSF called Neulasta® which also stimulates the growth of neutrophils. Neulasta® has an important advantage. Due to its pegylation Neulasta® has a longer half-life time and therefore has to be administered only once per chemotherapy cycle whereas Neupogen® has to be administered daily.



Research GmbH

Contact:
Gabriele Wilde

Josef-Engert-Str. 9
D-93053 Regensburg
Phone: +49 (0) 941 465-20000
Fax: +49 (0) 941 465-20100
E-Mail: gwilde@amgen.com
Internet: www.amgen.de

Amgen Research GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Drug Development, Small Molecules, Diabetics, Hematology, Inflammation, Neurology, Oncology

AMGEN, (Applied Molecular Genetics Inc.) was founded in 1980 as one of the pioneers of industrial biotechnology. The company develops, produces and sells biopharmaceutical products that are produced through recombinant DNA technologies. AMGEN Research GmbH was founded in Regensburg in 2000. Basic research is conducted with the aim of identifying new pharmaceutical lead structures for the development of innovative drugs. Low molecular weight compounds are identified by high throughput screening (HTS) procedures. Over 10 million compounds are analyzed every year.



Contact:
Dr. Lars Wassill

Werkstr. 2
D-83555 Gars-Bahnhof
Phone: +49 (0) 8073 91693-0
Fax: +49 (0) 8073 91693-33
E-Mail: info@amplexdiagnostics.de
Internet: www.amplexdiagnostics.de

AmplexDiagnostics GmbH – Gesellschaft für molekularbiologische Diagnostik

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Clinical Diagnostics, PCR, Infectious Diseases

AmplexDiagnostics GmbH is a privately held company for the development and production of In Vitro Diagnostics. Our aim is the improvement of the potential of the PCR-technology by implementing the main advantages of this technology into the diagnosis of bacterial infections. Founded in 2002 – Amplex developed its first product (hyplex StaphyloResist) and entered the market already in 2003. Additional systems (hyplex STD ID for detection of sexually transmitted mycoplasmas; hyplex EHEC for detection of EHEC/EPEC and hyplex EnterotoResist for characterisation of VRE) followed in 2006. Additionally, we developed the first PCR-system (hyplex ESBL ID) for the direct detection of ESBL producing bacteria direct from patient material. For further information please visit www.hyplex.info or contact us.

amYmed GmbH Referenzzentrum für Amyloidkrankheiten

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, Antibody Production Service, Devices, Antibody

We provide high precision immunohistochemical classification of the diverse amyloid diseases with respect to specific and causal treatment as a service for patients and physicians.

We are in the process of extending this service by producing and offering test kits in order to enable clinics and institutes of pathology to perform this classification by themselves.



Contact:
Prof. Dr. med. Reinhold P. Linke

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 52012638
Fax: +49 (0) 89 52389013
E-Mail: linke@amymed.de
Internet: www.amymed.de

AntiProt

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Antibody Production Service, Agrobiotechnology, Fine Chemicals / Reagents, Allergy

AntiProt produces and distributes antibodies raised against various proteins especially against plant proteins for scientific purposes. AntiProt helps scientists to produce monoclonal and polyclonal antibodies and supports them individually on the whole way from peptides till purified antibodies. AntiProt concentrates its research on production of antibodies-markers for photosynthesis, stress responses, pathogen resistance, toxins, allergenic reactions and other processes.



Contact:
Dr. Anna Niebling

Am Klopferspitz 19a
D-82152 Martinsried
Phone: +49 (0) 89 74442700
Fax: +49 (0) 89 74442701
E-Mail: info@antiprot.com
Internet: www.antiprot.com

Antisense Pharma GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Antisense Pharma is an innovative biotech company aimed at developing and marketing novel antisense technology based drugs for the treatment of cancer and other so far incurable diseases.

Founded in Göttingen 1998, the company is now headquartered in the BioPark in Regensburg, one of the most prominent Biotech centers in Germany.

Antisense Pharma develops antisense drugs that specifically block the production of key proteins responsible for the onset and progression of diseases such as cancer. This approach represents a novel therapeutic modality by which diseases are rather tackled directly at their pathogenic cause than by merely combating their effects. Antisense Pharma drugs are specifically targeted at pre-selected proteins such as TGF-beta. Thus the company's approach is unique in the field of antisense drug development. The lead product of Antisense Pharma is AP 12009. It has been developed to activate the body's own immune system against highly malignant tumors. It currently is in an advanced stage of clinical testing. A solid international patent portfolio includes this drug and further candidate antisense compounds as well as various target proteins.



Contact:
Josef-Engert-Str. 9
D-93053 Regensburg
Phone: +49 (0) 941 9201-300
Fax: +49 (0) 941 9201-329
E-Mail: info@antisense-pharma.com
Internet: www.antisense-pharma.com

apogene

Contact:

Prof. Dr. Gottfried Brem

Thalmannsdorf 25, Larehausen
D-86567 Hilgertshausen
Phone: +49 (0) 8250 928466
Fax: +49 (0) 8250 7166
E-Mail: gbremabg@apogene-gmbh.de
Internet: www.apogene-gmbh.de

apoGene GmbH & Co. KG

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: Tissue Engineering / Cell Culture, Knock Out, Xenotransplantation

apoGene is focused on the field of xenotransplantation. Rabbits and pigs are genetically modified (transfer, knock out and recombination of endogenous genes) for influencing the different steps of the rejection process after xenotransplantation of animals tissues and organs. We are also investigating the expression of endogenous retroviral sequences after xenogenetic transfer. For the development of knock out animals we have developed and patented an alternative strategy, the so called screen-out of hemizygote carriers of functional defects in natural or mutagenized populations. The technique will also be very interesting for the establishment of animal models for basic and applied research.

ARTHROGEN GmbH

Contact:

Priv.-Doz. Dr. med. Ulrich Schneider

Wiesseerstr. 103
D-83707 Ringsee
Phone: +49 (0) 8022 187978
Fax: +49 (0) 8022 187978
E-Mail: info@arthrogen.de
Internet: www.arthrogen.de

ARTHROGEN GmbH

PHARMA & CHEMICAL INDUSTRY

Arthrogen combines scientific and clinical know-how in order to successfully develop innovative gene therapeutic approaches for the treatment of patients with rheumatic diseases.

Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by persistent joint swelling and progressive destruction of cartilage and bone. Among the connective diseases RA is the commonest and the most important in socioeconomic terms. Biologicals targeting specific cytokines and their receptors have been proven useful as systemic therapies for RA and provide proof of principle of targeted therapies. Gene therapy can provide stable, regulated production of anti-inflammatory molecules and might provide a more efficient system to deliver therapeutic compounds at the site of inflammation. Local gene therapy for chronic diseases such as RA could permit long-term production of therapeutic molecules in the inflamed compartment.

Arzneimittel ProStrakan

Contact:

Yvonne Deppert

Moosstr. 7
D-82319 Starnberg
Phone: +49 (0) 8151 44690-22
Fax: +49 (0) 8151 44690-30
E-Mail: kontakt@prostrakan.com
Internet: www.arzneimittel-prostrakan.de

Arzneimittel ProStrakan GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Drug Development, Drug Delivery, Cardiovascular Diseases, Endocrinology, Metabolic Diseases, Oncology, Pain

Arzneimittel ProStrakan GmbH is the German affiliate of the Scottish ProStrakan Ltd, a pan-European pharmaceutical company. ProStrakan is engaged in the development and commercialisation of speciality prescription medicines for the treatment of unmet therapeutic needs.

In Germany the core products to date were in the field of mineral nutrients and generics for cardiovascular diseases, diabetes and lipometabolism. In 2007 two innovative products were launched, one for the treatment of anal fissures, the other for the treatment of testosterone deficiency. Further innovative products (cancer pain, post operative nausea and vomiting, etc.) will be launched in 2008.

Astellas Pharma GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Drug Development, Antibiotics, Allergy, Autoimmune Diseases, Immune Therapy, Infectious Diseases, Inflammation

Astellas Pharma Inc. was formed in April 2005 from a merger with Yamanouchi and Fujisawa. Astellas Pharma is Japan's second largest pharmaceutical company and is headquartered in Tokyo. It has operations in Europe, Asia, North America and Japan. Astellas is focused on four key therapy areas: Transplantation, urology, dermatology, and anti-infectives.

Astellas employs approximately 3,000 people in Europe across Sales and Marketing, Research & Development and Manufacturing. Astellas has 19 Sales and Marketing Affiliates, 3 plants and 1 R&D site in Europe. Astellas Europe is headquartered just outside London in Staines. The German headquarters are based in Munich. Located here are Sales, Marketing and Medical. The product portfolio includes therapies in transplantation, urology, dermatology, asthma/COPD, cardiology, antibiotics and gastroenterology.

Astellas Pharma GmbH Munich employs approximately 350 people including 225 sales representatives.



Contact:

Dr. Martin Marhoefer

Berg-am-Laim-Str. 129

D-81673 München

Phone: +49 (0) 89 4544-1440

Fax: +49 (0) 89 4544-1600

E-Mail: martin.marhoefer@de.astellas.com

Internet: www.astellas.de

Aurigon Life Science GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: Drug Development, Pharmacology, Toxicology

Aurigon Life Science is an independent contract research organization (CRO) which performs preclinical research and development. The main emphasis of the company is the combination of pharmacological studies and toxicological testing in accordance with international and national requirements (BfArM, EMEA, FDA, ICH, OECD, GLP). Aurigon offers an integrated service from strategic planning of the preclinical development continuing with the pharmacological characterisation and toxicological testing of the sponsors substance up to the preparation of expert reports for the legal authorities. This includes a comprehensive range of in house services in the fields of preclinical efficacy and safety testing for biotechnology and pharmaceutical companies and the chemical industry.



Contact:

Dr. Gundel Hager

Bahnhofstr. 9-15, Gebäude 214
D-82327 Tutzing

Phone: +49 (0) 8158 2597-30

Fax: +49 (0) 8158 2597-31

E-Mail: info@aurigon.de

Internet: www.aurigon.de

AVONTEC GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Respiratory Diseases, Inflammation, Dermatology

AVONTEC GmbH is a Munich-based biopharmaceutical company engaged in the development of a novel class of nucleic-acid-based anti-inflammatory drugs. These drugs, based on oligonucleotides that act as decoys for certain transcription factors, are all directed against biologically validated targets in major chronic diseases with high unmet medical need. AVONTEC focuses its technology on chronic inflammatory diseases of the respiratory system and skin. The company has two products in clinical phase II development.



Contact:

Dr. Thomas Schulze

Fraunhoferstr. 15

D-82152 Martinsried

Phone: +49 (0) 89 8565 1600

Fax: +49 (0) 89 8565 1620

E-Mail: info@avontec.de

Internet: www.avontec.de

Contact:
Derek Beggs

Fraunhoferstr. 13
D-82152 Martinsried
Phone: +49 (0) 89 8565 0030
Fax: +49 (0) 89 8565 1333
E-Mail: derek.beggs@bavarian-nordic.com
Internet: www.bavarian-nordic.com

Bavarian Nordic GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Vaccines, Infectious Diseases

Bavarian Nordic (BN) is a leading international biopharmaceutical company developing innovative vaccines to prevent and treat infectious diseases. The company is capable to meet the growing demand for safe 3rd generation smallpox vaccines due to its proprietary vaccine technology MVA-BN®. BN was founded in 1994 and is headquartered in Kvistgaard, Denmark with subsidiary operations in Martinsried and Berlin, Germany. BN recently founded in the US an operating company, BN ImmunoTherapeutics Inc., for research and development of cancer vaccines. The company employs about 180 people and is listed on the Copenhagen Stock Exchange.

More than 450 healthy and immune compromised subjects so far vaccinated with MVA-BN®, suggest an excellent safety and efficacy profile of the vector.

Baxter

Contact:
Jutta Brenn-Vogt

Edisonstr. 4
D-85716 Unterschleißheim
Phone: +49 (0) 89 31701 0
Fax: +49 (0) 89 31701 177
E-Mail: info_de@baxter.com
Internet: www.baxter.de

Baxter Deutschland GmbH

PHARMA & CHEMICAL INDUSTRY

The Bioscience business of Baxter is represented by the BioScience division. BioScience produces therapeutic proteins from plasma and through recombinant methods to treat hemophilia, immune deficiencies and other blood-related disorders. These include coagulation factors, immune globulins, albumin, wound-management products and vaccines. Further divisions of Baxter are Medication Delivery and Renal. Medication Delivery manufactures products used to deliver fluids and drugs to patients. The Renal division provides renal dialysis products and services to support people with kidney failure. The focus of Baxter Germany is sales and marketing. Manufacturing plants are located at Plattling (IV solutions) and Halle/Westfalen (Chemotherapeutics). Research capacities of Baxter Europe are located in Switzerland and Austria. Current R&D projects aim at new therapeutic proteins and regenerative medicine. Baxter also co-operates with a number of European and US based Biotech companies.



Helping all people
live healthy lives

Contact:
Patricia Mees

Am Klopferspitz 19a
D-82152 Martinsried
Phone: +49 (0) 89 7294949 0
Fax: +49 (0) 89 7294949 20
E-Mail: jutta_denter@europe.bd.com
Internet: www.bd.com

BD Diagnostics

BIOTECH DEVICES & REAGENTS

Keywords: Devices, Automation, Proteomics, Antibody, Ophthalmology,
Fine Chemicals / Reagents, Diabetics

BD (Becton, Dickinson and Company) is a global medical technology company that is focused on improving drug therapy, enhancing the diagnosis of infectious diseases and advancing drug discovery. BD manufactures and sells medical supplies, devices, laboratory instruments, antibodies, reagents and diagnostic products through its three segments: BD Medical, BD Diagnostics and BD Biosciences. It serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public.

BD is headquartered in the United States and has offices in nearly 50 countries worldwide with more than 26.000 employees.

Bernina Plus GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Delivery, Liposomes, Nanobiotechnology

Bernina develops smart oral drug delivery systems for therapeutic peptides. The proprietary technology is based on artificial envelopes created by lipids. In addition, these nano-particulate natural and synthetic lipids are used in coating and drug elution processes.



Bernina Plus

Contact:

Dr. Felix Groppe

Am Klopferspitz 19a
D-82152 Martinsried
Phone: +49 (0) 89 52388740
Fax: +49 (0) 89 52388333
E-Mail: groppe@berninaplus.de
Internet: www.berninaplus.de

Bicoll GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Infectious Diseases, Natural Compounds, Small Molecules, Oncology, Diabetics, Nutraceuticals

Bicoll is a biopharmaceutical company specializing in high-tech natural product chemistry to identify novel small molecules for drug discovery and related innovative fields. The research focus lies on making compounds from natural resources compatible with customers' screening systems for drug discovery and various other fields of application. Bicoll's advanced approach of property-based screening selects promising candidates early on and avoids investment in less promising compounds. Bicoll's products and services are tailored to its customers' needs to accelerate the development process of new pharmaceuticals.

The Bicoll Group is set-up with two legal entities: Bicoll GmbH in Munich, Germany and since 2001 Bicoll Biotechnology (Shanghai) Co. Ltd. in Zhangjiang Hi-Tech Park, P.R. China.



Contact:

Dr. Kai Lamottke

Richard-Riemerschmid-Allee 27
D-81241 München
Phone: +49 (0) 89 82072564
Fax: +49 (0) 89 529178
E-Mail: lamottke@bicoll-group.com
Internet: www.bicoll-group.com

BIOCAM GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

BIOCAM as an medical engineering company acts since 2001 and has 28 employees. The company develops, produces and sells hard and software imaging systems and guided imaging therapy systems. They are applied for early diagnoses, differential diagnoses and for the screening and the treatment of cancer and inflammation diseases *in vivo* on the patient. Anatomical and physiological information displayed simultaneously and are overlayable. The products which are already on the market apply to the skin sector; the current developments will enter the market sectors endoscopy, neurosurgery and plastic surgery.



Contact:

Monika Pirkenseer

Friedenstr. 30
D-93053 Regensburg
Phone: +49 (0) 941 785398-0
Fax: +49 (0) 941 785398-10
E-Mail: info@biocam.de
Internet: www.biocam.de



Contact:
Lydia Krybus

Carl-Zeiss-Ring 6
D-85737 Ismaning
Phone: +49 (0) 89 99617 0
Fax: +49 (0) 89 99617 199
E-Mail: lydia.krybus@biogenidec.com
Internet: www.biogenidec.com

Biogen Idec GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Biogen Idec, Inc., winner of the 1998 U.S. National Medal of Technology, is a biopharmaceutical company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. Headquartered in Cambridge, MA, the Company's revenues are generated from U.S. and European sales of AVONEX® (Interferon beta-1a) for treatment of relapsing forms of multiple sclerosis, and from the worldwide sales by licensees of a number of products, including alpha interferon and hepatitis B vaccines and diagnostic products. Biogen Idec's research and development activities are focused on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases and in developmental biology and gene therapy.

BioGents AG

Contact:
Universitätsstr. 31
D-93053 Regensburg
Phone: +49 (0) 941 94 33 064
Fax: +49 (0) 941 94 33 064
E-Mail: biogents@biogents.com
Internet: www.biogents.com

BioGents AG

BIOTECH AGRO, FOOD, ENVIRONMENT

We are specialists in the application and development of scents and aromas for the insect control market. An important part of our research is performed on blood-feeding insects and other arthropods. A spin-off of the Institute of Zoology at the University of Regensburg, BioGents combines the flexibility, efficiency and reliability of a state-of-the-art test laboratory with the expertise and scientific skills of an academic institution.

Research & Development: BioGents finds specific attractants, develops efficient traps, optimises natural repellents, and evolves monitoring and surveillance techniques against insect pests.

Evaluation & Screening: BioGents evaluates and screens products, substances and technology for a potential use in insect control.

Networking & Consulting: BioGents offers access to an international network of experts, producers and marketing companies in the fields of insect biology and pest control.



Contact:
Dr. Shannon Frances

Lochhamer Str. 9
D-82152 Martinsried
Phone: +49 (0) 89 895574-0
Fax: +49 (0) 89 895574-825
E-Mail: info@biomax.com
Internet: www.biomax.com

Biomax Informatics AG

BIOTECH BIOINFORMATICS

Keywords: Genomics, Proteomics

Biomax Informatics AG specializes in developing customized bioinformatics solutions for life science organizations. As a result of a systematic customization process that includes client consultation, intense evaluation and rounds of optimization, several products have been developed for a broad range of life science applications. These proven software tools serve as the foundation for comprehensive bioinformatics infrastructures. Ready-to-use solutions include the well-known Pedant-Pro™ Sequence Analysis Suite, the BioRS™ Integration and Retrieval System, the HarvESTer™ EST Assembly and Clustering System, and other bioinformatics tools used in metabolic pathway, proteomics, and gene expression analyses.

Biomed Labordiagnostik GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Clinical Diagnostics, PCR, ELISA / EIA, Analytical Chemistry, Neurology, Infectious Diseases, Hematology

BIOMED Labordiagnostik GmbH offers numerous proven in vitro diagnostic products and innovative solutions for specific problems in the field of clinical reagents, quality control, molecular biology, infection diagnostics and haematology. With the aims of complete product range, economic test packages, simple working methods, reliable measurement results, automated tests and system reagents for current automated analysers. Laboratories use high-grade enzymes for PCR diagnosis in detection of nucleic acids. These were specially developed for PCR diagnosis. The rapidity of molecular biology detection methods gives them a crucial advantage over conventional ELISA analysis especially in serology. High-grade DNA polymerases, cDNA/DNA polymerases and basic molecular biology reagents are available.



Contact:

Dr. Volker Schlüter

Bruckmannring 32
D-85764 Oberschleißheim
Phone: +49 (0) 89 315 700-0
Fax: +49 (0) 89 315 32 42
E-Mail: info@biomed.de
Internet: www.biomed.de

BIONORICA AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Fine Chemicals / Reagents, Bone / Joint Diseases, Cardiovascular Diseases, Respiratory Diseases, Medical Writing

Bionorica AG is one of the most successful manufacturers of phytotherapeutics in Germany. The product range focuses on diseases of the respiratory tract, gynaecological disorders and medications for the treatment of pain. As an essential Bionorica follows the principle of phytoneering as gold standard in modern phytotherapy. Phytoneering stands for deciphering the active principle in botanicals (PHYTO) using innovative technologies (engiNEERING) to develop and manufacture the most effective phytopharmaceuticals. Our expressed goal is to discover new active substances in order to develop effective drugs with minimized side effects.



Contact:

Sabine Kohl

Kerschensteiner Str. 11-15
D-92318 Neumarkt
Phone: +49 (0) 9181 23 19 0
Fax: +49 (0) 9181 23 12 65
Internet: www.bionorica.de

Biontex Laboratories GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Fine Chemicals / Reagents, Gene Transfer, Liposomes, RNAi & Antisense, Gene Therapy

Genetic engineering company Biontex Laboratories GmbH has been a leader in the field of transfection technology since 1998. Our products focus on the use of synthetic carrier molecules for the efficient transfer of genetic material (DNA, RNA, siRNA) to eucaryotic cells. Biontex products including DOTAP, INSECTOGENE and METAFECTENE™ have been marketed worldwide for several years; some products have been successfully licensed to globally operating partners. A completely new type of product, METAFECTENE™ PRO, is launched since 2006. Test samples can be ordered at www.biontex.com. Current research focuses on the development of new strategies for maximizing transfection efficiency for all cell types – in vivo or in vitro – by utilizing synthetic carrier components free from immunological effects.



Contact:

Dr. Stephan König

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 324799 50
Fax: +49 (0) 89 324799 52
E-Mail: contact@biontex.com
Internet: www.biontex.com



Contact:
Dr. Alexander von Nieciecki

Weihenstephaner Str. 28
D-81673 München
Phone: +49 (0) 89 2444129-44
Fax: +49 (0) 89 2444129-40
E-Mail: info@bioproof.de
Internet: www.bioproof.de

BioProof AG

CRO

BioProof offers high standard analytics of small molecules and biologicals (LC-MS/MS, HPLC, ELISA, bioassays) according to GLP, pharmacokinetic evaluation and support as well as medical writing (IDB, IMPD, IND etc.). Its multidisciplinary team has excellent expertise in registration-oriented project management at the intersections of chemistry, analytics, formulation, manufacturing, preclinical and clinical development, throughout the whole product-driven development process. BioProof is a privately owned and independent CRO, founded in 2001. Focusing on development until proof of concept, BioProof is continuously expanding its potential through partnering and networking.



Contact:
Dr. Susanne Seifert

Heidemannstr. 164
D-80939 München
Phone: +49 (0) 89 31884-121
Fax: +49 (0) 89 31884-123
E-Mail: info@bio-rad.com
Internet: www.biorad.com

Bio-Rad Laboratories GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Clinical Diagnostics, Gene Transfer, Genomics, Proteomics, Peptide/Protein, PCR, Chip / Array Technology

Bio-Rad Laboratories GmbH is a subsidiary of the Bio-Rad Group, one of the leading companies in the field of Life Science and Diagnostics with more than 5.400 employees throughout the world. Bio-Rad Laboratories develops, produces and distributes apparatus and consumables for molecular biological and biochemical research in Life Science and for Clinical Diagnostics.



Contact:
Dr. Günter Bertholdt

Boltzmannstr. 11a
D-85748 Garching
Phone: +49 (0) 89 28910916
Fax: +49 (0) 89 28910933
E-Mail: mail@bioregeneration.eu
Internet: www.bioregeneration.eu

bioregeneration™ GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

bioregeneration™ GmbH works in the field of tissue engineering using a proprietary technology. The technology comprises of the newly developed biomaterial "Xellulin", which can be individually shaped and causes no graft-reaction in the human body.



Contact:
Dr. Ralf Bäuerle

Obere Hauptstr. 10b
D-85386 Eching
Phone: +49 (0) 89 37 99 666-73
Fax: +49 (0) 89 37 99 666-99
E-Mail: info@biozol.de
Internet: www.biozol.de

BIOZOL Diagnostica Vertrieb GmbH

BIOTECH DEVICES & REAGENTS

Keywords: ELISA / EIA, Tissue Engineering / Cell Culture, Antibody Production Service, Clinical Diagnostics, Proteomics, Small Molecules, RNAi & Antisense

Biozol Diagnostica Vertrieb GmbH markets and distributes products for immunology, molecular biology, tissue culture and signal transduction, such as cytokines, antibodies, recombinant proteins, ELISAs and other test kits. The company represents over 15 different worldwide known suppliers in Germany. Biozol offers additionally all types of antibody production and bulk products for biotech, pharmaceutical and biotherapeutic industry.

Bristol-Myers Squibb GmbH & Co. KGaA

PHARMA & CHEMICAL INDUSTRY

Bristol-Myers Squibb is a diversified worldwide health and personal care company whose principal businesses are pharmaceuticals, consumer products, nutritionals and medical devices. Bristol-Myers Squibb is a leading maker of innovative therapies for cardiovascular, metabolic central nervous system and infectious diseases, dermatological disorders and cancer. The company is also a leader in consumer medicines, orthopaedic devices, ostomy care, wound management, nutritional supplements, infant formulas, and hair and skin care products.



Contact:

Dr. Bernd Winterhalter

Sapporobogen 6-8
D-80637 München
Phone: +49 (0) 89 12142-375
Fax: +49 (0) 89 12142-205
E-Mail: bernd.winterhalter@bms.com
Internet: www.b-ms.de

BSL-BIOSERVICE Scientific Laboratories GmbH

CRO

Keywords: Pharmacokinetics, Toxicology, Medical Writing, Pharmacology, Analysis, Clinical Research

Since 1984 BSL BIOSERVICE is world-wide active as an independent CRO that concentrates on biological trials of drugs, medical devices, biotechnological substances, chemicals and cosmetics. The internationally accepted approach of the institute, with its various accreditations and certifications (GLP, GMP, DIN EN ISO 17025), guarantees high-quality services. Areas of expertise include e.g. ADME and Metabolism, Bioassays, Cell-Based Immunoassays and Immuno-toxicological Investigations, Clinical Sample Services, Toxicology, Pharmacology, Microbiology, Analytics. BSL BIOSERVICE also offers comprehensive services for REACH. BSL BIOSERVICE is also active in the development of alternative test methods to animal experiments.



Contact:

Dr. Christina Grimm

Behringstr. 6/8
D-82152 Planegg
Phone: +49 (0) 89 899650-0
Fax: +49 (0) 89 899650-11
E-Mail: info@bioservice.com
Internet: www.bioservice.com

Cambrex GmbH

CMO

Cambrex is a top innovator entirely focussed on GMP custom manufacturing of small molecules (APIs and intermediates) for the pharmaceutical industry worldwide. 900 employees, turnover 250 million US dollar per year. Services: custom manufacturing from preclinic to launch of API, route selection, R&D, scale up, documentation, full scale production, chiral synthesis, chiral amines, microwave chemistry, cytotox compounds, hydrogenation, nitration, azide chemistry, high energy chemistry, full GMP documentation, stability studies, FDA and EMEA approved sites. Cambrex has successfully produced many APIs in preclinical, clinical and after launch volumes for European and US customers. Half of our business is here in Europe. We are locally present.



Contact:

Dipl.-Chem. Peter Berg

Gebrüder-Batscheider-Str. 4a
D-82041 Oberhaching
Phone: +49 (0) 89 666290-60
Fax: +49 (0) 89 666290-75
E-Mail: peter.berg@cambrex.com
Internet: www.cambrex.com



Contact:
Dr. T. Polifke

Eggenwatt 12
D-88138 Weißensberg
Phone: +49 (0) 8389 92 93 99-0
Fax: +49 (0) 8389 92 93 99-9
E-Mail: info@candor-bioscience.de
Internet: www.candor-bioscience.de



We make it visible.

Contact:
Dr. Richard Ankerhold

Am Neuland 9 + 12
D-82347 Bernried
Phone: +49 (0) 8158 9971-0
Fax: +49 (0) 8158 9971-249
E-Mail: info@zeiss.de
Internet: www.zeiss.de



Contact:
Dr. Torsten Gerike

Joseph-Wild-Str. 20
D-81829 München
Phone: +49 (0) 89 451519-010
Fax: +49 (0) 89 451519-019
E-Mail: info@celgene.de
Internet: www.celgene.de

CANDOR Bioscience GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Clinical Diagnostics, Analytical Chemistry, Fine Chemicals / Reagents, ELISA / EIA, Analysis, Chip / Array Technology, Toxicology

CANDOR – The Technology Solution Provider for Optimising your Immunoassays. CANDOR Bioscience GmbH provides services and products for optimising immunoassays. Due to optimisation you can significantly improve the reliability of results. We are supplier and service provider for diagnostics, GLP laboratories and pharmaceutical industry. CANDOR provides for every application the optimal solution.

The innovative LowCross buffer® reduces cross reactivities, interference and matrix effects which are characteristic for blood, serum and tissue specimen. All products are available in bulk quantities to manufacturers of test kits. For pharmaceutical research and diagnostics we develop and validate ELISA according to relevant guidances (e.g. FDA). CANDOR is DIN EN ISO 9001:2000 certified.

Carl Zeiss Microlmaging GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Analysis, Tissue Engineering / Cell Culture, Microscopy, Clinical Diagnostics, Clinical Research

Carl Zeiss Microlmaging GmbH is the only manufacturer of microdissection and micromanipulation systems with the patented LMPC technology. PALM systems are used both in biomedical and clinical research and in routine applications. Flexible system for contact free harvesting of small samples, from archive material to living cells. Harvesting of purest samples for subsequently molecular analyses of DNA, RNA and proteins. Modular components for image processing and optimization, fluorescence applications, higher throughput. Application laboratory with service and trainings.

Celgene GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Small Molecules, Oncology, Hematology

Celgene is a globally acting biopharmaceutical company, founded in New Jersey (USA) in 1986. Celgene is mainly active in developing and distributing drugs in oncology and immunotherapy. Since 2006, Celgene operates a German subsidiary in Munich-Riem.

For further information visit: www.celgene.de

cellasys GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Clinical Diagnostics, Devices, Chip / Array Technology, Pharmacokinetics, Drug Development, Tissue Engineering / Cell Culture

cellasys offers system solutions for online analysis of living cells. These include services as research and development, production and maintenance of cell based assays. Furthermore we are consultant for development of applications, data analysis and data interpretation.



Contact:
Joachim Wiest

Karlstr. 96
D-80335 München
Phone: +49 (0) 89 2000110-74
Fax: +49 (0) 89 2000110-76
E-Mail: wiest@cellasys.com
Internet: www.cellasys.com

CellMed AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Biocompatibles International plc is a leading medical technology company in the field of drug device combination products, operating through two businesses. CellMed is developing a bead product for cosmetic dermatology and a Drug-Eluting Bead product for the treatment of stroke, based on proprietary stem cell technology. Biocompatibles UK supplies bead and Drug-Eluting Bead products, primarily for use in oncology, and supplies polymer for Medtronic's Endeavor® drug-eluting stent product. Our strategic partners include Angiodynamics Inc, Medtronic Inc, Merz AG and Terumo Corporation.



Contact:
Industriestr. 19
D-63755 Alzenau
Phone: +49 (0) 6023 9181-0
Fax: +49 (0) 6023 9181-33
E-Mail: info@cellmed.de
Internet: www.cellmed.de

Centronic GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Clinical Diagnostics, Medicinal Chemistry, Analytical Chemistry, Automation

Centronic GmbH is a german manufacturer and distributor of a big range of high qualitative clinical chemistry reagents in fluid and lyophilised form, Latex reagents, controls-calibrators and full automated clinical Analyzer (Centrolyser). The management is consisting of scientists of different areas with the experience of many years in the clinical chemistry sector.



Contact:
Dr. Johannes Betz

Am Kleinfeld 11
D-85456 Wartenberg
Phone: +49 (0) 8762 724300
Fax: +49 (0) 8762 724312
E-Mail: info@centronic-gmbh.com
Internet: www.centronic-gmbh.com

Cephalon Pharma GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: CNS, Hematology, Neurology, Oncology, Pain

Cephalon GmbH is the German affiliate of the biopharmaceutical company Cephalon Inc. headquartered in Frazer, Pennsylvania. Cephalon GmbH markets and promotes drugs for the treatment of epilepsy, Parkinson's Disease, narcolepsy, bipolar disorders, breakthrough cancer pain and leukemia with its own sales forces in Germany, Austria and Switzerland.



Contact:
Julia von Hummel

Fraunhoferstr. 9a
D-82152 Martinsried
Phone: +49 (0) 89 895570-0
Fax: +49 (0) 89 895570-15
E-Mail: aroemer@cepalon.de
Internet: www.cepalon.de



Contact:
Dr. Andrea Kofler

Mühlenstr. 1
D-83064 Raubling
Phone: +49 (0) 8035 9849-28
Fax: +49 (0) 8035 9849-30
E-Mail: kofler@chrombios.com
Internet: www.chrombios.com

ChromBios GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Founded in 1998, ChromBios is focused on the field of Molecular Cytogenetics (fluorescence in situ hybridisation, FISH). The company's aims are to provide service and products for chromosome analysis tailored to the needs of the customers. We offer "FISH service" such as chromosome analysis with "chromosome painting", mapping of clones, characterisation of cancer cell lines and animal models in genome research. We especially focus on multi colour karyotyping human tumour cells and other transformed cell lines (for example for patent applications). ChromBios also offers multi colour chromosome painting of mouse cells to identify translocations in mouse tumours and to characterise mouse ES cells. Apart from human and mouse, we also provide service in the characterization of chromosomes from other animal model species including rat, hamster, cat, and various live stock animals.



Contact:
Astrid Birkmayer

Guerickestraße 25
D-80805 München
Phone: +49 (0) 89 189292-36
Fax: +49 (0) 89 189292-92
E-Mail: abirkmayer@clintec.com
Internet: www.clintec.com

ClinTec GmbH

CRO

Keywords: Clinical Research, Medical Writing, Oncology, Drug Development

ClinTec International is committed to providing high-quality clinical research support to the pharmaceutical and biotechnology industries. In the endeavour towards clinical development of medicines for the benefit of mankind, we provide a wide range of services with the key advantage of cost-effectiveness. We work as a Full Service CRO, Global Clinical Resourcing and Consultancy.

CNAssays GmbH

Contact:
Ludwig Aigner

Josef-Engert-Str. 9
D-93053 Regensburg
Phone: +49 (0) 941 944-8950
Fax: +49 (0) 941 944-8951
E-Mail:
ludwig.aigner@klinik.uni-regensburg.de
Internet: www.cnassays.com

CNAssays GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

CNAssays® is a start-up company active in drug discovery in the field of regenerative medicine for central nervous system (CNS) diseases such as Alzheimer's disease, Parkinson's disease and stroke. For a long time it was thought that neurons were only produced during the embryonic and early postnatal period. However, recent breakthroughs have overturned this dogma and it is now clear that new neurons continue to be generated in the adult brain from stem cells. CNAssays® uses its proprietary technology for the analysis of potential therapeutics to stimulate endogenous CNS stem cells in order to generate new nerve cells and to regenerate the CNS.

CodonSense Biosystems GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, Analytical Chemistry, Aptamer Technology, Chip / Array Technology, Proteomics, Oncology

The main goal of the CodonSense Biosystems GmbH is to develop diagnostic tools for human diseases and cell profiling concerned with ribonuclease, expression defects and codon usage. Codonsense Biosystems GmbH has been funded by the german government: Federal Ministry of Education and Research (BMBF) in the framework of the program "EXIST SEED" promoting business start ups from university research.



Contact:
Dr. Merold Müller

Kriegerstr. 24h
D-82110 Germering
Phone: +49 (0) 89 89211298
Fax: +49 (0) 89 89211298
merold.mueller@codonsensebiosystems.com
www.codonsensebiosystems.com

conoGenetix biosciences GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Peptide/Protein, CNS, Pain, Cardiovascular Diseases

conoGenetix biosciences GmbH is a biotechnology company that focuses on the development of peptide-based drugs for the treatment of currently untreatable neurological and cardiovascular disorders. These therapeutics – isolated from complex animal venoms – display the advantage of an extremely high specificity resulting in reduced side effects for the patient. Alliances with academic research groups and a network of co-operators throughout the world enhance the company's capabilities of drug discovery and development.



Contact:
Dr. Andreas Klostermann

Helmholtz Zentrum München
Institut für Toxikologie (Haus 57)
Ingolstädter Str. 1
D-85764 München
Phone: +49 (0) 89 74080520
Fax: +49 (0) 89 74080588
E-Mail: info@conogenetix.de
Internet: www.conogenetix.de

Conreso GmbH

CRO

Keywords: Clinical Research, Logistics, Monitoring, Medical Writing, Pharmacology

Conreso GmbH, established in 1990, is an independent CRO offering a wide range of high-quality clinical research and development services. Conreso is a member of the Bundesverband Medizinischer Auftragsinstitute (BVMA) and is subject to that organization's regular independent system audits. The company shows an impressive record of significant contributions to important developmental programs and new product licenses in Europe and the USA. The Hannover Clinical Trial Center (HCTC), a joint venture of Conreso and the Hannover Medical School (MHH), provides Conreso's clients access to the clinical expertise and the comprehensive diagnostic and therapeutic facilities of one of the leading academic medical institutions in Germany.



Contact:
Jürgen Schäfer

Neuhauser Str. 47
D-80331 München
Phone: +49 (0) 89 236650-0
Fax: +49 (0) 89 236650-50
E-Mail: info@conreso.com
Internet: www.conreso.com



Contact:
Dr. Günter Wich

Zielstattstr. 20
D-81379 München
Phone: +49 (0) 89 74844-263
Fax: +49 (0) 89 74844-350
E-Mail: guenter.wich@wacker.com
Internet: www.wacker.de



Contact:
Dr. Goetz Münch

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 700 655 57
Fax: +49 (0) 89 700 655 43
E-Mail: muench@corimmun.com
Internet: www.corimmun.com



Contact:
Christian Huber

Schindmühlenerstr. 53
D-93133 Burglengenfeld
Phone: +49 (0) 9471 307 50
Fax: +49 (0) 9471 307 501
E-Mail: welcome@cowatec.com
Internet: www.cowatec.com

Consortium für elektrochemische Industrie GmbH

BIOTECH DEVICES & REAGENTS

The Consortium für elektrochemische Industrie GmbH is the corporate research facility of Wacker Chemie GmbH. At the Consortium about 200 employees, which are organised in 30 research groups, are working in five areas of research: catalysis, polymers, function materials, organic synthesis and biotechnology. With core competences like biotransformation, metabolic engineering, protein production and fermentation, the research unit Biotechnology is mainly focused on production of biologicals and on the development of biological systems for synthesis of chiral organic compounds like cyclodextrins, amino acids and chiral alcohols.

Corimmun GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Peptide/Protein, Cardiovascular Diseases, Inflammation

CORIMMUN is a spin-off from the universities of Würzburg and of Tübingen. The projects are funded by two grants of the GoBio project of the BMBF. Corimmun is funded by the Hightech Gründerfonds, Bayernkapital and Bio-M. The company will develop high-profile new drugs to treat congestive heart failure and atherosclerosis, the most common causes of mortality in developed countries. Two innovative products COR-1 and COR-2 are currently in preclinical development. COR-1 is a peptide drug candidate to prevent the auto-antibody-mediated propagation of heart failure. COR-2 is a biological which prevents foam cell formation in atherosclerotic plaques. The founders and management of Corimmun bring together knowledge and reputation in research and clinical medicine together with biotech experience.

Cowatec AG

BIOTECH AGRO, FOOD, ENVIRONMENT

Cowatec AG, based in Burglengenfeld in Bavaria, specialises in hi-tech biogas plants for the efficient generation of energy. Its range of services covers the planning, construction and operation of new plants, as well as the project optimisation of existing biogas projects.

CRELUX GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: 3 D Structural Analysis

CRELUX provides fast and affordable access to co-crystal structures of your compounds in complex with their protein targets. Crystallization conditions of numerous relevant therapeutic targets have been established at CRELUX.

Co-crystal structures of these targets in complex with your compounds of interest will be delivered at a fixed price with a typical turn around time of six to eight weeks.

At CRELUX we do everything to protect your most important asset: compound IP. We are entirely dedicated to solving client structures and don't perform any internal screening and drug discovery activities. Please enquire to find out if structural services for your targets of interest are available from CRELUX.



Contact:
Sonja Knoth

Am Klopferspitz 19a
D-82152 Martinsried
Phone: +49 (0) 89 700 760-170
E-Mail: schaeffer@crelux.com
Internet: www.crelux.com

CRENANO GmbH

BIOTECH DEVICES & REAGENTS

Keywords: New Materials, Devices

CRENANO GmbH has developed the JETHAMMER™, a novel device for microbial disruption, water treatment and the generation of emulsions and nano particles. The technology makes use of the energies set free by hydrodynamic cavitation. Moderate hydrostatic pressure (5 to 10 bar) is used to induce controlled three dimensional zones of supercavitation that can readily be adjusted to disrupt micro organisms, crush particles down to nano metre scales and generate stable emulsions. The JETHAMMER™ operates in a flow through process allowing flow rates of up to 50m³/h. CRENANO is the sole supplier of JETHAMMER™ and offers the full system engineering for the integration of the device into industrial production processes and water circuits.



Contact:
Sonja Knoth

Am Klopferspitz 19a
D-82152 Martinsried
Phone: +49 (0) 89 700760170
Fax: +49 (0) 89 700760222
E-Mail: schaeffer@crenano.com
Internet: www.creanano.com

CRO-PHARMANET SERVICES GmbH

CRO

Keywords: Drug Development, Antibody, Antisense/Nucleotides, Small Molecules, Vaccines, Analysis, Clinical Research

PharmaNet Development Group, a global, drug development services company, provides clinical development services including consulting, Phase I and bio-equivalence clinical studies, Phase II-III clinical development programs, Phase IIIb-IV surveys, registries, and programs, as well as bioanalytical laboratory services through its subsidiaries Anapharm, Anapharm Europe, Keystone Analytical, and Taylor Technology.



Contact:
Dr. Tobias Schmidt

Pionierstr. 2 / KIM
D-82152 Krailling
Phone: +49 (0) 89 895577-77
Fax: +49 (0) 89 895577-99
E-Mail: tschmidt@pharmanet.com
Internet: www.pharmanet.com



Contact:
Dr. Bettina Kipp

Grillparzerstr. 14
D-81675 München
Phone: +49 (0) 89 2000 14210
Fax: +49 (0) 89 2000 14279
E-Mail: Bettina.Kipp@curacyte.com
Internet: www.curacyte.com

Curacyte AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Small Molecules, Cardiovascular Diseases, Multi organ failure

Curacyte AG is a research-based biopharmaceutical company dedicated to the discovery and development of hospital therapeutics for acute and critical care conditions.

Curacyte's pipeline comprises projects from discovery to late-stage clinical development. Hemoximer (PHP, pyridoxalated hemoglobin polyoxyethylene) is the company's most advanced drug candidate and is about to enter a pivotal phase III trial as treatment for patients suffering from distributive shock.



Contact:
Dr. Heike Wöhling

Haringstr. 19
D-85635 Höhenkirchen
Phone: +49 (0) 8102 8950 6
Fax: +49 (0) 8102 8950 89
E-Mail: info@dabio.com
Internet: www.dabio.com

DABIO Gesellschaft für Auftragsforschung mbH

CRO

Keywords: Drug Development, Allergy, Cardiovascular Diseases, Dermatology, Hepatology, Oncology, Ophthalmology, Pain, Respiratory Diseases, Rheumatology

DABIO is a privately owned, independent CRO founded in 1994. DABIO provides a wide range of cost effective services as an external R&D partner for pharma and biotech companies. DABIO's qualified staff has many years of industrial experiences. We provide full or partial services for clinical trials phase II-IV, post marketing surveillances and phase I trials in cooperation with different partners. Our services include concept and protocol development, trial administration and monitoring, data management, biometrics and medical writing according to ICH-GCP guidelines and national law. DABIO provides special services such as pharmacoconomics, expert reports, publications, organization of meetings and online solutions for EDC.



Contact:
Olaf Lamberz

Zielstattstr. 48
D-81379 München
Phone: +49 (0) 89 7808-442
Fax: +49 (0) 89 7808-288
E-Mail: olaf_lamberz@sankyo-pharma.com
Internet: www.sankyo-pharma.com

Daiichi Sankyo Europe GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Drug Development, Antibiotics, Bone / Joint Diseases, Cardiovascular Diseases, Infectious Diseases, Metabolic Diseases, Oncology

Daiichi Sankyo Europe GmbH's R&D activities centre around a permanent increase of our broad product line, with focus on the priority fields:

- Cardiovascular diseases ■ Carbohydrate metabolic diseases ■ Bone and joint diseases ■ Immunological and allergic diseases ■ Cancer ■ Infectious diseases

Daiichi Sankyo Europe GmbH is recognised for being among the leading pharmaceutical companies with the broadest spectrum of products affecting the atherosclerosis continuum:

Olmesartan (A-II receptor blocker), Pravastatin (HMG-CoA reductase inhibitor), CS 505 (Pactimibe, ACAT inhibitor, phase II), CS 011 (antidiabetic, Glitazone, phase II), CS 917 (antidiabetic, gluconeogenesis inhibitor, phase II) and CS 747 (Antiplatelet, ADP-receptor-antagonist, phase III). Daiichi Sankyo Europe GmbH's concerted research approach does ideally link our high R&D efforts to the benefits for doctors and patients.

Definiens AG

BIOTECH BIOINFORMATICS

Keywords: Drug Development, 3 D Structural Analysis, Automation, Microscopy, Oncology, Toxicology, Analysis

Definiens is the number one Enterprise Image Intelligence company for analyzing and interpreting images on every scale – from microscopic cell structures to satellite images. Based on human cognitive perception processes, Nobel laureate Prof. Gerd Binnig developed the Definiens Cognition Network Technology® to extract intelligence from images.

Definiens enables Life Science organizations to analyze and interpret vast numbers of images accurately and consistently. By automating image analysis processes, Definiens improves the measurement of cell assays, the examination of tissue samples and the interpretation of non-invasive imaging, enabling high-content screening and digital pathology.



Contact:
Mark Watson

Trappentreustr. 1
D-80339 München
Phone: +49 (0) 89 231180-0
Fax: +49 (0) 89 231180-90
E-Mail: mwatson@definiens.com
Internet: www.definiens.com

DiaServe Laboratories GmbH

BIOTECH DEVICES & REAGENTS

DiaServe is a primary manufacturer of human and animal blood derived raw materials for diagnostic industry. Based on this raw materials DiaServe also offers tailor-made in vitro controls/calibrators for medical laboratories. The company was established in 1997 with a mission to identify, develop and manufacture in vitro diagnostics mainly on OEM basis for diagnostic manufacturers and clinical laboratories.



Contact:
Dr. Ulf Henseling

Seeschafter Str. 27
D-82393 Iffeldorf
Phone: +49 (0) 8856 803605
Fax: +49 (0) 8856 803607
E-Mail: DiaServe@t-online.de
Internet: www.diaserve.de

Diavir GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, ELISA / EIA

Diavir GmbH focuses on the development of innovative diagnostics for viral and bacterial infections, especially of ELISA kits based on synthetic peptides. Another main focus of Diavir is the development of novel gene assembly systems and highly efficient DNA vaccines using synthetic sequences, which are improved in terms of immunogenicity and safety.



Contact:
Dr. Octavian Schatz

Steinbergstr. 30
D-85250 Altomünster
Phone: +49 (0) 89 21806852
Fax: +49 (0) 89 21806855
E-Mail: haas@lmb.uni-muenchen.de
Internet: www.diavir.de



Contact:
Dr. Franz Kerek

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 856625-55
Fax: +49 (0) 89 856625-56
E-Mail: kerek@donatur.de
Internet: www.donatur.de

DoNatur GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Rheumatology

DoNatur GmbH develops new therapeutics from herbal extracts with traditionally confirmed therapeutic efficiency. The comprehensive analysis of the genuine extracts, the isolation and structural characterization of the active substances and the test of their pharmacological activities constitutes the main competence of the company. Over the last years DoNatur has successfully developed a new immunomodulatory acting natural substance which has been proved highly efficacious for the therapy of rheumatic diseases.



Contact:
Dr. Reinhard Nibler

Fürstenriederstr. 105
D-80686 München
Phone: +49 (0) 89 56823726
Fax: +49 (0) 89 92185265
E-Mail: mail@dr-nibler.de
Internet: www.dr-nibler.de

Dr. Nibler & Partner

CRO

Keywords: Clinical Research, Monitoring, Medical Writing

We deliver medical consulting services for customers throughout the health care system – Enterprises of the pharmaceutical and medical devices industry, but also service providers in the area of training and certification. The focuses of our consulting services are quality management, pharmacovigilance as well as medical-scientific advice and technical translations. We deliver services, oriented on our customers' straight and practical needs.



Contact:
Dr. Hans-Peter Klenk

Poeckinger Fussweg 7a
D-82340 Feldafing
Phone: +49 (0) 8157-9963-164
Fax: +49 (0) 8157-9963-162
E-Mail: info@egene-biotech.de
Internet: www.egene-biotech.de

e.gene Biotechnologie GmbH

BIOTECH BIOINFORMATICS

Keywords: Genomics, Pharmacogenomics

e.gene Biotechnologie GmbH is a service provider in microbial genomics and pharmacogenomics.

We perform for our academic and industrial customers complete microbial genome analyses from genome sequencing to annotation and pathway reconstruction.



Contact:
Staffelseestr. 8
D-81477 München
Phone: +49 (0) 89 7240608-02
Fax: +49 (0) 89 7240608-30
E-Mail: info@egomedical.com
Internet: www.egomedical.de

egomedical AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

egomedical AG, based in Munich, Germany, develops and produces innovative and effective biochemical test systems for the patient self-monitoring market. The monitoring of metabolic markers and parameters as well as diet-related risk factors plays a major role in our solutions. Our technology complies with the required cost reduction of health care providers as well as demanding quality standards for delivering optimal patient systems.

ELLA Biotech GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, Fine Chemicals / Reagents, Clinical Research, Antisense/Nucleotides, Genomics, RNAi & Antisense

Our focus is the synthesis of special oligoribonucleotides for selected projects in diagnostics, chip technologies, genesynthesis and further topics – following quality standards which you would appreciate and expect in your own lab. The guidelines for the synthesis standards can be defined by our customers themselves.

Through our validated technology platform, our experienced interdisciplinary team and our resolute attitude towards the highest quality in our products we offer tangible advantages to our customers and partners.



Contact:

Dr. Peter Frischmann

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 70939316
Fax: +49 (0) 89 70939440
E-Mail: info@ellabiotech.com
Internet: www.ellabiotech.com

Emergent Product Development Germany GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Vaccines, Infectious Diseases, Gene Transfer

Emergent BioSolutions Inc. is a biopharmaceutical company dedicated to one simple mission – to protect life. The company develops, manufactures and commercializes immunobiologics, consisting of vaccines and therapeutics that assist the body's immune system to prevent or treat disease. The company's biodefense business focuses on immunobiologics for use against biological agents that are potential weapons of bioterrorism and biowarfare. Emergent's marketed product, BioThrax® is the only vaccine approved by the U.S. FDA for the prevention of anthrax infection. The commercial business focuses on immunobiologics for use against infectious diseases and other medical conditions that have resulted in significant unmet or underserved medical needs. The company currently employs over 500 people worldwide.



Contact:

Petra Willnauer

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 895449-28
Fax: +49 (0) 89 895458-81
E-Mail: hartmanna@ebsi.com
Internet: www.emergentbiosolutions.com

Emergent Sales and Marketing Germany GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Vaccines, Infectious Diseases

Emergent BioSolutions Inc. is a biopharmaceutical company dedicated to one simple mission – to protect life. The company develops, manufactures and commercializes immunobiologics, consisting of vaccines and therapeutics that assist the body's immune system to prevent or treat disease. The company's biodefense business focuses on immunobiologics for use against biological agents that are potential weapons of bioterrorism and biowarfare. Emergent's marketed product, BioThrax® is the only vaccine approved by the U.S. FDA for the prevention of anthrax infection. The commercial business focuses on immunobiologics for use against infectious diseases and other medical conditions that have resulted in significant unmet or underserved medical needs. The company currently employs over 500 people worldwide.



Contact:

Dr. Andreas Hartmann

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 856897-70
Fax: +49 (0) 89 895458-81
E-Mail: hartmanna@ebsi.com
Internet: www.emergentbiosolutions.com



Contact:
Christiane Proll

St.-Veit-Weg 2
D-93051 Regensburg
Phone: +49 (0) 941 9468360
Fax: +49 (0) 941 9468366
E-Mail: deininger@entelechon.de
Internet: www.entelechon.com

Entelechon GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Antibody Production Service, Genomics, Gene Transfer, PCR, Antibody, Proteomics, Peptide/Protein

Regensburg biotech-venture Entelechon GmbH is an expert in providing integrated solutions in synthetic biology. Entelechon GmbH is mainly focused on the production of optimized and customized artificial DNA sequences based on a highly flexible and efficient gene synthesis platform with high-through-put manufacturing with guaranteed product quality. Complex gene sequences are processed with specialized technologies developed in-house based on several years of experience.

Entelechon also provides proteome solutions (expression profiling, protein expression upscaling and protein purification) and manufacturing of protein-based diagnostics with the innovative QconCat technology.

A highly-advanced bioinformatic platform completes the synthetic biology service with in silico solutions.

...EPICEPT GmbH

Contact:
Uschi Lang

Goethestr. 4
D-80336 München
Phone: +49 (0) 89 680872-0
Fax: +49 (0) 89 680872-20
E-Mail: info@epicept.de
Internet: www.epicept.com

EpiCept GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Drug Development, Pain

EpiCept GmbH is a subsidiary of EpiCept Corp. (Englewood Cliffs, NJ) which is a specialty niche pharmaceutical company that applies proprietary topical technologies to develop new drugs and improved formulations of existing drugs for the prescription pain management market. The pain product candidates address unmet medical needs for lower back pain, post-operative incisional pain, neuropathic pain as well as other pain indications. EpiCept's product candidates offer potentially enhanced pain relief, improved side effect profiles, are potentially additive to systemically administered therapies, can eliminate systemic drug interactions and can be opioid sparing in their analgesic effect.



Contact:
Vera Sturma

Am Neuland 1
D-82347 Bernried
Phone: +49 (0) 8158 99 85 0
Fax: +49 (0) 8158 99 85 48
E-Mail: contact@epidauros.com
Internet: www.epidauros.com

EPIDAUROS Biotechnologie AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, Pharmacogenomics, Pharmacogenetics, Drug Development, Genomics

Epidauros Biotechnologie AG, subsidiary of Clinical Data Inc., is a leading Pharmacogenetic Research Organization delivering innovative and integrated solutions from sample preparation to clinically relevant output based on its unique expertise, skill set and own clinically valid intellectual property. Epidauros holds one of the broadest portfolios of pharmacogenetic-related assays in the industry. The company has a very strong track record in the field of high quality clinical genotyping with about 400 studies performed to date from small scale to multicenter trials. Epidauros analyses variations of genes that encode for e.g. drug transporter proteins, metabolizing enzymes and targets. Epidauros is geared towards becoming the worldwide leading enabler of Personalized Medicine solutions for Pharma and Diagnostic industry.

EpiGene GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: Agrobiotechnology, Genomics

EpiGene GmbH, founded in 1999, is a genomics-based research and development company focusing on applications in plant protection. The core competences comprise the molecular characterization of plant-pathogen interactions and the development of high throughput systems for molecular diagnostics of involved genetic factors. In addition, research efforts include investigations of the mode of action of plant protective agents at the molecular level and the identification of mutations or differentially expressed genes in pathogens as potential new targets.

EpiLogic GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: Agrobiotechnology, Genomics

EpiLogic is a new European wide operating company involved in product development based on genomic analysis of fungal pathogens propagated by wind in agricultural crops (at present: cereals and vine). Pathogen analysis of virulence and fungicide sensitivity are used as decision support for breeding, choice of cultivar and fungicide management to ensure sustainable agriculture. A genotype bank of several pathogens is currently being set up to offer high quality inoculum for selection in laboratory, greenhouse and field. Additionally, methods are under development for analysing and culturing new pathogens.

essex pharma GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Drug Delivery

essex pharma is the German subsidiary of a multinational U.S.-based company, leading in research of pharmaceutical and health care products with a strong position in biotechnology. 2.2 billion US \$ were spent on R&D in 2006. The most prominent result in biotech is interferon alfa-2b for several anti-cancer and anti-viral indications, later as pegylated interferon alfa-2b in hepatitis C. essex pharma supplements its range by partnerships and licensing of new biotech products, i.e. in immunology with infliximab, an immune modulating agent, for the treatment of Crohn's disease, colitis ulcerosa, spondylitis, rheumatoid and psoriatic arthritis. Further innovative products for cardiovascular diseases and in oncology, hepatology, allergology, dermatology and pulmology belong to the portfolio.

EPIGENE

Contact:

Dr. Friedrich G. Felsenstein

Hohenbachernstr. 19-21
D-85354 Freising
Phone: +49 (0) 8161 4990-80
Fax: +49 (0) 8161 4990-89
E-Mail: Friedrich.Felsenstein@EpiLogic.de
Internet: www.epigene.de



Contact:

Dr. Friedrich G. Felsenstein

Hohenbachernstr. 19-21
D-85354 Freising
Phone: +49 (0) 8161 4990-80
Fax: +49 (0) 8161 4990-89
E-Mail: Friedrich.Felsenstein@EpiLogic.de
Internet: www.EpiLogic.de



Contact:

Inge Bartel

Thomas-Dehler-Str. 27
D-81737 München
Phone: +49 (0) 89 62731-293
Fax: +49 (0) 89 62731-292
E-Mail: werner.weis@essex.de
Internet: www.essex.de



Contact:
Felix Raslag

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 12 59 81-0
Fax: +49 (0) 89 12 59 81-19
E-Mail: info@eticur.de
Internet: www.eticur.de

eticur GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

eticur) is headquartered in the IZB in Martinsried and cooperates with the Department of Transfusion Medicine and Haemostaseology of the University Hospital of Erlangen. Based on the idea that umbilical cord blood contains multipotent adult stem cells, the cord blood is prepared and stored for potential later use. These cells might in future play an important role in therapies including regenerative medicine. Our priority is to grant the most secure storage, highest quality and extensive testing by highly qualified personnel. eticur) grants the storage of stem cells following the highest quality-standards of the Federal Board of Physicians and the Institute for Sera and Vaccine (Paul-Ehrlich-Institute).



Contact:
Dr. Brigitte Obermaier

Fraunhoferstr. 22
D-82152 Martinsried
Phone: +49 (0) 89 899892-0
Fax: +49 (0) 89 899892-90
E-Mail: info@medigenomix.de
Internet: www.medigenomix.de

Eurofins Medigenomix GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Agrobiotechnology, Genomics, Pharmacogenetics, Clinical Research, Analysis

Eurofins Medigenomix is specialised in DNA analysis. Since foundation in 1998 it has evolved into a recognised reliable outsourcing partner for the biopharmaceutical industry and academic institutions for high fidelity DNA sequencing incl. GLP sequencing and molecular biological techniques. It expanded successfully with services for DNA forensics, animal and plant breeding, food authenticity testing and health care. Medigenomix is e.g. the largest private owned lab providing DNA profiles for the National German Forensic Database. Special strength is the extensive experience with all kinds of DNA-samples for various applications. Medigenomix is audited by pharmaceutical clients for GLP, certified according to ISO 9001 and according to ISO 17025.



Contact:
Albert Stumpf

Aubinger Str. 30
D-82166 Gräfelfing
Phone: +49 (0) 89 895300-24
Fax: +49 (0) 89 895300-25
E-Mail: info@fermcom.de
Internet: www.fermcom.de

FermCom Bio-VNT Biologische Verfahrenstechnik und Netzwerk-Technologie

BIOTECH DEVICES & REAGENTS

Keywords: Devices, Monitoring

FermCom Bio-VNT is a research and development company focused on biotechnology and network applications. FermCom Bio-VNT is in development of an innovative in-situ online-analysis system by using a high-technology bioreactor. With the help of the device for classification of biomolecules in liquid there will be new technologies brought together to a new biosensor system "Multisensor-MiniLab". The use of bio-chips allows to miniaturize online real-time-analysis. In cooperation with appropriate high-tech partner companies FermCom Bio-VNT creates a national / international network via Internet / Intranet for data tele-transfer. International patent-applications (PCT) are the cornerstone of the company's strategy. FermCom's field of activity is development a new compact system for non-invasive process-monitoring in the area of biotechnology, fermentation- and environment-analytics.

FGK Clinical Research GmbH

CRO

Keywords: Clinical Research, Drug Development

As contract research organization FGK Clinical Research GmbH in connection with a network of partners provides a wide range of services in drug and medical device development, from early conception until final report (statistical consulting, project management, monitoring, data management, statistical analysis, medical writing). FGK has a focus on biotech and medical device companies which need more support and consulting in the clinical drug development process than pharmaceutical companies. In detail, services offered include: Phase I trials in cooperation with university-based pharmaceutical institutions, Phase II-IV trials, Post marketing surveillance, and special services such as Pharmacoeconomics, Quality of life reviews, Expert reports, and Organization of Opinion-Leader Meetings.



Contact:
Martin Krauss

Heimeranstr. 35
D-80339 München
Phone: +49 (0) 89 893119-0
Fax: +49 (0) 89 893119-20
E-Mail: martin.krauss@fgk-cro.de
Internet: www.fgk-cro.de

FGK Representative Service GmbH

CRO

Keywords: Drug Development, Clinical Research

FGK Representative Service GmbH was founded as a subsidiary of FGK Clinical Research GmbH and Dr. Anthony W. Fox, Carlsbad, CA, to offer the service of legal representation for sponsors outside the European Community. According to European legislation (2001/20/EC), an EU based legal representative is a prerequisite for trials initiated by sponsors that are not established inside the European Community. As a legal representative, FGK Representative Service GmbH may act on behalf of a sponsor concerning interaction with local ethics committees and local authorities as well as liability and indemnity. This service is not limited to studies overseen by the parent company FGK Clinical Research GmbH, but it is open for studies performed by other CROs, pharmaceutical, biotech or virtual companies.



Contact:
Dr. Edgar J. Fenzl

Heimeranstr. 35
D-80339 München
Phone: +49 (0) 89 893119 22
Fax: +49 (0) 89 893119 20
E-Mail: edgar.fenzl@fgk-rs.com
Internet: www.fgk-rs.com

Fresenius Biotech GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Drug Development, Hematology, Immune Therapy, Antibody, Cell Therapy, Gene Therapy, Oncology

Fresenius Biotech GmbH, a company of the Fresenius Health Care Group, focuses on the clinical development and marketing of biopharmaceuticals in the fields organ transplantation, oncology, viral infection and organ regeneration. Fresenius Biotech's Antibody Division includes the production and marketing of the immunosuppressive agent ATG Fresenius S and, together with TRION Pharma GmbH, the clinical development of the trifunctional antibodies catumaxomab and ertumaxomab for cancer therapy. The Cell Therapy Division concentrates on the development of innovative strategies for treatment of AIDS, tolerance induction and organ regeneration.



Contact:
Dr. Axel Wiest

Am Haag 6-7
D-82166 Gräfelfing
Phone: +49 (0) 89 30 65 93 39
Fax: +49 (0) 89 30 65 93 67
E-Mail: info@fresenius-biotech.com
Internet: www.fresenius-biotech.com



Contact:
Thomas Kratzmüller

Floriansbogen 2 - 4
D-82061 Neuried
Phone: +49 (0) 89 72 44 09-0
Fax: +49 (0) 89 72 44 09-10
E-Mail: info@frizbiochem.de
Internet: www.frizbiochem.de

FRIZ Biochem Gesellschaft für Bioanalytik mbH

BIOTECH DEVICES & REAGENTS

Keywords: Clinical Diagnostics, Devices, Infectious Diseases, Chip / Array Technology

FRIZ Biochem develops and produces highly reliable user-friendly and inexpensive biochip systems for applications in medical diagnostics, food testing and pharmaceutical research. Key products are DNA-chips with direct electrical read-out where SNPs (single nucleotide polymorphism) can unambiguously be detected and time-consuming labeling of the target-DNA is no longer necessary. This enables a broad range of simple and fast analyses making the system ideal for biological medical studies. The company's proprietary combination of micro arrays, electrical detection and semiconductor technology opens the way to compact multiplex analyses directly at a PC without the expensive instrumentation commonly needed.



GE imagination at work

Contact:
Rudolf Beyenburg

Oskar-Schlemmer-Str. 11
D-80807 München
Phone: +49 (0) 212 2802-0
Fax: +49 (0) 212 2802-28
E-Mail: Rudolf.Beyenburg@ge.com
Internet: www.gehealthcare.com

GE Healthcare Europe GmbH

MEDTECH

GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, performance improvement, drug discovery, and biopharmaceutical manufacturing technologies is helping clinicians around the world re-imagine new ways to predict, diagnose, inform and treat disease, so their patients can live their lives to the fullest.

Our vision for the future is to enable a new "early health" model of care focused on earlier diagnosis, pre-symptomatic disease detection and disease prevention.



Contact:
Dr. Jorge Garcia

Gut Keferloh 1c
D-85630 Grasbrunn b. München
Phone: +49 (0) 89 456729 15
Fax: +49 (0) 89 456729 18
E-Mail: jgarcia@MZD.de
Internet: www.MZD.de

Geelen & Geelen GmbH MZD (Recruiting Department)

CRO

Monitor Zentrale Deutschland (MZD) a department of Geelen & Geelen GmbH, is a clinical research service provider, located in Grasbrunn near Munich. It started in 1994 as a monitoring service and has become an agency for the recruitment (out- and in-sourcing) of temporary experienced freelance clinical research professionals for the R&D sector (e.g. CRAs, Study Nurses, Project Managers, Medical Writers, Regulatory Affairs and Drug Safety Managers, Clinical Trials Administrators or Coordinators, Data Managers. Besides this Geelen & Geelen is the publisher of the German Magazine of Clinical Research (Deutsche Zeitschrift für Klinische Forschung www.dzkf.de).

GENEART AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Genomics, Combinatorics

GENEART provides integrated system solutions for DNA engineering and processing based on the gene synthesis technology platform to deliver improved drugs and biotech products. The services portfolio ranges from the production of optimized synthetic genes and the generation of gene variants and gene libraries in combinatorial biology (gene evolution) right through to the production of DNA-based agents.



Contact:
Bernd Merkl

Josef-Engert-Str. 11
D-93053 Regensburg
Phone: +49 (0) 941 942-760
Fax: +49 (0) 941 942-7611
E-Mail: ralf.wagner@geneart.com
Internet: www.geneart.com

Genedata Bioinformatik GmbH

BIOTECH BIOINFORMATICS

Genedata is a bioinformatics company that specializes in developing software systems for the comprehensive analysis of genomes, transcriptomes, proteomes, metabolomes, and biochemical compounds. By working closely with key partners, the company combines its extensive product portfolio with expert scientific consulting services to offer tailor-made solutions for specific applications and multiple therapeutic areas. The company's solutions are key for moving the focus of life science research from high-throughput data acquisition to high-content data interpretation. Founded in 1997 as a spin-off from Novartis, the company is headquartered in Basel (Switzerland) with branch offices in Munich (Germany), San Francisco (USA), and Boston (USA).



Contact:
Dr. Peter Haberl

Lena-Christ-Str. 50
D-82152 Martinsried
Phone: +49 (0) 89 8951102-0
Fax: +49 (0) 89 8951102-15
E-Mail: peter.haberl@genedata.com
Internet: www.genedata.com

Genedia AG Biotec Services and Products

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Medicinal Chemistry, Genomics, Antisense/Nucleotides

Genedia AG Biotec Services and Products is a provider of DNA testing services including private DNA paternity testing, legal DNA paternity testing as well as other relationship testing services (full or half sibling testing, grandparents testing, aunt or uncle testing, 1st cousin testing, maternity testing as well as twin testing). An other area is DNA genealogy and anthropology, which includes ancestral origin DNA population test, Y-Chromosome Analysis, mt-DNA analysis. The forensic area includes DNA identification and banking services forensic testing services especially stain analysis. DNA molecular testing of diseases (Factor V and II, MTHFR, CFTR-Mutation). DNA testing of animals.



Contact:
Dr. biol. hom. Hildegard Haas

Schwanthalerstr. 60
D-80336 München
Phone: +49 (0) 89 54 34 48 0
Fax: +49 (0) 89 54 34 48 20
E-Mail: info@genedia.de
Internet: www.genedia.de



Contact:
Dr. Albert Röder

Am Neuland 1
D-82347 Bernried
Phone: +49 (0) 8158 9223-0
Fax: +49 (0) 8158 9223-35
E-Mail: a.roeder@genelux.de
Internet: www.genelux.de

Genelux GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Drug Development, Clinical Diagnostics, Drug Delivery, Immune Therapy, Oncology

Genelux Corp., San Diego, CA, US, was founded in 2001. Its assets are built on its founder's experience on genetically modified light-emitting bacteria, viruses and mammalian cells:Luminescent or fluorescently labelled microorganisms, when injected into tumor bearing mice, specifically colonize tumors plus metastases and can be imaged. They grow and replicate within the tumors. Tumors are remitted.

These scientific results should enable diagnosis and treatment of cancer, combining in vivo imaging (diagnostics) with bacteria/virus induced tumor regression (therapy), and should add a potent theragnostic alternative to existing therapies and diagnostics.Genelux GmbH, Bernried, Germany, was established mid 2004 and aims to translate the scientific results into commercial services and products.



Genetic ID (Europe) AG

Contact:
William F. Thompson

Am Mittleren Moos 48
D-86167 Augsburg
Phone: +49 (0) 821 747 76-30
Fax: +49 (0) 821 747 76-39
E-Mail: info@genetic-id.de
Internet: www.genetic-id.de

Genetic ID (Europe) AG

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: ELISA / EIA, Genomics, PCR, Analysis

Genetic ID is a global leader in testing for the presence of genetically modified organisms (GMOs) in food and agricultural products. In addition Cert IDSM, the first internationally operating certification program for "Non-GMO" products, provides documented traceability. Founded in 1996, Genetic ID Inc. maintains global headquarters in USA, as well as premier testing laboratories in Japan and Germany, offices in Brazil, and the Global Laboratory Alliance of affiliated laboratories and representatives spanning five continents. We develop technologies that address all aspects of the GMO-testing segment and provide all clients with the technology, services and information they need to operate in the increasingly high-tech global marketplace.

Genetix GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Fine Chemicals / Reagents, Devices, Automation, Chip / Array Technology, Microscopy

Genetix GmbH is the German subsidiary of Genetix Ltd., New Milton, UK. Genetix is a pioneer in the development of automated systems for use in scientific research. The company was founded in 1991 to design, manufacture and market equipment and consumables for use in genome research. By evolving to meet market needs Genetix has achieved excellent growth both in turnover and profits, and in November 2000 went public on the London Stock Exchange (LSE). Genetix designs, develops and produces innovative equipment, consumables and reagents for the following markets: Genomics, Proteomics, High Throughput Screening and Cell Biology. For most of these applications services are provided as well. Genetix is well known for its QBot and QPix colony pickers and has launched its new micro-arrayer and scanner family in 2001. The German subsidiary markets the complete Genetix product range in Germany, Austria and Switzerland and is interested in collaborations with research scientists for developing new technologies.

Genetix

Take the lead

Contact:

Dr. Miguel Jimenaez

Humboldtstr. 12

D-85609 Dornach bei München

Phone: +49 (0) 89 94490275

Fax: +49 (0) 89 94490110

E-Mail: miguel.jimenez@genetix.com

Internet: www.genetix.com

Genomatix Software GmbH

BIOTECH BIOINFORMATICS

Keywords: Genomics

Genomatix is a systems biology company with a unique edge in gene regulation analysis, created as a spin-off of the GSF (now: Helmholtz Research Center for Environment and Health in Neuherberg) in autumn 1997.

We have been developing information systems aimed at understanding gene and protein regulation at the molecular level for well over 15 years. More than 15,000 researchers and academics around the world currently use our tools to drill down so deeply into genomics analysis that they can go beyond merely observing transcriptional events to be able to truly understand how the molecular mechanisms work. By integrating current systems biology data with gene regulation analysis, time and funds can be used more efficiently for genomic research or every phase of the drug development value chain.

Genomatix

understanding gene regulation

Contact:

Karl Blank

Bayerstr. 85a

D-80335 München

Phone: +49 (0) 89 599766 0

Fax: +49 (0) 89 599766 55

E-Mail: info@genomatix.de

Internet: www.genomatix.de

Gilead Sciences GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Gilead Sciences is dedicated to providing accelerated solutions for patients and the people who care for them. The evolution of Gilead – from a promising biopharmaceutical company to a leader in the international development and commercialisation of medicines for life-threatening infectious diseases (viral, fungal and bacterial infections) – is testament to what the company has achieved through disciplined science, visionary thinking and diversified planning. Gilead's headquarter is based in Foster City, California with additional operations in San Dimas, California. Sales and marketing organisations are located in the following cities: Athens, Greece; Cambridge, UK; Lisbon, Portugal; Madrid, Spain; Istanbul, Turkey; Munich, Germany; Paris, France; Dublin, Ireland; Milano, Italy.

 **GILEAD**

Contact:

Dr. Andrea Kücherer-Ehret

Fraunhoferstr. 17

D-82152 Martinsried

Phone: +49 (0) 89 899890-0

Fax: +49 (0) 89 899890-90

E-Mail: info@gilead-sciences.de

Internet: www.gilead.com

Contact:
Jasmin Amstadt

Lessingstr. 14
D-80336 München
Phone: +49 (0) 89 209 120-0
Fax: +49 (0) 89 209 120-30
E-Mail: re.hippe@gkm-therapieforschung.de
Internet: www.gkm-therapieforschung.de

GKM Gesellschaft für Therapieforschung mbH

CRO

GKM Gesellschaft für Therapieforschung mbH is a privately owned full service Contract Research Organisation for designing and conducting clinical trials phase II-IV as well as post-marketing-surveillances.

Since 1981 GKM is a much valued partner for many pharmaceutical, biotech and medical device companies. GKM provides flexible services with expert knowledge and dedication to your Projects according to ICH-GCP and international guidelines for research projects.

25 years experience: Cost-effective quality combined with the latest standards and technologies.

- Concept ■ Statistical planning ■ Study material ■ Regulatory services
- Site recruitment ■ Monitoring ■ Clinical trial management
- Quality assurance ■ Data management ■ Medical coding / writing
- Statistical analysis



Contact:
Claudia Kubacki

Theresienhöhe 11
D-80339 München
Phone: +49 (0) 89 360 440
Fax: +49 (0) 89 360 448000
E-Mail: service.info@gsk.com
Internet: www.gsk.com

GlaxoSmithKline GmbH & Co. KG

PHARMA & CHEMICAL INDUSTRY

GlaxoSmithKline is a leading pharmaceutical company with biotech developments in the area of vaccines and biopharmaceuticals. A cooperation with Human Genome Sciences Inc. has led to the sequence and functional analysis of a large number of genes which are the basis of ongoing developments. Besides GSK has signed a collaboration agreement with the Max-Planck Institutes of Psychiatry and Biochemistry to establish a genotyping platform (GRC, Genetic Research Centre) focusing on common diseases with complex genetic background.



Contact:
Martin Brändle

Fraunhoferstr. 20
D-82152 Martinsried
Phone: +49 (0) 89 8565-2693
Fax: +49 (0) 89 8565-2610
E-Mail: ir@gpc-biotech.com
Internet: www.gpc-biotech.com

GPC Biotech AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Antibody, Small Molecules, Oncology, Genomics, Proteomics

GPC Biotech AG is a publicly traded biopharmaceutical company focused on discovering, developing and commercializing new anticancer drugs. GPC Biotech has ongoing various drug development and discovery programs and also has an active program to identify and pursue promising drug development in-licensing opportunities. GPC Biotech AG is headquartered in Martinsried/Munich (Germany) and has a wholly owned U.S. subsidiary headquartered in Princeton, New Jersey.

Harrison Clinical Research Deutschland GmbH

CRO

Keywords: Cardiovascular Diseases, CNS, Metabolic Diseases, Nephrology, Oncology, Pain, Clinical Research, Monitoring

Harrison Clinical Research Deutschland GmbH is an independent ISO 9001 certified CRO founded 1987 in Munich with affiliates in UK, Belgium, Israel, Spain, Italy, France, Austria, Poland, Ukraine and Russia and representative offices in the USA and Japan. Our team comprises more than 300 research professionals. We offer all services required for the clinical development and registration of new pharmaceutical products/medical devices: international project management, monitoring, data management (CDISC), statistics, medical writing, auditing, training and outsourcing. Besides conduct of standard Phase I studies our Phase I/Ia clinic is specialized on proof-of-concept studies in special patient populations and efficacy studies in various indications. For more information please visit www.harrisonclinical.com.

Harrison
Clinical
Research

Harrison

Contact:
Birgit Mund

Albrechtstr. 43
D-80636 München
Phone: +49 (0) 89 126 680-0
Fax: +49 (0) 89 126 680-2444
E-Mail: bmund@harrison-cro.com
Internet: www.HarrisonClinical.com

Hematris Wound Care GmbH

MEDTECH

Keywords: Devices

Hematris Wound Care GmbH develops, manufactures and markets products in the area of wound care. Our major initial focus is the marketing of hemostatic products to control bleeding. We are experts in the field of hemostasis and wound healing. Our vision is to build up an attractive company together with our investors in this business area.

hematris

Contact:
Dr. Dr. Stefan Bertsch

Lena-Christ-Str. 31b
D-85521 Ottobrunn
Phone: +49 (0) 89 6008761-0
Fax: +49 (0) 89 6008761-24
E-Mail: bertsch@hematris.de
Internet: www.hematris.de

Hepa Wash GmbH

MEDTECH

Keywords: Devices, Hepatology

The Hepa Wash GmbH is a medical device company developing a new liver assist device for the treatment of patient with life-threatening liver disease. Main features of Hepa Wash's extracorporeal technology are its highly efficient albumin-dialysis and its innovative albumin regeneration circuit. Hepa Wash is dedicated to developing a therapy that's several times more effective than currently available treatments and to significantly increase the survival rate and quality of life of patients with life-threatening liver disease.

Hepa
Wash®

Contact:
Dr. Katja Rosenkranz

Boltzmannstr. 11a
D-85748 Garching
Phone: +49 (0) 89 3270 9586
Fax: +49 (0) 89 3276 0099
E-Mail: katja.rosenkranz@hepawash.com
Internet: www.hepawash.com

hepacult

Contact:
Kurt Martin

Postfach 1351
D-85767 Unterföhring
Phone: +49 (0) 89 95001711
Fax: +49 (0) 89 9612087
E-Mail: Kurt.Martin@hepacult.de
Internet: www.hepacult.de



Contact:
Dr. Carsten Brockmeyer

Industriestr. 25
D-83607 Holzkirchen
Phone: +49 (0) 89 613670200
Fax: +49 (0) 89 613670164
E-Mail: carsten.brockmeyer@sandoz.com
Internet: www.hexal.de

hepacult GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: Analysis, Toxicology, Clinical Research, Tissue Engineering / Cell Culture, Drug Development, Analytical Chemistry

hepacult develops and markets cell culture technology based on human liver cells and other human organs. The cell culture technology is used to prognose the metabolism of novel drugs and for the in vitro simulation of liver dysfunctions. With their cutting edge cell and tissue products hepacult provides to the scientific community and pharmaceutical industry an outstanding in vitro test system coming close to the human in vivo conditions. Animal experiments can be replaced to a large extent. Results gained during the preclinical stage with hepatocytes show a better prognostic value. Partially even the cost-intensive clinical experiments on humans and related risks to humans can be reduced.

HEXAL Biotech Forschungs GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Peptide/Protein, Hematology, Nephrology, Oncology

Biosimilars are approved versions of existing biopharmaceuticals whose patents have expired. Sandoz / Hexal is a pioneer in the development of this kind of drugs imposing special requirements in the process of development and approval. Last October, the company launched the first biosimilar version of a major anaemia medicine – Epoetin alfa Hexal® and Binocrit®, a recombinant version of human erythropoietin, developed in-house by Oberhaching-based Hexal Biotech. Following the merger of Sandoz and Hexal in 2005, Hexal Biotech is part of Sandoz Biopharmaceutical Development and now has 64 employees. As well as being the scientific competence center for Epoetin alfa, Hexal Biotech is responsible for coordinating the development and registration of all Sandoz biotechnology products worldwide. Following the Sandoz launch in 2006 of the world's first ever biosimilar – human growth hormone Omnitrope® – Epoetin alfa Hexal® and Binocrit® represented the next major step in biosimilar development. Sandoz, a business division of the Novartis group, is a world leader in the generics industry with 2007 sales of USD 7.2 billion. Sandoz is based in Holzkirchen near Munich.

HTI bio-X GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Devices, Automation

HTI bio-X GmbH is a innovative company and is focussing on products and customer service for biotechnological and pharmaceutical laboratories as well as Life Science industry. We develop products from the simple lab device to complex automated solutions. Our service is focused on engineering tasks and technical support, project management, technical and management consulting. Our current product portfolio covers consumables and instruments (e.g. cleavage machines) for DNA-synthesis as well as for microarray techniques (e.g. hybridization chambers). We also provide instruments for the dosage of powder as well as a complete robotic platform and devices for sample preparation and DNA extraction. Our biomagnetic workstation X-Tract facilitates all kinds of magnetic beads applications.



Contact:
Ditte Heimberg

Anzinger Str. 7
D-85560 Ebersberg
Phone: +49 (0) 8092 2092-0
Fax: +49 (0) 8092 2092-28
E-Mail: info@hti-bio-x.com
Internet: www.hti-bio-x.com

i.DRAS GmbH international Drug Regulatory Affairs Services

CRO

Keywords: Drug Development, Analytical Chemistry

i.DRAS is a consultancy company for international drug regulatory affairs. i.DRAS offers strategic support and services for human and veterinary medicinal products from the preclinical/early clinical development stages to the first submission of the MA dossier throughout post marketing activities, covering the whole product life cycle. Services provided cover new and established drug substances and the corresponding drug products, including herbal and biological/biotechnological medicinal products. If requested i.DRAS takes over the project management for complex projects with further partners who may be assigned through us or our clients. Furthermore, i.DRAS provides and organises in-house training and education, covering all topics related to the services offered by i.DRAS.



Contact:
Prof. Dr. Markus Veit

Fraunhoferstr. 18B
D-82152 Martinsried
Phone: +49 (0) 89 856536-50
Fax: +49 (0) 89 856536-66
E-Mail: info@i-dras.com
Internet: www.i-dras.com



Contact:
Simon Herzog

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 800 00 11 11 28
Fax: +49 (0) 800 00 11 11 29
E-Mail: sherzog@ibidi.de
Internet: www.ibidi.de

ibidi GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Devices, Nanobiotechnology, Tissue Engineering / Cell Culture, Chip / Array Technology, Microscopy

ibidi develops and distributes cell culture biochips, so called μ -Slides. The Slides are made for the analysis of cells and biomolecules. The parallel cultivation, staining and imaging of cells inside the carriers allows various applications as immunofluorescence, chemotactical analysis, perfusion assays and the simulation of blood vessels for adhesion and migration studies.

The read out for ibidi's optically high-end cell culture systems is performed via microscopy. So far, the μ -Slide family consists of 10 different types/ geometries. The volume inside these carriers is minimized ranging from 10 μ l up to 1 ml. The high optical quality of the μ -Slides allows microscopical cell investigations via phase contrast or DIC, fluorescence as well as confocal microscopy.



ICON
GENETICS

Contact:
Dr. Stefan Herz

Briener Str. 21a
D-80333 München
Phone: +49 (0) 8161 23 38 13
Fax: +49 (0) 8161 23 38 22
E-Mail: herz@icongenetics.de

ICON Genetics AG

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: Agrobiotechnology, Gene Transfer, Transgenic Plants, Antibody, Vaccines, Peptide/Protein

ICON Genetics is an integrated platform technology provider developing proprietary technologies and production hosts with application to a broad range of agricultural and pharmaceutical biotechnology products. ICON's new generation technologies of plant engineering (Transgene Operating Systems[®]) provide higher expression levels/yield, better expression control and higher biosafety. Our proprietary magnICON[®] biomanufacturing platform technology provides a process for producing therapeutic and other high-value recombinant proteins using non-food plants as production hosts. Corporate offices are headquartered in Munich, Germany and the Company's Research divisions are located in Halle: Weinbergweg 22, 06120 Halle and Freising-Weihenstephan: Lise-Meitner-Str. 30, 85353 Freising-Weihenstephan, Germany.

For more information about ICON Genetics AG, please visit the Company's website at <http://www.icongenetics.com>.

IDEA AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Delivery, Drug Development, Small Molecules, Dermatology, Bone / Joint Diseases, Inflammation, Pain, Rheumatology, Clinical Research

IDEA AG develops therapeutics using self-optimising carriers for targeted and non-invasive delivery of drugs, including proteins. The proprietary carrier, Transfersome®, is typically applied on the skin and can be engineered to achieve high drug concentration at or near the site of application, diminish local or systemic adverse side effects, and often increase drug potency; this can transform established drugs into superior and newly patented products. The Company's leading product is in the area of peripheral pain. In-house capabilities range from formulation and small-scale (GMP) manufacturing work up to late stage clinical testing.



Contact:

Dipl.-Volkswirt Jens-Peter Wartmann

Frankfurter Ring 193a
D-80807 München
Phone: +49 (0) 89 3246330
Fax: +49 (0) 89 3241684
E-Mail: idea@idea-ag.de
Internet: www.idea-ag.de

IMGM Laboratories GmbH your partner for GENOMIC SERVICES

BIOTECH DNA / PROTEIN ANALYTICS

Keywords: PCR, Genomics, Chip / Array Technology, Pharmacogenetics, Analysis

IMGM Laboratories was founded in 2001 and provides advanced genomic services tailored to the needs of customers coming from academia, pharma and biotech. IMGM is accredited according to DIN EN ISO/IEC 17025, DIN EN ISO 15189 and EFL and is fully accredited for microarray-based gene expression analysis and quantitative real-time PCR.

We cover the areas of:

- DNA services: e.g. whole genome SNP genotyping, DNA-sequencing, HLA typing, pharmacogenetics
- RNA services: e.g. RNA isolation service, whole genome microarray screening (e.g. human, mouse, rat), quantitative real-time PCR for gene expression analysis, microRNA analysis
- Bioinformatics: e.g. for whole genome gene expression and SNP genotyping data, building of classifiers
- Consulting: e.g. assay development, QC etc.



Contact:

Dr. Ralph Oehlmann

Lochhamer Str. 29
D-82152 Martinsried
Phone: +49 (0) 89 8955784-0
Fax: +49 (0) 89 895578-77
E-Mail: info@imgm.com
Internet: www.imgm.com

Immumed GmbH Gesellschaft für angewandte Immunologie

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, ELISA / EIA, Analysis

Applied Immunology – Testing Services

We offer testing services for human, mouse or rat samples:

- Analysis of cytokines, chemokines and phosphoproteins
- Cell-characterization
- Cell-separation
- Cytotoxicity

Our team is specialized in measuring multiplex-parameter analysis with Luminex-Technology in various samples like serum, cell cultures, saliva, urine. We perform every application for flow-cytometry analysis, for example cell phenotyping, intracellular cytokine detection or cytotoxicity assays as well as positive or negative selection of cells with magnetic-bead technology.



Contact:

Wolfgang Mayer

Goethestr. 10
D-80336 München
Phone: +49 (0) 89 55279919
Fax: +49 (0) 89 55279922
E-Mail: info@immumed.de
Internet: www.immumed.de



Contact:
Rudolf-Diesel-Str. 8A
D-97267 Himmelstadt
Phone: +49 (0) 9364 810-610
Fax: +49 (0) 9364 810-613
E-Mail: info@immunoglobe.com
Internet: www.immunoglobe.com

immunoGlobe Antikörpertchnik GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Laboratory, Antibody Production Service, Antibody

immunoGlobe® GmbH is a privately owned company, founded in 1997. Core competences are 1) the manufacturing of novel research antibodies, 2) full service custom antibody production and purification, as well as 3) marketing of own and licensed antibodies through a global network of OEM partners, wholesalers, and distributors.

Specialisations: Through sophisticated antigen design and purification schemes immunoGlobe® has particularly specialised in the generation of highly specific polyclonal rabbit antibodies against:

- phosphorylation sites
- neo-epitopes
- isoforms and mutants differing in as few as a single amino acid

As an option, these polyclonal approaches may directly lead over to rabbit monoclonal projects.



Contact:
Dr. Andrea Kreuz

Schatzbogen 52
D-81829 München
Phone: +49 (0) 89 7263718-0
Fax: +49 (0) 89 21758349
E-Mail: info@implen.de
Internet: www.implen.de

Implen GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Peptide/Protein

Implen GmbH is a leading supplier for system solutions for the analysis and processing of small volumes. We develop and distribute key technologies to optimize processes needed for molecular biological as well as cytogenetic applications. Together with our partners we combine customized complete-solutions and bring them to the market worldwide.



Contact:
M.D. Ilka Rother

Lärchenstr. 3
D-82166 Gräfelfing
Phone: +49 (0) 89 89665425
Fax: +49 (0) 89 82084607
E-Mail: info@imr-partner.de
Internet: www.imr-partner.de

IMR Partner International GmbH

CRO

IMR Partner GmbH is a contract research organization located in Munich and Jena. We provide specialized services for the development of pharmaceuticals and medical devices.

- Supervision of clinical studies by MD's
- Consultancy
- Conduct of the clinical part of Phase II-IV studies (principal investigator, site management)

Inamed Research GmbH & Co. KG

CRO

Keywords: Drug Delivery, Clinical Research, Monitoring, Medical Writing, Respiratory Diseases

Inhalation medicine is our expertise. Inamed Research was founded in 1998 as a spin off from the GSF. You profit from more than 30 years of our experience in aerosol bio-physics and aerosol technology and from our large network of experts. Inamed's competence is inhalation therapy with regard to clinical trials from phase I to IV and inhalation device testing. One of our specialties is the use of radioactive labeled drugs to determine lung deposition in scintigraphy trials, investigating mucociliary clearance and the analysis of the breathing pattern. In the division device testing, we characterize devices, not only with regard to particle size, output and flow, but also in realistic simulations, to establish the performance of the device when a patient is using it.



Contact:
Dr. Thomas Meyer

Robert-Koch-Allee 29
D-82131 Gauting
Phone: +49 (0) 89 89 35 69 0
Fax: +49 (0) 89 89 35 69 22
E-Mail: info@inamed.eu
Internet: www.inamed.eu

Infors GmbH

BIOTECH DEVICES & REAGENTS

Infors is specialised in marketing and maintenance of fermenters and shakers. As a subsidiary of Infors AG in Basel, Switzerland, it not only sees itself as a trading and service company but also cooperates with researchers in order to develop new equipment used in the field of microbiology and cell culture.



Contact:
Werner Mayer

Tannenweg 2
D-85254 Einsbach
Phone: +49 (0) 8135 8333
Fax: +49 (0) 8135 8320
E-Mail: infors.de@infors-ht.com
Internet: www.infors-ht.com

Ingenium Pharmaceuticals AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Autoimmune Diseases, Knock Out, Medicinal Chemistry, Small Molecules, Inflammation, Rheumatology

Ingenium Pharmaceuticals is advancing its expertise in drug target discovery and genetics-based therapeutic research toward the development of novel treatments for pain and inflammatory disease. To date, Ingenium has used its forward and reverse genetics technologies for its partners and for its internal drug development programs across several therapeutic areas. Ingenium's largest partnership is a multi-year drug discovery and development collaboration with Elan Pharmaceuticals. In addition, Ingenium has signed numerous agreements across the biopharmaceutical industry and academia to provide genetic expertise and animal models. Privately-held, Ingenium has raised three rounds of funding from premier US and European venture funds.

In 2007 Probiodrug AG acquired Ingenium.



Contact:
Susanne Imsel

Fraunhoferstr. 13
D-82152 Martinsried
Phone: +49 (0) 89 8565-2310
Fax: +49 (0) 89 8565-2305
E-Mail: info@ingenium-ag.com
Internet: www.ingenium-ag.com



Contact:
Prof. Dr. Toni Lindl

Balanstr. 6
D-81669 München
Phone: +49 (0) 89 48777-4
Fax: +49 (0) 89 48777-2
E-Mail: info@I-A-Z-zellkultur.de
Internet: www.I-A-Z-zellkultur.de



virion\serion

Contact:
Jürgen Schipper

Friedrich-Bergius-Ring 19
D-97076 Würzburg
Phone: +49 (0) 931-30 45-0
Fax: +49 (0) 931-30 45-100
E-Mail: dialog@virion-serion.de
Internet: www.virion-serion.de



Contact:
Dr. Hermann Schulz

Bayerstr. 53
D-80335 München
Phone: +49 (0) 89 741393-0
Fax: +49 (0) 89 741393-39
E-Mail: CEO.Schulz@INTERLAB.de
Internet: www.INTERLAB.de

Institut für angewandte Zellkultur Dr. Toni Lindl GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Tissue Engineering / Cell Culture, Antibody Production Service

The Institut für angewandte Zellkultur Dr. Toni Lindl offers services in the area of cell culture and tissue culture, training in cell culture work, distribution of cell lines, consulting in cell culture, molecular biology, genetic engineering and development of monoclonal antibodies and in vitro processes. The core competences cover cell culture services and genetic engineering with a product range of recombinant human interleukin-2 and human monoclonal antibodies against rabies. Partnerships are sought with university research institutes in immunology and virology, where know-how in cell culture and in vitro technologies can be transferred.

Institut Virion\Serion GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, ELISA / EIA, Autoimmune Diseases, Infectious Diseases, Respiratory Diseases

Virion\Serion has a very clear philosophy: since the company's foundation in 1978 we have been dedicated to supplying superior test kits for the diagnosis of infectious diseases – a high target which requires continuous improvement and development of advanced diagnostic methods. At our Würzburg facilities, more than 100 highly qualified specialists combine their expertise to fulfill this task. With its 30-year experience, Virion\Serion stands for competence and reliability in in vitro diagnostics.

INTERLAB central lab services – worldwide GmbH

CRO

Keywords: Clinical Research, Logistics, Clinical Diagnostics, Analytical Chemistry

INTERLAB is an independent central laboratory supporting clinical trials for pharmaceutical and biotechnology companies covering Europe, North and South America, Australia, Africa and Asia. The international head office is in Munich, Germany.

INTERLAB performs routine and esoteric testing on a daily basis: over 25.000 samples daily: clinical chemistry, hematology, endocrinology, genetics, PCR, microbiology, virology, immunology, serology, histopathology, cytology, toxicology, drug assays, incl. LC-MS/MS.

Additional services: professional project managers, flexible data management and transfer, cost-effective shipment logistics worldwide, EN 45.000, ISO 9001 and EC/ISO/EN 15189 (17025).

IRIS BioTech GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Drug Development, Drug Delivery, Fine Chemicals / Reagents, Medicinal Chemistry, Combinatorial Chemistry, New Materials, Natural Compounds

IRIS Biotech is specialized in reagents for Peptide Synthesis and products for Life Science Research. We have specific know-how and production capabilities to manufacture and supply products from the following areas from Grams to Multi-Ton Lots: Starting Materials for Peptide Synthesis (Protected Amino Acids, Coupling Reagents, Linkers and Resins). Reagents for PEGylation (monodisperse and polydisperse; short (MW 300) to very long (MW 20.000) Glycol Spacers, hydrophobic and amphiphilic SpacerMolecules; Contract Manufacturing of PEG Spacers and PEGylation. Reagents for Life Science Research (Aflatoxines, Cyclosporines, Cytochalasins, Geldanamycin, Methoxatin, Rapamycin, etc.) Carbohydrates (Derivatives of Arabinose, Galactose, Glucose, Mannose, Xylose, etc.) We are carrying out many Contract Manufacturing projects in these areas; our strong points are unusual derivatives with one or several chiral centres. We follow cGMP and ISO9000 and supply from typical lab scale for R&D to multi-ton bulk quantities for production, in order to escort our customers' projects during their evolution from R&D projects to commercial production.



Contact:

Waldershofer Str. 49-51
D-95615 Marktredwitz
Phone: +49 (0) 9231 9619-73
Fax: +49 (0) 9231 9619-99
Internet: www.iris-biotech.de

Kindle GmbH

CRO

Keywords: Clinical Research, Monitoring, Allergy, Diabetics, Medical Writing, Pharmacology, Oncology

Kindle International Inc. is a full-service, phase I - IV clinical development organization. It contracts with pharmaceutical and biotechnology companies to provide clinical testing and ancillary services necessary to get a new drug or medical device approved by worldwide regulatory agencies. Kindle currently employs more than 3,400 research professionals. Kindle provides services in project planning and protocol development, clinical trials management and monitoring, human pharmacology.

Please find more information about Kindle under <http://www.kindle.com>

Kindle

Contact:

Dr. Dieter Seitz-Tutter

Stefan-George-Ring 6
D-81929 München
Phone: +49 (0) 89 99 39 13-565
Fax: +49 (0) 89 99 39 13-429
E-Mail: luckner.andrea@kindle.com
Internet: www.kindle.com

KINAXO Biotechnologies GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: Drug Development, Oncology, Genomics, Proteomics, Small Molecules, Inflammation, Metabolic Diseases

KINAXO Biotechnologies GmbH is a spin-off from the Max Planck Institute of Biochemistry in Martinsried. We offer a comprehensive chemical-proteomics technology – known as KinaTor™ – to identify and characterise the interaction of small molecule inhibitors with their protein targets in the physiological context of a cell. Tailored to protein kinases, the KinaTor™ technology represents a highly efficient approach to developing selective kinase inhibitors for targeted therapies.

KINAXO

Biotechnologies GmbH

Contact:

Dr. Andreas Jenne

Am Klopferspitz 19a
D-82152 Martinsried/München
Phone: +49 (0) 89 700763-831
Fax: +49 (0) 89 700763-833
E-Mail: info@kinaxo.com
Internet: www.kinaxo.de



Contact:
Dr. Klaus Hellmann

Geyerspergerstr. 27
D-80689 München
Phone: +49 (0) 89 580082-0
E-Mail: info@klifovet.com
Internet: www.klifovet.com

KLIFOVET AG

CRO

Keywords: Logistics, Monitoring, Medical Writing, Analysis, Clinical Research

KLIFOVET is one of the very few providers of high quality services for the Animal Health Industry in Europe regarding the registration and marketing of products. In accordance to our high quality and established Standard Operating Procedures (SOP's) we are in command of well organised logistics, a motivated team, a comprehensive net of cooperators and skilled investigators throughout Europe. We are capable running studies locally or throughout Europe in a fast and efficient manner according to the demanding standards of FDA, EMEA and or clients. We perform efficacy studies, field safety studies, marketing studies and palatability studies.



Contact:
Michael Miller

Münchhausenstr. 21
D-81247 München
Phone: +49 (0) 89 8107-117
Fax: +49 (0) 89 8107-217
E-Mail: info@kmbioservices.de
Internet: www.kmbioservices.de

kmbs – Knebelsberger & Miller Bioservices GbR

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Genomics, PCR

kmbs is a small enterprise working as service partner for e. g. Conservation Biologists, Zoologists, Phylogeneticists, Taxonomists and Molecular Biologists to clear up specimens' identities by means of molecular / genetic analyses (PCR, DNA sequencing, Gene Fragment analysis) for purposes like resolving species relationships, detecting sibling species, delimiting species boundaries, investigating population integrity, a.s.o. In addition to this we are experienced in making microscopic preparations, but also we are carrying out outdoor services like mapping species inventories or searching for special organisms within a given habitat including the collection of organisms on demand.



Contact:
Dr. Elisabeth Müller

Steubenstr. 4
D-97688 Bad Kissingen
Phone: +49 (0) 971-72020
Fax: +49 (0) 971-68546
E-Mail: laboklin@t-online.de
Internet: www.laboklin.de

Laboklin GmbH &Co KG – Unternehmensbereich Labogen

BIOTECH THERAPEUTICS & DIAGNOSTICS

Our laboratory provides a complete testing service for veterinary surgeons to meet the diagnostic needs of your practice. You can find all important information and our laboratory profiles and screens (microbiology, haematology, allergy, pathology and genetic testing. Furthermore you can download submission forms or order sample collection material. If you are registered you are able to locate your samples, the stage of investigation and much more.

Loewe Biochemica GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Agrobiotechnology, ELISA / EIA

LOEWE is committed to the development and production of high quality reagents for the detection of plant diseases caused by bacteria, fungi, nematodes, and viruses. Furthermore we offer contract testing services for all kinds of crops and ornamentals (ELISA techniques, Immuno Fluorescence Antibody Assays, Blotting, and PCR).

Lophius Biosciences GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

The Lophius Biosciences GmbH, which was founded in the year 2002, is a spin-off of the Institute for Medical Microbiology and Hygiene and the Department of Internal Medicine I, University of Regensburg, Germany. The core business of Lophius is R&D for innovative diagnostic and therapeutic products in T-cell immunology and immunotherapy.

Lophius offers clinical sample-testing services based on a broad repertoire of immunological routine assays. In addition, Lophius uses its proprietary technology for the highly sensitive detection and characterization of active T cells.

medicomp GmbH

CRO

medicomp GmbH was founded in 1985 and has developed ever since into a full service CRO. We offer a wide range of services for phase I-IV trials, PMS and medical devices: medical and biometrical planning, protocol and CRF design, project management, data management, monitoring, statistical analysis and medical writing. medicomp is a member of the Bundesverband Medizinischer Auftragsinstitute (BVMA), which implies regular independent system audits. Furthermore, medicomp is a founding member of Pharmaceutical Service Network (PSN), a network of independent European CROs, which allows us to offer services for studies conducted on a European scope in collaboration with our partners.

LOEWE

Contact:
Dr. Renate Loewe

Mühlweg 2A
D-82054 Sauerlach
Phone: +49 (0) 8104 61620
Fax: +49 (0) 8104 61648
E-Mail: dr.loewe@loewe-info.com
Internet: www.loewe-info.com

Lophius GmbH Biosciences

Contact:
Dr. Fritz Schwarzmann

Josef-Engert-Str. 9
D-93053 Regensburg
Phone: +49 (0) 171 3627852
Fax: +49 (0) 941 4612471
E-Mail: info@lophius-biosciences.de
Internet: www.lophius-biosciences.de

medicomp

Gesellschaft für Versuchsplanung und Datenanalyse mbH

Contact:
Dr. med. vet. Michael Gierend

Fraunhoferstr. 17
D-82152 Martinsried
Phone: +49 (0) 89 895286-0
Fax: +49 (0) 89 895286-66
E-Mail: medicomp@medicomp-cro.de
Internet: www.medicomp-cro.de



Contact:
Prof. Dr. Peter Schlieper

Bergstr. 7
D-86926 Greifenberg
Phone: +49 (0) 8192 9336-0
Fax: +49 (0) 8192 9336-17
E-Mail: info@medicore.de
Internet: www.medicore.de

medicore International AG / MediCliPha Ltd

CRO

Keywords: Drug Development, Clinical Research, Monitoring, Medical Writing

medicore International AG was founded in 1992 and is a contract research organisation (CRO) with services for biotech- and pharmaceutical companies. Recently, a close cooperation was formed with MediCliPha Ltd.

The full-service concept includes consultations in drug development (from the active principle to marketing approval), clinical trials (phase II to IV, phase I in co-operation), data management, biostatistics, quality assurance (audits of different type), expert reports (pharmacology/ toxicology and clinical), medical writing, marketing surveillance studies, regulatory affairs, medical information and drug safety. Both companies offer full service packages or a modular approach. The reputation is based on competent staff, on GCP-conformance, on strict keeping timelines and budget.



Contact:
Gabriele Jegge

Lochamer Str. 11
D-82152 Martinsried
Phone: +49 (0) 89 85 65 29-0
Fax: +49 (0) 89 85 65 29-20
E-Mail: medigene@medigene.com
Internet: www.medigene.com

MediGene AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Immune Therapy, Drug Development, Oncology, Autoimmune Diseases, Dermatology

MediGene AG is a publicly quoted (Frankfurt: Prime Standard: MDG) biotechnology company located in Martinsried/Munich, Germany, with subsidiaries in Oxford, UK and San Diego, USA. MediGene is the first German biotech company with a drug on the market. Another drug obtained marketing authorization for the USA, two drug candidates are currently undergoing the European approval procedures. Furthermore MediGene has several drug candidates for the treatment of various types of cancer and autoimmune diseases in clinical development, and possesses innovative platform technologies for drug development. It is MediGene's strategy to integrate all core divisions of a bio-pharmaceutical company from research and development to commercialization of drugs.



Contact:
Karin Stedtler

Fraunhoferstr. 12
D-82152 Martinsried
Phone: +49 (0) 89 8955718-36
Fax: +49 (0) 89 8955718-9
E-Mail: V.Koepke@medpace.com
Internet: www.medpace.de

Medpace Germany GmbH

CRO

Keywords: Clinical Research, Cardiovascular Diseases, Metabolic Diseases, Oncology, Monitoring

Medpace, established in 1992, is a full-service Contract Research Organization (CRO), who partners with leading pharmaceutical and biotech organizations to bring promising new drugs to market. Medpace combines comprehensive regulatory consulting with efficient clinical trial management to provide sponsors with exceptional support in drug development. Proven leaders in medical and scientific research monitor every project. Medpace physicians have first-hand experience working with regulatory agencies to successfully guide projects through the complexities of the regulatory process. The medical expertise and regulatory guidance provided by Medpace leads to reduced costs and increased efficiencies for our valued customers.

MedPharmTec-Services

CRO

MedPharmTec-Services is a Pharmaceutical Contract Service Organisation providing expert assistance in drug development, clinical research (phase II through IV), medical information, regulatory affairs and drug safety to pharmaceutical and biotechnology companies. Our clinical research services range from protocol planning, CRF design, trial management, monitoring and auditing up to data management, biometrics and report writing. Further areas of MedPharmTec-Services' activities include medical information, i.e. medical and scientific translations, proof-reading, writing/designing of brochures, publications and scientific literature searches as well as consulting and services in terms of regulatory affairs and drug safety.



Contact:

Dr. med. Horst H. Langenbahn

Olschewskibogen 7
D-80935 München
Phone: +49 (0) 89 354 998-0
Fax: +49 (0) 89 354 998-99
E-Mail: office@MedPharmTec.de
Internet: www.MedPharmTec.de

Merck KGaA; Merck Serono – Institute of Drug Metabolism and Pharmacokinetics

PHARMA & CHEMICAL INDUSTRY

Keywords: Drug Development, ELISA / EIA, Pharmacokinetics, Antibody, Small Molecules

The Institute of Drug Metabolism and Pharmacokinetics (DMPK) is located in Grafing near Munich and is part of Global Research of Merck Serono, Geneva. The institute was established in 1969 and has grown considerably over the years. Currently 80 people are working at Grafing. The scope of the Institute of DMPK includes ADME studies of NCEs and NBEs in laboratory animals during drug discovery and development phases. Support is given to toxicology (toxicokinetics) and to clinical R&D by providing bioanalytical data and information about the metabolism in humans. The institute is equipped with state of the art instruments (e.g. LC-MS/MS, NMR, biacore, phosphor-imaging systems) and laboratories for radiolabelling of drugs with various radioisotopes (e.g. C-14, H-3, J-125).



Contact:

Dr. Bernhard Ladstetter

Am Feld 32
D-85567 Grafing
Phone: +49 (0) 8092 7008-0
Fax: +49 (0) 8092 7008-99
E-Mail: Mathias.Locher@merck.de
Internet: www.merck.de

metabion Gesellschaft für angewandte Biotechnologie mbH

BIOTECH DEVICES & REAGENTS

metabion's core business is custom synthesis and analysis of modified and unmodified oligonucleotides, special and high throughput oligos. Having developed its own fully automated 96-well parallel DNA synthesiser for fast and cost effective production of high quality – high throughput oligonucleotides, metabion became a leading supplier for high quality – high throughput oligonucleotides worldwide. Furthermore, metabion is one of worldwide only six licensees entitled by Roche to produce LightCycler™ probes. Apart from LightCycler™ probes, metabion GmbH is specialised on the synthesis of a broad spectrum of probes for real time PCR applications. Since 03/2001 metabion is a certified unit according to DIN EN ISO 9001:2000 which reflects the high quality profile of its products and services.



Contact:

Dr. Regina Bichlmaier

Lena-Christ-Str. 44
D-82152 Martinsried
Phone: +49 (0) 89 899363-0
Fax: +49 (0) 89 899363-11
E-Mail: metabion@metabion.com
Internet: www.metabion.com



Contact:
Dieter Meyer

Paul-Gerhardt-Allee 42
D-81245 München
Phone: +49 (0) 89 829265-100
Fax: +49 (0) 89 829265-099
E-Mail: info@metronomia.net
Internet: www.metronomia.de

Metronomia Clinical Research GmbH

CRO

Keywords: Analysis, Clinical Research, Logistics, Monitoring, Medical Writing, Drug Development

Metronomia Clinical Research, is a mid-size European CRO with special focus on biostatistical, data management and e-clinical full-service offers. Since more than 15 years Metronomia's mission statement is to combine cutting-edge e-clinical technologies and innovative but accepted study designs in order to improve drug development. A pronounced customer orientation, flexibility and cost-effectiveness – these are Metronomia's attributes highlighted most frequently by our customers.

Studies in a wide range of indications were successfully performed, specialities being oncology, transplantation, dermatology, pulmonology, immunology, cardiology and CNS.E-clinical trials are run with clincase, one of the top EDC systems, with an oustanding performance, flexibility and user friendliness.



Contact:
Dr. Erwin Soutschek

Floriansbogen 2-4
D-82061 Neuried
Phone: +49 (0) 700 50 50 2002
Fax: +49 (0) 700 50 50 2003
E-Mail: info@microbionix.com
Internet: www.microbionix.com

MICROBIONIX GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, Infectious Diseases, Analysis, Clinical Research

MICROBIONIX specializes in the development of Multiplex Assay Systems. The basis of all our applications is Luminex "xMAP-Technology", a bead-based multiplex platform technology for rapid and cost-efficient analysis. Furthermore, MICROBIONIX offers Multiplex Testing Services for analytes relevant to biomarker studies, hormone-analytic, cellular signal transduction and pathways:

- Quantification of Cytokines, Chemokines and Growth Factors ■ Activity Assays for Protein-Kinases ■ Activity State Assays for Signalling Proteins
- Binding-Assays for Transcription Factors ■ Immunglobulin Isotyping
- MMP-AnalysisJust get in touch for further information!



Contact:
Dr. Günter Müller

Am Neuland 3
D-82347 Bernried
Phone: +49 (0) 8158 9981-0
Fax: +49 (0) 8158 9981-10
E-Mail: info@microcoat.de
Internet: www.microcoat-biotechnologie.de

MicroCoat Biotechnologie GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Clinical Diagnostics, ELISA / EIA, PCR, Analytical Chemistry

Founded in 1992, MicroCoat is a biotechnology company focused on the field of Immune- and Nucleic acid-Diagnostics. The major work areas are:

- Coating of various biological reagents (streptavidin; antibodies; nucleic acids; and others) on solid phases (e.g. microtiterplates, tubes, chips)
- Development and manufacturing of diagnostic assays ■ Service in the field of Immune and Nucleic acid-Diagnostics like: measurement of samples, also for clinical trials; method comparison of assays; configuration and handling of "sample panels"; system verification and validation.

MicroCoat has been certified for EN ISO 13485:2003 (9001/EN 46001).

Micromet AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Antibody, Immune Therapy, Oncology

Micromet puts novel concepts in immunotherapy to work. Using proprietary technologies, the Company is building a strong pipeline of innovative drug candidates for the treatment of cancer, inflammation and autoimmune disease. Two candidates are currently in clinical trials. The Company has established a powerful drug development platform: BiTE™ ("Bispecific T cell engagers"), a unique drug format that leverages the outstanding cytotoxic potential of T cells to precisely eliminate pathogenic cells.

In addition, Micromet is exploiting the potential of SCAs (single-chain antibodies) for the development of novel drug candidates. The Company has attracted both top-tier life science investors and corporate partners such as MedImmune, Inc., Enzon Pharmaceuticals, Inc., and Serono.



Contact:
Angela Lucks

Staffelseestr. 2
D-81477 München
Phone: +49 (0) 89 895277-0
Fax: +49 (0) 89 895277-105
E-Mail: info@micromet.de
Internet: www.micromet.de

MIKROGEN GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, ELISA / EIA, Infectious Diseases, Automation, Autoimmune Diseases, Chip / Array Technology

Founded in 1989 MIKROGEN GmbH offers innovative solutions for medical laboratories. The companies scope is the development and production of clinical diagnostic test systems based on recombinant antigens, with the focus on bacterial, viral, parasitic and autoimmune diseases. MIKROGEN's core competencies covers genetic engineering and the scientific quality of research and development, which is reflected in various patent applications and publications in international journals. The key success factors of the company are the consequent customer orientation, the strong product competence and highly skilled employees. MIKROGEN meets ongoing market demands by emphasising its activities on automation and standardisation in the in-vitro diagnostics, to improove processes in medical laboratories.

MIKROGEN

Contact:
Dr. Erwin Soutschek

Floriansbogen 2 - 4
D-82061 Neuried
Phone: +49 (0) 89 54801-0
Fax: +49 (0) 89 54801-100
E-Mail: mikrogen@mikrogen.de
Internet: www.mikrogen.de

Contact:
Prof. Dr. Dr. Torsten Haferlach

Max-Lebsche-Platz 31
D-81377 München
Phone: +49 (0) 89 99017-0
Fax: +49 (0) 89 99017-111
E-Mail: info@mll-online.com
Internet: www.mll-online.com

MLL Münchner Leukämie Labor GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, Chip / Array Technology, Genomics, PCR, Hematology, Oncology

MLL Munich Leukemia Laboratory is working as a reference laboratory for the diagnosis of hematologic malignancies focussing on leukemia and lymphoma. All 30 coworkers (physicians, molecular biologists, and technicians) have outstanding reputation in the field of comprehensive diagnostics. In parallel, cytomorphology, cytochemistry, immuno pheno typing, cytogenetics, FISH, and molecular genetic techniques such as PCR are performed. The seven day available work-flow is orientated to the clinical needs of patients and physicians. MLL is testing new techniques such as microarrays. We serve as a reference laboratory for German and European leukemia studies and are a SME-member in the European Leukemia Network (ELN). Together with ROCHE MLL leads the worldwide MILE (Microarray Innovation in Leukemia) study to test microarrays for leukemia diagnostics.

Contact:
Dr. Oliver Sacher

Nägelsbachstr. 25
D-91052 Erlangen
Phone: +49 (0) 9131 81 56 68
Fax: +49 (0) 9131 81 56 69
E-Mail: info@mol-net.com
Internet: www.mol-net.com

Molecular Networks GmbH

BIOTECH BIOINFORMATICS

Keywords: Drug Development, Molecular Modelling, Small Molecules

Molecular Networks is a chemoinformatics company serving the chemical, pharmaceutical and biotechnology industry worldwide with innovative scientific software products, consulting, development and research services to improve the speed and productivity of chemical discovery. Founded in 1997, the company established international business relationships and Molecular Networks' technology is utilized in major industrial, governmental and academic discovery laboratories to design and optimize chemical products and processes. Molecular Networks' product portfolio comprises 15 different software tools, databases and decision support applications for the design and synthesis of chemical compounds as well as for the prediction of their chemical, physico-chemical and biological properties, their reactivity and metabolic fate.

MorphoSys AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Antibody Production Service, Antibody, Dermatology, Infectious Diseases, Oncology, CNS

MorphoSys is one of the world's leading biotechnology companies focusing on fully human antibodies. With its proprietary technologies, MorphoSys is developing the next generation of antibodies not only for research and diagnostics purposes, but also as highly effective and precise therapeutics. HuCAL® (Human Combinatorial Antibody Library) is a very powerful technology for the rapid and automated production of specific antibodies. The most distinctive feature of the library is its unique capability to optimize fully human antibodies to predefined specifications, allowing MorphoSys researchers and their partners to "Engineer the Medicines of Tomorrow". MorphoSys's goal is to establish HuCAL® as the technology of choice for antibody generation in all market sectors.



Contact:

Dr. Claudia Gutjahr-Löser

Lena-Christ-Str. 48
D-82152 Martinsried
Phone: +49 (0) 89 89927-0
Fax: +49 (0) 89 89927-222
E-Mail: info@morphosys.com
Internet: www.morphosys.com

M-Scan Mass Spectrometry Consultants and Analysts

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Pharmacokinetics, Proteomics, Antibiotics, Antibody, Peptide/Protein, Small Molecules, Vaccines, Analytical Chemistry

M-Scan is an independent group of companies, offering consulting, analytical and training services, particularly in chromatography and mass spectrometry, for the pharmaceutical and chemical industries. In addition to routine testing, M-Scan, as a specialised problem solving analytical consultancy, provides solutions to the most demanding problems in chemistry and biochemistry. In the Life Science field, M-Scan is expert in the structural characterisation of biomolecules (e.g. Proteins, Antibodies, Oligonucleotides) in compliance with the US FDA definition of a "well-characterised or specified" molecule and ICH Q6B Guidelines. M-Scan is GLP/cGMP certified. M-Scan laboratories are currently equipped with a range of 18 high performance mass spectrometers providing a full range of ionisation procedures.



Contact:

Dr. Jörg Müller

Hauptstr. 68
D-82008 Unterhaching
Phone: +49 (0) 89 66 50 84 52
Fax: +49 (0) 89 66 50 84 54
E-Mail: services.de@m-scan.com
Internet: www.m-scan.com



Contact:
Dr. Lukas Pfister

Lindenplatz 1
D-85540 Haar
Phone: +49 (0) 89 4561-1120
Fax: +49 (0) 89 4601-281121
E-Mail: lukas_pfister@msd.de
Internet: www.msd.de

MSD Sharp & Dohme GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Cardiovascular Diseases, Dermatology, Diabetics, Oncology, Ophthalmology, Respiratory Diseases, Rheumatology

MSD SHARP & DOHME GMBH is the German subsidiary of Merck & Co., Inc., a research-driven, worldwide acting pharmaceutical company based in the US, which develops, produces and distributes medicines and vaccines in different therapeutic fields. MSD wants to contribute to medical care in order to guarantee and improve access to urgently needed medicines worldwide. Thus, MSD supports numerous poor countries with donations of pharmaceuticals. For more than 100 years MSD publishes the renowned "MSD-Manual", a standard publication for physicians and pharmacists (www.msd.de/msdmanual/). Medical knowledge and advice for the public is published in the "MSD-Manual Handbuch Gesundheit". MSD Germany has more than 1.400 employees. The company is situated in Haar near Munich.



Contact:
Kerstin Orth

Promenadeplatz 12
D-80333 München
Phone: +49 (0) 241 75 00 700 (Ext.4512)
Fax: +49 (0) 89 210194 50
E-Mail: korth@msource-cro.com
Internet: www.msource-cro.com

MSOURCE Medical Development GmbH

CRO

Keywords: Cardiovascular Diseases, CNS, Infectious Diseases, Oncology, Clinical Research, Analysis, Monitoring

As a rapidly expanding ISO 9002 certified full-service CRO organization, MSOURCE has provided a range of clinical development and professional services to the pharmaceutical, biotechnology and medical device industries since 1994.

Through a strong focus on client needs, our people, processes and continued emphasis on quality, MSOURCE has built services to address: Clinical Trial Management, Clinical Data Services, Clinical Contract Hire and Quality Assurance Consulting.

Multimetrix GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Clinical Diagnostics, Chip / Array Technology, Autoimmune Diseases, Clinical Research

Multimetrix's major field of expertise is based on the Luminex technology. This technology allows the simultaneous quantitative measurement of up to one hundred different parameters in a single drop of a liquid sample. At the same time it saves time and money even when compared to a single parameter measurement using conventional methods. Due to its high flexibility the Luminex technology can be used to measure all kinds of different analytes that are characterized by specific binding of two defined molecular interaction partners, e.g. antigens and antibodies, enzymes and substrates, receptors and ligands and complementary nucleic acids. The Luminex technology is particularly suitable for high-throughput applications in the fields of laboratory diagnostics, pharmacological screening, expression profiling and SNP analysis.

The advantages of the Luminex technology as compared to conventional assay systems such as ELISA and Western blotting are obvious: it is fully automated, smaller sample volumes are needed and it provides higher sensitivity and specificity at a lower price.

Multimetrix develops multiplex test systems for applications in the fields of diagnostics, pharmacological screening and quality control.

Multimetrix offers the assay development on demand including all required validation and quality assurance procedures as well as a testing service for detection of multiple analytes on customer request.



Contact:

Dipl.-Biol. Elisabeth Dove

Josef-Engert-Str. 9

D-93053 Regensburg

Phone: +49 (0) 941 30 74 386

Fax: +49 (0) 941 30 74 798

E-Mail: info@multimetrix.com

Internet: www.multimetrix.com

multimmune GmbH, c/o Strahlentherapie der TU München

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Clinical Diagnostics, Antibody, Cell Therapy, Vaccines, Oncology

multimmune is a biopharmaceutical company dedicated to the discovery and development of new products for the treatment of cancer. The company focuses on the development of drug candidates to treat heat shock protein 70 (Hsp70) positive tumors, as surface-bound Hsp70 is a tumor-specific marker expressed on about 50-75% of various cancer entities, e.g. lung, breast, colon, pancreas.

Currently, four approaches are being explored to destroy cancer cells:

(1) by extracorporeal activation of Natural Killer (NK) cells with a synthetic peptide (ready to go into phase II), (2) by using an antibody against Hsp70 (preclinical), (3) by direct infusion of an Hsp70 peptide (R&D), (4) by inducing tumor specific apoptosis with a serine protease(R&D).



Contact:

Dr. Claus Botzler

Ismaringer Str. 22

D-81675 München

Phone: +49 (0) 89 4140-4298

Fax: +49 (0) 89 4140-4299

E-Mail: info@multimmune.de

Internet: www.multimmune.de

multi-service-monitoring

Contact:
Dr. Josef Reisinger

Waffnergasse 1
D-93047 Regensburg
Phone: +49 (0) 941 3782498
Fax: +49 (0) 941 6308648
josef.reisinger@multi-service-monitoring.de
www.multi-service-monitoring.de



Contact:
Dr. Jutta Huber

Anzinger Str. 7a
D-85560 Ebersberg
Phone: +49 (0) 8092 8289-0
Fax: +49 (0) 8092 21084
E-Mail: info@mwdna.com
Internet: www.mwg-biotech.com

multi-service-monitoring

CRO

Central European Investigator Sponsored Research Institute is an investigator sponsored research institute that specialises in monitoring clinical studies in Central Europe. With its locations in the Biopark in Regensburg and Bratislava, multi-service-monitoring integrates with networks in Germany, Austria, Switzerland, the Czech Republic, Slovakia and Hungary. All tasks are carried out in accordance with the international guidelines ICH/GCP or the appropriate national regulations. Our staff and testers undergo continuous further training and are very experienced in carrying out studies.

MWG Biotech GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Genomics, Antisense/Nucleotides, Automation, PCR, Small Molecules

MWG Biotech GmbH is an international provider of genomic services established around the core business lines DNA sequencing, oligonucleotide, siRNA and gene synthesis. The companies main mission is focussed on customer convenience and high quality services in industrial scale for the life science industries and academic research institutions around the world.



Contact:
Dr. Niels Fertig

Erzgiessereistr. 4
D-80335 München
Phone: +49 (0) 89 218997972
Fax: +49 (0) 89 218997960
E-Mail: info@nanion.de
Internet: www.nanion.de

Nanion Technologies GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Devices, Nanobiotechnology

Nanion Technologies is a spin-off from the Center for Nanoscience (CeNS) of the University of Munich (LMU). Nanion combines bio- and microtechnology in a company serving the life sciences industry by offering products and services which will dramatically increase the speed and efficiency of the drug discovery process in an important segment of the pharmaceutical market. Nanion bases its business on a proprietary chip technology and will design and develop High Throughput Screening (HTS) systems for ion channel active drugs (ICADs). Ion channels are prime targets for innovative medicines aimed at many important diseases.

NascaCell Technologies AG

BIOTECH DEVICES & REAGENTS

Keywords: Drug Development, Aptamer Technology, Peptide/Protein

NascaCell Technologies AG is a global leader in the automated production and marketing of aptamers and Microbodies™. Aptamers are small, functional oligonucleotides binding to target proteins with very high affinities and specificities. Because of their drug like binding characteristics, aptamers typically show strong inhibition of protein function. NascaCell selects aptamers in a rapid, automated procedure. This allows their generation in 8-10 weeks with proven track record in target validation and drug discovery. Microbodies™ are very small (ca 35 amino acids) and extremely stable proteins. Active peptides can be grafted or new sequences identified with bacterial display. Microbodies™ combine the selectivity of biologic agents with the ease of handling and storage of small molecule drug compounds.



Contact:
Dr. Michael Szardenings

Max-Lebsche-Platz 31
3. OG, Modul D
D-81377 München
Phone: +49 (0) 89 54 72 72 10
Fax: +49 (0) 89 54 72 72 22
E-Mail: customer@nascacell.de
Internet: www.nascacell.de

NeuroProfile GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

NeuroProfile is committed to the discovery and development of novel therapeutics for the treatment of Central Nervous System (CNS) diseases. The main objective is the identification and commercialization of novel neuronal drug targets (disease-related genes or proteins) for the most important neurodegenerative diseases Alzheimer and Parkinson and for psychiatric disorders such as schizophrenia and depression. Our targets will be the basics for forthcoming drug generations with new mechanisms of action that not only ameliorate the disease symptoms, but potentially prevent or block progression of the disease.

Several patent pending target candidates are run in preclinical validation projects.



Contact:
Dr. Thomas Rohrmeier

Josef-Engert-Str. 9
D-93053 Regensburg
Phone: +49 (0) 941 7853690
Fax: +49 (0) 941 7853699
E-Mail: info@neuroprofile.com
Internet: www.neuroprofile.com

NIGU Chemie GmbH

PHARMA & CHEMICAL INDUSTRY

Nigu offers a full range of high-purity guanidine salts for biotechnological applications, which meet the supreme quality standards set by the biopharmaceutical industry. The product group includes several grades of guanidine hydrochloride for separation and purification of recombinant proteins and antibodies. Guanidine thiocyanate for nucleic acid based diagnostics is another integral part of the portfolio. A typical example is to provide guanidine-salts and recycling of used solutions as a complete package to the biopharmaceutical industry.



Contact:
Dr. Frank Fleischer

Beuthener Str. 2
D-84478 Waldkraiburg
Phone: +49 (0) 8638 962-0
Fax: +49 (0) 8638 962-286
E-Mail: info@nigu.de
Internet: www.nigu.de



Contact:
Dr. Klaus-Peter Stengele

Beuthenerstr. 2
D-84478 Waldkraiburg
Phone: +49 (0) 8638 98420
Fax: +49 (0) 8638 984211
E-Mail: stengele@nimblegen.de
Internet: www.nimblegen.de



Contact:
Martin Bischof

Zielstattstr. 40
D-81379 München
Phone: +49 (0) 89 7877-0
Fax: +49 (0) 89 7877-250
E-Mail:
communications.munich de@novartis.com
Internet: www.novartis-consumerhealth.de



Contact:
Astrid Oelsner

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 700 769-60
Fax: +49 (0) 89 700 769-61
E-Mail: info@octagene.com
Internet: www.octagene.com

NimbleGen Systems GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Clinical Diagnostics, Fine Chemicals / Reagents, Chip / Array Technology, Genomics

NimbleGen Systems, the leading supplier of flexible high-density microarray products and services, is enabling a new era of High-Definition Genomics (SM). NimbleGen uniquely produces high-density arrays of isothermal long oligos that provide superior results for advanced genomic analysis methods such as CGH, ChIP, microbial Comparative Genome Sequencing, and expression tiling. NimbleGen's High-Definition Genomics enables scientists to obtain and integrate complex genomic data sets not previously accessible, providing a much clearer understanding of genome structure and function, and how this relates to biology and medicine. NimbleGen Systems GmbH is the wholly owned German subsidiary of Nimblegen Systems Inc and the chemistry arm of NimbleGen.

Novartis Consumer Health GmbH

PHARMA & CHEMICAL INDUSTRY

Novartis Consumer Health, located in Munich, merchandises and distributes OTC and prescription drugs for self-medication.

OCTAGENE GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Drug Development, Hematology, Peptide/Protein

Octagene GmbH is a product-oriented R&D company with 25 employees located in Martinsried. The main focus of Octagene is the development of cell lines for production of recombinant proteins. Using a High-Throughput Screening Technology for optimized clone selection, Octagene has achieved a significant increase in efficiency and productivity of the cell clones. This technology is offered as service to other companies. The use of human cells as host cells has substantially improved the compatibility of Octagene's final drug product in patients in comparison to hamster cell-derived products. One product developed by Octagene, recombinant human Factor VIII, will soon enter clinical phase II.

Olympus Life Science Research Europa GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Devices, Nanobiotechnology, Automation

Located at the global competence centre in Munich since October 2007 Olympus Life Science Research Europa GmbH expands global research, development and production capacity for Life Science in Europe. The areas of In Vitro Diagnostics, Lab Automation (ODL), Molecular Biology (Advalytix) and Digital Image Processing and Applications in Microscopy (the Munich-based parts of OSIS) are united here under one roof to pool resources, utilise synergies and create an interdisciplinary work atmosphere in close co-operation with Olympus Tokyo.

OLYMPUS

Your Vision, Our Future

Contact:

Dr. Christoph Gauer

Sauerbruchstr. 50

D-81377 München

Phone: +49 (0) 89 579 589-0

Fax: +49 (0) 89 579 589-3503

E-Mail: microscopy@olympus-europa.com

Internet: www.olympus.de

OMX GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Proteomics, Peptide/Protein, Analysis, Devices

The OMX GmbH develops and markets innovative technology and offers mass spectrometry services in proteomics. Products facilitate new work flows for laboratory routines to yield highest quality results. The laboratory disposable OMX-S has been established to ease protein sample preparation from polyacrylamide gels. The all in one device OMX-S facilitates a four step protocol in an aqueous buffer to yield highest quality peptides in one hour. Peptides are ready for MALDI- or ESI- based mass spectrometry analysis. With OMX-MS, customers pick a single protein with OMX-S, and send the device by ordinary mail to OMX or to any laboratory to perform the sample preparation and mass spectrometry analysis.



Contact:

Prof. Dr. Lutz Eichacker

Adelbergweg 14

D-82234 Wessling

Phone: +49 (0) 89 17861-272

Fax: +49 (0) 89 17861-209

E-Mail: info@omx-online.com

Internet: www.omx-online.com



Contact:
Michael Almstetter

Am Klopferspitz 19a
D-82152 Martinsried
Phone: +49 (0) 89 7801676-0
Fax: +49 (0) 89 7801676-777
E-Mail: info@origenis.de
Internet: www.origenis.de

origenis GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Combinatorial Chemistry, Medicinal Chemistry, Automation, Combinatorics, Molecular Modelling, Small Molecules

origenis is a contract research organisation offering services in drug design, synthesis, and characterisation. origenis has implemented a novel drug design and discovery platform, MOREsystem® and MolMind®, based on a multi-disciplinary approach, which integrates state of the art ■ molecular modelling ■ chemo-informatics ■ innovative chemistry ■ high throughput secondary screening into a seamless, fast and cost-effective process. This interdisciplinary process is built to design and discover promising and novel target focussed compound series, with optimized properties for their pre-defined therapeutic use.



Contact:
Dr. Jörg Rennecke

Elsenheimerstr. 61
D-80667 München
Phone: +49 (0) 2247 757727
Fax: +49 (0) 2247 915439
E-Mail: Joerg.Rennecke@orioncro.com
Internet: www.orioncro.com

Orion Clinical Services GmbH

CRO

Keywords: Clinical Research, Monitoring, Medical Writing, Drug Development

ORION Clinical Services is a full-service clinical development organisation performing all aspects of clinical trials internationally. The company is a dynamic, proactive, multicultural CRO, offering a high quality, customised and flexible service.

ORION's European operations are managed from offices in the United Kingdom, France and Germany, while North America is managed from the USA, and Australasia from Australia. These central hubs are augmented by regional staff – who are particularly important in providing coverage of central and Eastern Europe.

Founded in 1997, ORION Clinical Services has steadily built a reputation for reliability. This worldwide success has been recognised by the winning of The Queen's Award for Enterprise for services in support of drug development.

OSE Oncology Services Europe S.a.r.l.

CRO

Keywords: Clinical Research, Pharmacology, Toxicology, Immune Therapy, Oncology, Cell Therapy, Gene Therapy

OSE is a full service CRO specialised in the field of Oncology. OSE can provide an organically grown international network of international investigator sites and opinion leaders.

From Phase I to Phase IV OSE offers a range of services to assist the pharmaceutical and biotech industries in executing their clinical studies.

Our services include: study planning, medical writing, patient and investigator recruitment, data management, biostatistics, site monitoring, in-house monitoring, project management, study reporting and much more. OSE has clinical expertise with different drugs like: antibodies, antisense cytotoxics, hormones, radio-sensitizer, small molecules, proteins, vaccines and biologicals.



Contact:

Dr. Christine Unger

Cuvilliésstr. 14a

D-81679 München

Phone: +49 (0) 89 895218-0

Fax: +49 (0) 89 895218-50

E-Mail: christine.unger@os-europe.com

Internet: www.os-europe.com

pab productions GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Antibody Production Service

pab productions produces polyclonal antibodies in rabbits and chicken.

Immunological test systems, are developed as customer service.

An innovative product line based on renewable resources has been invented

- microtiterplates from polylactic acid (PLA) especially for peptide coating
- an innovative immunostick-cuvette-system for ELISA (adhesive and covalent binding) from polyhydroxybutyrate (PHB)
- adjuvant for immunostimulation from PHB and biomicroparticles for affinity chromatography.



Contact:

Elvira Schecklies

Bürgermeister-Herzog-Str. 5

D-85241 Hebertshausen

Phone: +49 (0) 8131 20709

Fax: +49 (0) 8131 20709

E-Mail: pab.productions@web.de

Internet: www.pabproductions.de

Paktis GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Agrobiotechnology, Transgenic Animals, Xenotransplantation, Antibody Production Service

Paktis offers business development services, providing strategic consulting and active management support to diagnostic, material and life sciences companies. This includes business plan evaluation, due diligence services, interim management, corporate development as well as sales and marketing.

We support companies dealing with:

- Special TypiFix® ear tags for farm animals that allow easy and convenient taking of tissue samples for further analyses (Scrapie, Bovine Virus Diarrhea) or for identification of the meat's origin
- One-step ultra-quick DNA-purification columns (Nexttec)
- Polyclonal antibody production using rabbits
- Large scale production of industrial proteins with transgenic farm animals (sheep, cattle).



Contact:

Prof. Dr. Gottfried Brem

Lise-Meitner-Str. 30

D-85354 Freising

Phone: +49 (0) 8161 141-1160

Fax: +49 (0) 8161 141-1166

E-Mail: info@paktis.com

Internet: www.paktis.com



Contact:
Dr. Frank Hensel

Friedrich-Bergius-Ring 15
D-97076 Würzburg
Phone: +49 (0) 931 230795-0
Fax: +49 (0) 931 230795-19
E-Mail: info@patrys.com
Internet: www.patrys.com

Patrys GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Antibody, Infectious Diseases, Oncology

Patrys – the natural human antibody based company Patrys Limited (ASX: PAB) is an Australian public company committed to the development of novel treatments for cancer and other diseases, including the commercialisation of a unique natural human antibody based therapies for the treatment of lung, pancreatic, gastric and colon cancers.

The company has the world-wide and exclusive rights to technologies that have been developed over 25 collective years of research and development and which uniquely allow for the capture, development and production of natural human antibodies for potential therapeutic applications. The technologies, and resulting deep product pipeline, have achieved positive results in animal studies in the treatment of human lung, pancreatic, gastric and colon cancers.

Patrys also currently benefits from the prior establishment of drug development collaborations with three large pharmaceutical companies.

In addition to its internal drug development projects and existing collaborations, the company has also acquired a substantial preferred equity holding in Acceptys, Inc., an American company developing the platform natural human antibody technology for the treatment of infectious diseases, including Hepatitis C, Hepatitis B, Pneumonia and Staph A. Patrys' commercial strategy is to blend the internal development of lead product candidates while simultaneously benefiting from partnerships and collaborations aimed at developing additional product candidates from the company's deep product pipeline.



Contact:
Gabriele Hochmuth

Landsberger Str. 408
D-81241 München
Phone: +49 (0) 89 9999-7733
Fax: +49 (0) 89 9999-7744
E-Mail: gabriele.hochmuth@pfc-cro.com
Internet: www.pfc-cro.com

PFC Deutschland GmbH

CRO

The core competency of PFC Pharma Focus AG is the planning and conduction of clinical Phase II to IV studies. It is our aim to handle each of our projects with great respect and care: for the patient, for the investigator, for the sponsor and for our collaborators.

We believe that the most important quality assurance is the continuous training and coaching of our staff, allowing them to take ownership of the projects.

PHARMALOG Institut für klinische Forschung GmbH

CRO

Pharmalog acts as a European full service CRO with an excellent reputation in clinical trials Phase I - IV since 1983. Our staff of 50 colleagues (incl. central field based monitors) conducts clinical and non-interventional trials in Germany and all EU/EEU-countries, using our pool of 9,800 investigators in clinics/ practices. Special advantages: Fast patient recruitment, motivated investigators, local monitors are native speakers. We have performed about 300 clinical trials in all medical indications for medical products/-devices/biotechnology products according to ICH- and FDA-Standards for 50 nat./internat. pharmaceutical companies. We offer full service or modular approach (e.g. monitoring, data management/statistics), reasonable pricing due to short contact ways and low overhead costs.

PHARMALOG Institut
für klinische Forschung GmbH, München

Contact:
Stefan Feick

Hermann-Schmid-Str. 10
D-80336 München
Phone: +49 (0) 89 544 637-0
Fax: +49 (0) 89 544 637-50
E-Mail: pharmalog@pharmalog.com
Internet: www.pharmalog.com

Pharm-Olam International Deutschland GmbH

CRO

Pharm-Olam International is a multi-national contract research organization offering a wide range of comprehensive, clinical research services to the pharmaceutical, biotechnology and medical device industries. Our global network, including the emerging markets of Central Eastern Europe, Latin America, and India enables us to recruit patients on-time for even the most challenging studies. By accelerating enrolment, we reduce costs for our sponsors and take trials to the next Phase faster. From pre-clinical to Phase IV, POI is focused on delivering the highest quality data, achieving targeted enrolment and meeting projected timelines.

POI Pharm-Olam INTERNATIONAL
A Contract Research Organization

Contact:
Dr. Peter Sonner

Ingolstädter Str. 20
D-80807 München
Phone: +49 (0) 89 375 0899-0
Fax: +49 (0) 89 375 0899-20
E-Mail: german.office@pharm-olam.de
Internet: www.pharm-olam.com

Phytochem Referenzsubstanzen GbRmbH

BIOTECH DNA/PROTEIN ANALYTICS

Phytochem develops, produces and markets high purified substances for the pharmaceutical industry, research, analytics and authorities (main focus over 3000 Natural Compounds). Phytochem synthesizes or isolates also Degradation products and Impurities in remedies or other rare drugs especially for customers needs with best equipment and experience. Lot specific testing is guaranteed. Phytochem products were used as Reference Standards for research and development: (Identity standard Data File: IDF) also for quality control as Primary Standards (Reference Substance Masterfile: RMF) and full documented Method Validation. Additional products and consulting services in the fields of Functional Foods, Dietary Supplements, Food Additives and Cosmetics are new focuses from Phytochem.

Phytochem
Referenzsubstanzen GbRmbH


Contact:
Hans Rausch

Krumbacherstr. 9
D-89335 Ichenhausen
Phone: +49 (0) 731 9720545
Fax: +49 (0) 731 9720546
E-Mail: phytochem@t-online.de
Internet: www.phytochem-standards.de



Contact:
Rita Fischer

Lise-Meitner-Str. 30
D-85354 Freising-Weihenstephan
Phone: +49 (0) 8161 1411400
Fax: +49 (0) 8161 1411444
E-Mail: info@pieris-ag.com
Internet: www.pieris-ag.com

Pieris AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Peptide/Protein

Pieris AG is a biopharmaceutical company engaged in the discovery and development of Anticalins® for the diagnosis and treatment of life-threatening human disorders. Exploiting extensive know-how in protein engineering as part of a broad intellectual property portfolio, the Company applies a balanced risk business model to the development of its Anticalin® candidates. Recognizing the enormous market potential of protein-based drugs, Pieris is committed to becoming an integrated drug discovery and development company.



Contact:
Dr. Gudrun Vogeser

Lise-Meitner-Str. 30
D-85354 Freising-Weihenstephan
Phone: +49 (0) 8161 49658-00
Fax: +49 (0) 8161 49658-01
E-Mail: info@pika-weihenstephan.de
Internet: www.pika-weihenstephan.de

PIKA Weihenstephan GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

PIKA Weihenstephan GmbH is a spin-off from the Technical University of München-Weihenstephan. It was founded by scientists of the section "Technologie der Brauerei II" (Chair of Brewing Sciences) and is specialised in the development, production, and sales of detection systems for micro-organisms, mainly based on PCR technology. In the beginning, the company focused on the detection of microbial spoilers which may occur during food production, especially the growth of bacteria in drinks like beer-spoiling lactobacilli. New products for the detection of various microorganisms in different organic sample materials are continuously developed. Besides R&D and the production of kits, PIKA Weihenstephan GmbH offers custom analysis for the detection and identification of contaminating microorganisms as a service.



Contact:
Dr. Thorsten Klein

Max-Planck-Str. 14
D-86899 Landsberg a. L.
Phone: +49 (0) 8191 428181
Fax: +49 (0) 8191 428175
E-Mail: info@postnova.com
Internet: www.postnova.com

postnova analytics GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Devices

postnova analytics provides complete analytical solutions for the characterization of proteins, biopolymers, macromolecules and nanoparticles. (1000 Da - 10E12 Da, 10 nm - 100 µm) Postnova's products are used by all major global companies and institutions in the field of biotechnology, pharma, polymer and environmental research, e.g. Amgen, DOW, BASF, Roche, MIT, TUM. postnova's product portfolio includes systems, supplies and services based on its proprietary patented FFF technology for protein-virus, aggregate characterization, polymer-rubber characterization, nanoparticle characterization and preparative micron particle separation.

Postnova has two locations in Landsberg, Germany (headquarters) and Salt Lake City, Utah, USA.

PPD Development GmbH & Co. KG

CRO

PPD is a leading global contract research organization (CRO) providing discovery, development and post-approval services as well as compound partnering programs. Our clients and partners include pharmaceutical, biotechnology and medical device companies as well as academic and governmental organizations. With offices in 30 countries and with more than 10,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help its clients and partners maximizing returns on their R&D investments and accelerating the delivery of safe and effective therapeutics to patients.

PPD Development GmbH & Co. KG

Contact:

Dr. Wolfgang Ermer

Hansastra. 32

D-80686 München

Phone: +49 (0) 89 57877-0

Fax: +49 (0) 89 57877-400

E-Mail: wolfgang.ermer@europe.ppd.com

Internet: www.ppd.com

Priaton GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Combinatorial Chemistry, Drug Development, Drug Delivery, Fine Chemicals / Reagents, Medicinal Chemistry

Innovative Chemistry, Lead Finding and Optimization, Drug Discovery. Basing on MCR-Technology expanded to a chemotechnological platform we accompany and support drug discovery in all fields of medicinal chemistry. We provide compounds, services and technologies to make lead finding and optimization faster and much more effective.

Combining these with a highly new chemoinformatic platform lead research can be revolutionized. Benefit from our broad range of Products and Services in all stages of the drug discovery process:

- Isocyanides as Key Compounds
- Bioactive Building Blocks to integrate MCR-scaffolds in all kinds of chemistries
- Custom synthesis based on MCR and classical organic chemistry
- MCR applications in innovative Libraries ■ Optimized library design by unique chemoinformatic tools.



Contact:

Dr. Christoph Burdack

Gmunder Str. 37-37a

D-81379 München

Phone: +49 (0) 89 4521308-0

Fax: +49 (0) 89 4521308-22

E-Mail: contact@priaton.de

Internet: www.priaton.com

Prionics Deutschland GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: Clinical Diagnostics, Agrobiotechnology, ELISA / EIA, Infectious Diseases

Prionics Deutschland GmbH, founded in September 2005, is responsible for the marketing, sales and technical support of innovative tests for the early detection of important zoonotic diseases of production animals. The company provides its customers in Germany and Austria with a portfolio of more than 50 diagnostic kits, accessories and biochemicals.

Prionics Deutschland offers diagnostic solutions for all major animal disease areas including TSE, BVDV, FMD, Paratuberculosis, Classical Swine Fever, Salmonella, Trichinella and Brucella.

The parent company Prionics AG, Switzerland, is one of the world's leading providers of farm animal diagnostics and a recognized center of expertise in BSE and prion diseases.



Contact:

Dr. Anthony Harris

Am Klopferspitz 19

D-82152 Martinsried/München

Phone: +49 (0) 89 517 39 49-1

Fax: +49 (0) 89 517 39 49-9

E-Mail: info@prionics.de

Internet: www.prionics.de



Contact:
Dr. Christian Philipp

Ernsbergerstr. 5A
D-81241 München
Phone: +49 (0) 89 5800812-0
Fax: +49 (0) 89 5800812-2
E-Mail: info@probior.com
Internet: www.probior.com



Contact:
Josef-Engert-Str. 11
D-93053 Regensburg
Phone: +49 (0) 941 94262-0
Fax: +49 (0) 941 94262-42
E-Mail: info@profos.de
Internet: www.profos.de



Contact:
Dr. Torsten Neufeind

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 700761-0
Fax: +49 (0) 89 700761-15
E-Mail: business@proteros.com
Internet: www.proteros.com

probior GmbH

BIOTECH DEVICES & REAGENTS

probior offers products in the areas of biotechnology, pharmacy and medicine: special reagents for biotechnology and life science research from our partner company Dojindo (e.g. cell counting kit, DNA damage quantification kit, SOD quantification kit, etc.; overall ca. 500 reagents).

Profos AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Natural Compounds, PCR, Peptide/Protein, Infectious Diseases

Profos AG, founded in 2000, employs a total of 58 permanent staff and is certified according to ISO 9001:2000 and ISO13485:2003. Profos' core competency is to exploit the principles of bacteriophage biology for diagnostics and the combat of pathogen bacteria and bacterial toxins.

Proteros biostructures GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: 3 D Structural Analysis, Fine Chemicals / Reagents

Proteros biostructures GmbH is Europe's market leading in industrial x-ray structure analysis of proteins and protein-ligand complexes for structure guided drug design. Our successful business comprises a large number of collaborations with renowned international life science companies.

Proteros offers fast and reliable collaborations, with a success rate of more than 90%, in important and ambitious protein structure analysis supported by unique and proprietary technologies focusing on complex structure analysis of compounds of poor solubility and/or weak affinity.

In addition, Proteros has a portfolio of more than 40 pre-established structures for a range of pharmacologically relevant proteins in order to generate protein-ligand structures within a few weeks.

P.SS.T Pharma Scientific Services Team

CRO

P.SS.T is a small international consultancy and service provider for pharmaceutical and related industries. We accompany your drug / medical device .. development projects with advise and services in:

- regulatory affairs (from Clinical trials to Marketing authorisation filings, strategies + services including e.g. eCTD, User testing for PILs) ■ drug dev. project management organisation+services, quality management ■ clinical dev. (incl. scientific writing, protocol development, EUDRACT filings, IMPD etc)
- general services and consultancy ■ training and information provision

P.SS.T's range includes scientific services for all sections of pharmaceutical, medical and healthcare industry. For support in other countries we established partnerships with local CROs and consultant.



Contact:

Dr. Axel F. Wenzel

Kreillerstr. 65

D-81673 München

Phone: +49 (0) 89 92 20 03-0

Fax: +49 (0) 89 92 20 03-90

E-Mail: office@p-ss-t.de

Internet: www.p-ss-t.de

PULSION Medical Systems AG

MEDTECH

PULSION is one of the worldwide leading specialists for intelligent medical diagnosis and therapy management systems. With its innovative product lines PULSION has constituted a paradigm shift in the field of hemodynamic therapy management in critically ill patients. In addition to the product lines for hemodynamic management, PULSION offers a number of systems for function and perfusion monitoring of other organs and tissues. The headquarters of PULSION Medical Systems is in Munich, Germany. Moreover subsidiaries have been developed in United Kingdom, France, Belgium, Spain, Australia and in the USA. PiCCO plus, CeVOX, LiMON, ICG-PULSION, IC-VIEW, VoLEF



Contact:

Dipl.-Ing. Matthias Bohn

Stahlgruberring 28

D-81829 München

Phone: +49 (0) 89 459914 0

Fax: +49 (0) 89 459914 18

E-Mail: info@pulsion.com

Internet: www.PULSION.com

quattro research GmbH

BIOTECH BIOINFORMATICS

quattro research GmbH develops and markets software solutions for the management and analysis of chemical and biological data in drug discovery and development. quattro's suite of products contains solutions for registering new chemical substances, for managing biological assay data, for stock management particularly for research laboratories, and an electronic laboratory notebook. The efficiency of the quattro products is a result of the integrated Chemistry Engine, which facilitates work with chemical structures in all areas of the software package. The quattro's suite has been developed under realistic conditions, in close collaboration between quattro research's developer team and scientists in the laboratory. In addition to the quattro's suite, quattro research also offers its customers consultancy services and specific system solutions to manage chemical and biological data.



Contact:

Dr. Bernhard Schirm

Am Klopferspitz 19a

D-82152 Martinsried

Phone: +49 (0) 89 700763 16

Fax: +49 (0) 89 700763 29

E-Mail: info@quattro-research.com

Internet: www.quattro-research.com



Contact:
Stefan Schöffel

Mühlweg 2
D-82054 Sauerlach
Phone: +49 (0) 8104 8980 13
Fax: +49 (0) 8104 8980 99
E-Mail: stefan.schoeffel@quintiles.com
Internet: www.quintiles.de

QUINTILES GmbH

CRO

Keywords: Monitoring, Medical Writing, Clinical Research

Quintiles' Product Development, Commercialization and Novaquest Development divisions help improve healthcare worldwide by providing a broad range of professional services, information and partnering solutions to the pharmaceutical, biotechnology and healthcare industries. Headquartered near Research Triangle Park, North Carolina, Quintiles has about 17,000 employees in offices in 50 countries and is the world's leading pharmaceutical services organization. For more information visit the company's Web site at www.quintiles.com.



Contact:
Dr. Aldo Ammendola

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 547 265 880
Fax: +49 (0) 89 547 265 889
E-Mail: aammendola@quonova.com
Internet: www.quonova.com

QuoNova Europe GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Small Molecules, Infectious Diseases, Respiratory Diseases, Ophthalmology

QuoNova was founded in December 2006 as a Joint Venture of US-based XL TechGroup (Melbourne, Florida) and 4SC AG (Martinsried). QuoNova aims to develop and commercialize novel antibacterial drugs, so called "Quorum Sensing Blocker" (QSB). 4SC developed this proprietary technology by applying its in silico drug screening engine until pre-clinical stage while QuoNova seeks to commercialize this novel approach with a broad application potential. QSB can be used as antibacterial therapeutics, in medical devices, consumer care products or industrial applications. QuoNova's QSB technology is superior compared to conventional antibiotics and biocides since it is efficacious against so called bacterial "biofilms" and do not induce resistance.



Contact:
Dr. Wolfgang Richter

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 70 07 64 90
Fax: +49 (0) 89 70 07 64 99
E-Mail: wolfgang.richter@rdbiopharma.de
Internet: www.rdbiopharma.de

R&D Biopharmaceuticals GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Natural Compounds, Small Molecules

R&D-Biopharmaceuticals is a biopharmaceutical company focusing on the pre-clinical and clinical development of unique small molecules deriving from natural products for diseases with unmet medical need. The Company has exclusive access to the natural product class of the Tubulysins discovered by Prof. Höfle and Prof. Reichenbach from the Gesellschaft für Biotechnologische Forschung in Braunschweig (now: Helmholtz Center for Infection Research) and to proprietary second generation Epothilones, a highly promising new drug class for the treatment of cancer. The Company is pursuing an active partnering strategy for further development of these compound classes. They are suited especially for conjugation and targeting approaches.

RadPharm Europe GmbH

CRO

Keywords: Drug Development, Clinical Research, Oncology, CNS

RadPharm ("The Medicine behind the Image™") is a provider of core lab services to the pharmaceutical, biotechnology and medical device industry and is managing all facets of the imaging segment of global clinical trials, Phases I-IV. We are committed to the value that full-time physicians bring to clinical trials and rely on consistent medical interpretations, rather than just the technical handling of images. In the last 10 years, RadPharm has participated in over 100 global trials, in 56 countries and at over 5,000 sites. While a majority of our studies have been in the area of oncology, RadPharm has experience in the therapeutic areas of cardiology, neurology, musculoskeletal and diagnostic imaging agents. For more information please visit www.radpharm.com.



Contact:
Dr. Karoline Meures

Ottoste. 3
D-80333 München
Phone: +49 (0) 89 20244497-0
Fax: +49 (0) 89 20244497-9
E-Mail: meures@radpharm.com
Internet: www.radpharm.com

RAPID Biomedical GmbH

MEDTECH

Keywords: Clinical Research

RAPID Biomedical GmbH is specialised in the research and production of probeheads for MRI and NMR spectroscopy. The company collaborates with research institutions, hospitals and MR equipment manufacturers worldwide. Our products include 1H MR resonators for clinical studies at all magnetic field strengths and for all organs. We also supply multi-nuclear (e.g. 1H / 31P) MR-probeheads for combined MRI and MRS in clinical and basic science investigations. We offer custom made MR probeheads for routine animal research (RAPID COMPLETE™) and various accessory devices.



Contact:
Ulrike Haase

Ketteler-Str. 3-11
D-97222 Rimpar
Phone: +49 (0) 9365 88 26 12
Fax: +49 (0) 9365 88 26 99
E-Mail: info@rapidbiomed.de
Internet: www.rapidbiomed.de

RatioScreen GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Clinical Diagnostics, Devices, Nanobiotechnology, Clinical Research

RatioScreen (RS), founded 2003 by H. Nixdorf chair for medical electronics at the Technical University of Munich (Prof. Wolf). RS develops, qualifys and validates automated, multi-parametric, micro-physiological miniaturized analysis systems for cell and molecular biology, environmental analytics, biomedical diagnostics and therapy. RS develops and realises cell based micro-electronic assays. The assays act as dynamic and multi-parametric analysis of living cells for indication in medicine, pharmacology, cell biology/biotechnology and food production incl. evaluation and data management. RS carries out order development in the range of application and evaluation of multi-parametric sensor chips (lab on chip technology) and individual examination of tumor cells from biopsy-material for the definition of individual tumor-therapeutic options. RS evaluates chemo-therapeutics regarding individual cytostatistic/toxic potential.



Contact:
Michael Winkler

Am Neuland 1
D-82247 Bernried
Phone: +49 (0) 8158 997349
Fax: +49 (0) 8158 997367
E-Mail: ratioweb@t-online.de
Internet: www.ratioweb.de



Contact:
Dr. Ortwin Faff

Carl-von-Linde-Str. 40
D-85716 Unterschleißheim
Phone: +49 (0) 89 321419-60
Fax: +49 (0) 89 321419-59
E-Mail: info@retrotech-online.de
Internet: www.retrotech-online.de

Retro-Tech GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, Infectious Diseases, Devices, Automation, Natural Compounds, Xenotransplantation, Small Molecules

Retro-Tech focuses on technology and product development based on magnetic beads (core technology) for diagnostics of retroviruses (HIV, HTLV, MLV, Hepatitis, other) and therapy of viral diseases (AIDS, Leukemia, Hepatitis, Autoimmune), with special focus on retroviral enzymes (reverse transcriptase, integrase), receptors (CD4, chemokine) and regulatory proteins. Services offered include Biosafety & Quality testing of bio-pharmaceuticals, organs, cell banks, blood products, antiviral drug screening by cellular and biochemical assays, toxicity testing, kinetic and inhibition studies on mechanism of action. The products currently offered are retroviral diagnostic kits, reagents & accessories, e.g. assay kits for reverse transcriptase (RTA), magnetic bead separation and handling devices.



Contact:
Barbara Jopp-Heins

Nonnenwald 2
D-82377 Penzberg
Phone: +49 (0) 8856 60-0
Fax: +49 (0) 8856 60-3896
E-Mail: penzberg.allgemein@roche.com
Internet: www.roche.de

Roche Diagnostics GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Drug Development, Clinical Diagnostics, Analytical Chemistry

Roche Diagnostics GmbH is part of Roche, Basel, Switzerland. Roche is one of the world's leading research-focused healthcare groups for pharmaceuticals and diagnostics and supplies products and services for the detection, prevention, diagnosis and treatment of disease. Roche is a world leader in diagnostics, the leading supplier of medicines for cancer and transplantation and a market leader in virology. At Penzberg, Roche operates one of the largest biotechnology facilities in Europe. Diagnostics Research develops innovative reagents and test-systems for diagnosis, patient stratification and therapy monitoring. Pharmaceutical Research has broad experience in research, development and production of therapeutic human proteins and focuses on new protein projects.



Contact:
Dr. Roland Kreutzer

Fritz-Hornschnuh-Str. 9
D-95326 Kulmbach
Internet: www.roche-kulmbach.de

Roche Kulmbach GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Antisense/Nucleotides, Inflammation, Metabolic Diseases, Oncology, Respiratory Diseases

Roche Kulmbach GmbH is Roche's Center of Excellence for the discovery and development of a new class of therapeutics based on the principle of RNA interference (RNAi). RNAi is a natural process to selectively silence endogenous genes and is mediated by Small Interfering RNAs (siRNAs). Roche Kulmbach GmbH uses synthetic siRNAs to specifically silence disease-associated genes. This universal approach is applied to develop novel therapeutics for the treatment of oncological, respiratory and metabolic diseases.

Sandoz Pharmaceuticals GmbH

PHARMA & CHEMICAL INDUSTRY

Sandoz Pharmaceuticals GmbH belongs to the global Sandoz-Group – number two worldwide in the field of generics. In Germany, we specialize on premium generics, biopharmaceuticals and well known minerals.

Scil Technology GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Drug Delivery, Peptide/Protein, Bone / Joint Diseases

Scil Technology develops products for bone and cartilage regeneration in dental and orthopaedic indications. Scil's products consist of growth-stimulating biomolecules (protein-based growth factors) and biomaterials being completely biodegradable and biocompatible. These innovative products are tailor-made to meet the specific requirements of each target indication and will be applied locally to induce or enhance tissue regeneration. In the dental field, Scil Technology develops products for dental bone augmentation, periodontal disease and dental implantology. Orthopaedic products are developed for spinal fusion, trauma, cartilage defects and osteoarthritis.

Contact:
Hubert Hirzinger

Carl Zeiss-Ring 3
D-85737 Ismaning
Phone: +49 (0) 89 24404 0
Fax: +49 (0) 89 24404 100
E-Mail: info@sandoz.de
Internet: www.sandoz.com



Contact:
Iris Margraf

Fraunhoferstr. 15
D-82152 Martinsried
Phone: +49 (0) 89 8565 1800
Fax: +49 (0) 89 8565 1819
E-Mail: info@sciltechnology.com
Internet: www.sciltechnology.com



Contact:
Dr. Marcus Meyr

Am Mittleren Moos 48
D-86167 Augsburg
Phone: +49 (0) 821 7493-173
Fax: +49 (0) 821 7493-171
E-Mail: info@sension-gmbh.de
Internet: www.sension-gmbh.de



Contact:
Eva Metzger

Bahnhofstr. 30
D-85591 Vaterstetten
Phone: +49 (0) 8106 8887
Fax: +49 (0) 8106 301565
E-Mail: service@sequiserve.de
Internet: www.sequiserve.de

Sension GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, ELISA / EIA, Autoimmune Diseases, Antibody

Sension develops immunoassays and rapid test systems for on-site analysis. The tests find broad applications in the fields of food analysis, environmental analysis, medical diagnostics, reproductive management in agriculture, and in the monitoring of samples for mold. Also technologies for label production to prevent products from counterfeiting are realized. Sension is realizing own product developments, but also performs R&D developments for partners and customers and specifically focus on the specific needs required.

SequiServe GmbH

BIOTECH DNA/PROTEIN ANALYTICS

SequiServe offers the following custom services in molecular biology: DNA-sequencing (plasmids, PCR-products, BACs, PACs, primer-walking).



Contact:
Dr. Brigitte Hanke

Freisinger Str. 5
D-85716 Unterschleißheim
Phone: +49 (0) 89 32156-120
Fax: +49 (0) 89 32156-107
E-Mail: brigitte.hanke@serono.com
Internet: www.serono.de

Serono GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Autoimmune Diseases, CNS, Dermatology, Neurology, Devices, Clinical Research, Endocrinology

Serono is a global biotechnology leader. The Company has eight biotechnology products, Rebif®, Gonal-f®, Luveris®, Ovidrel®/Ovitrelle®, Serostim®, Saizen®, ZorbtiveTM and Raptiva®. In addition to being the world leader in reproductive health, Serono has strong market positions in neurology, metabolism and growth and has recently entered the psoriasis area. The Company's research programs are focused on growing these businesses and on establishing new therapeutic areas, including oncology.



Contact:
Franziska Sprinz

Elsenheimer Str. 53
D-80687 München
Phone: +49 (0) 89 5709501
Fax: +49 (0) 89 57095-125
E-Mail: info@de.netgrs.com

SERVIER Deutschland GmbH

PHARMA & CHEMICAL INDUSTRY

Following its international success, SERVIER Deutschland GmbH has established an independent branch in Munich since 1996. Servier is one of the very dynamic pharmaceutical companies in Germany, experiencing a growth-rate in double figures on average. The reason for this are not only the approved and merchandised drugs but also new, innovative products. The success of the new drugs is supported by the Servier Research and Development GmbH (also in Munich), which manages many different projects throughout the German-speaking region.



Internet: www.servier.de

Contact:
Dr. Udo Sticher

Eschenstr. 5
D-82024 Taufkirchen
Phone: +49 (0) 89 6513-1504
Fax: +49 (0) 89 6513-1399
E-Mail: udo.sticher@sial.com
Internet: www.sigma-aldrich.com

Sigma-Aldrich Chemie GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Antibody Production Service, Proteomics, PCR, Genomics, RNAi & Antisense, Antibody, CNS

Sigma-Aldrich is a leading Life Science and High Technology company. Our biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing. We have customers in life science companies, university and government institutions, hospitals and in industry. Sigma-Aldrich operates in 36 countries and has over 7,600 employees providing excellent service worldwide.

siRion GmbH

BIOTECH DEVICES & REAGENTS

SIRION's expertise comprises services for RNAi expression and solutions for customized gene expression. In virtually any cell type, SiRIONs newly developed QSTEP technology allows for optimal knock down efficiency, which means also cells resistant to transfection. By means of the proprietary viral QSTEP technology, the limitations of conventional siRNA transfection are eliminated. When using QSTEP frozen cells, no time consuming and tedious optimization of transfection protocols, which give little reproducible results, are needed. QSTEP guarantees high reproducibility, reliability and optimal knock down efficiencies for our customer's assays.



Contact:

Dr. Lars Behrend

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 7009619-99
Fax: +49 (0) 89 7009619-98
E-Mail: info@sirion-biotech.de
Internet: www.sirion-biotech.de

Sloning BioTechnology GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Automation, Genomics, PCR, Proteomics

Sloning BioTechnology GmbH is a Biotech company in the vicinity of Munich, Germany, which has developed a novel way of synthesising double-stranded DNA molecules (gene constructs). Based on a library of standardised, double-stranded building blocks, gene constructs are synthesised on a fully automated robotic platform. Purely research driven in the past, the company has successfully entered the market in 2006 as a service provider of customised genes and high quality SlonoMax mutant libraries.

Sloning's mission is to industrialise the synthesis of artificial genes to unlock the huge potential of genome data for drug development and production applications.



Contact:

Sascha Meyer

Zeppelinstr. 4
D-82178 Puchheim
Phone: +49 (0) 89 809095-0
Fax: +49 (0) 89 809095-50
E-Mail: info@sloning.de
Internet: www.sloning.com

SpheroTec GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: Drug Development, Oncology, Tissue Engineering / Cell Culture

SpheroTec means Spherotechnology. Spheroids are miniature tumors in vitro mimicking micrometastases in cancer patients. The three-dimensional tissue like model allows predictive drug testing with respect to efficacy, cell toxicity, drug penetration into the micrometastasis and pharmacokinetic in a very early preclinical phase of drug development. The advantages are obvious: early identification of ineffective and highly toxic drugs, effective selection of therapeutically relevant drugs, high probability of success in advanced clinical trials and thus FDA approval as well as reduction of animal experiments, time and costs. The Spherotechnology is appropriate for all kind of drugs including antibodies and small molecules.



Contact:

Dr. Barbara Mayer

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 7095-6438
Fax: +49 (0) 89 7095-6263
E-Mail: bmayer@spheroTec.com
Internet: www.spheroTec.com

SuppreMol

Contact:

Prof. Dr. Peter Buckel

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 30905068-13
Fax: +49 (0) 89 30905068-68
E-Mail: info@suppremol.com
Internet: www.suppremol.com

SuppreMol GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Peptide/Protein, Autoimmune Diseases, Rheumatology, Antibody

SuppreMol is developing biological medicines based on a new therapeutic principle with the potential to significantly improve the quality of life of patients suffering from Autoimmune Diseases which affect more than 3% of the worldpopulation.

SuppreMol is promoting its lead product for the treatment of orphan drug indications bridging to block buster markets of Systemic Lupus Erythematosus and Rheumatoid Arthritis.

SuppreMol is a spin-off company out of the laboratory of Nobel laureate Robert Huber of the Max-Planck-Institute of Biochemistry in Martinsried, Germany, where the "proof of principle" of sFcR in animals has been shown.

Syntacoll GmbH

Contact:

Frau Wittmann

Donaustr. 24
D-93342 Saal/Donau
Phone: +49 (0) 9441 68600
Fax: +49 (0) 9441 686030
E-Mail: info@syntacoll.de
Internet: www.innocoll.de

Syntacoll GmbH

PHARMA & CHEMICAL INDUSTRY

Syntacoll is the manufacturing division of Innocoll, Inc. and produces clinical supply or commercial product to its marketing partners and to Innocoll's two other divisions, Innocoll Technologies and Innocoll Pharmaceuticals. Using proprietary manufacturing processes, Syntacoll converts raw collagen material and incorporates medicinal compounds yielding finished pharmaceutical product in the form of a sponge or membrane. This system forms the basis of Innocoll's lead collagen-based technology, CollaRx. The sponge or membrane product format is a unique way to locally deliver a wide variety of medicinal compounds and is fully biodegradable and resorbable. The sponge and the membrane formats can be implanted at the time of surgery or applied topically to a chronic, acute or traumatic wound. Delivering drug locally to the site of action has a number of benefits, including the safe delivery of higher doses than could be achieved through systemic routes and avoidance of systemic side effects.



Contact:

Dr. Thomas Wein

Steinachtalweg 6
D-81549 München
Phone: +49 (0) 89 21 58 87 55
Fax: +49 (0) 89 21 58 16 82
E-Mail: twein@t2-consult.de
Internet: www.t2-consult.de

T2-Consult

BIOTECH BIOINFORMATICS

Keywords: Combinatorial Chemistry

T2-Consult provides professional and independent service and consultancy in computational chemistry. Our scientific expertise reflects more than 25 years of combined experience with the industrial leaders in this field.

Some examples of our service are: ■ prediction of 3D protein structures with homology modelling ■ protein sequence analysis ■ structure based drug design ■ virtual screening ■ molecular dynamics ■ calculation of physical and chemical properties ■ proof-of-concept studies for computer aided molecular design.

TILL Photonics GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Devices, Automation

TILL Photonics develops and markets opto-electronic instrumentation for fluorescence microscopy as used in fundamental research, applied science and diagnostics. The equipment, which is based on several patents for confocal and conventional fluorescence microscopes, is developed in collaboration with the Biolmaging Zentrum (BIZ) at the Ludwig-Maximilians-Universität in Munich. TILL Photonics also collaborates with several leading German research institutions. The majority of TILL's customers are found in the fields of neurobiology, cell biology, biomedicine and pharmacology. In 2008 Agilent Technologies acquired TILL Photonics.



Contact:
Marion Schädler

Lochhamer Schlag 19
D-82166 Gräfelfing
Phone: +49 (0) 89 89 56 62-0
Fax: +49 (0) 89 89 56 62-101
E-Mail: info@till-photonics.com
Internet: www.till-photonics.com

TNS Healthcare Clinical Research GmbH

CRO

Keywords: Clinical Research, Logistics, Analysis, Monitoring, Medical Writing, Allergy, Rheumatology

TNS Healthcare GmbH Clinical Research conducts phase II-IV clinical trials as well as post-marketing surveillance studies world-wide. Our operations span local agencies in over seventy countries in Europe. TNS Healthcare combines more than 20 years of CRO expertise in drug research with the development of innovative web-based applications in project and data management (InTrial and InDrums). Our services include: protocol and CRF design, eCRF solutions, feasibility and site selection, investigators training, handling and completion of legal and ethical requirements, monitoring and site management, project management, implementation of risk management programs, data management, medical coding, quality assurance, statistical planning and analysis, medical writing.



Contact:
Siegfried Freytag

Landsberger Str. 338
D-80687 München
Phone: +49 (0) 89 5600-1421
Fax: +49 (0) 89 5600-1590
E-Mail: siegfried.freytag@tns-global.com
Internet: www.tns-healthcare.de

TopLab GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Proteomics, Analysis

TopLab GmbH was founded in 1994 by three scientists as a private spin off of the Max-Planck-Institute for Biochemistry in Martinsried and the Gene Center of the University of Munich. The leading idea for TopLab was to offer a technology platform with bioanalytical tools to the pharmaceutical industry and to public institutes as partner for outsourcing projects. TopLab is one of the leading companies in the field of proteomics, combining the extensive know-how of its experienced scientists with its highly specialised state of the art infrastructure. Services are offered to both public research institutes and to the pharmaceutical and biotechnology industry. In addition to absolute confidentiality, TopLab guarantees the highest possible analytical precision and reliability, no matter whether single analyses or big proteome projects are concerned. The contracts, which are customer-oriented and flexible, make it possible for all property rights that may arise during specific projects to remain with the customer.



Contact:
Dr. Elfriede Müller

Fraunhoferstr. 18a
D-82152 Martinsried
Phone: +49 (0) 89 856512-83
Fax: +49 (0) 89 856512-86
E-Mail: info@toplаб.de
Internet: www.toplab.de



Contact:
Marcus Irsfeld

Fraunhoferstr. 9
D-82152 Martinsried
Phone: +49 (0) 89 8565-2840
Fax: +49 (0) 89 8565-2849
E-Mail: munich@trigen.de
Internet: www.trigen.de

Trigen Holdings AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Small Molecules, Peptide/Protein, Cardiovascular Diseases

Trigen Holdings AG is a biopharmaceutical company, with operations in Munich and London and a leader in cardiovascular drug discovery and development, focusing on thrombosis and vascular dysfunction. The company was formed in 2005 through the merger of Trigen Holdings plc (London,UK) and ProCorde GmbH (Munich, Germany). Next to an extensive portfolio of exiting pre-clinical and discovery stage programmes targeting thrombosis, atherosclerosis and other cardiovascular pathologies, the company benefits from two established discovery platforms, SIGSCREEN® and THROMSCAN® which have been applied in collaborations with a number of multinational pharmaceutical companies.



Contact:
Brigitte Stempfer

Frankfurter Ring 193a
D-80807 München
Phone: +49 (0) 89 324 266-0
Fax: +49 (0) 89 324 266-199
E-Mail: mail@trionpharma.de
Internet: www.trionpharma.com

TRION Pharma GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Antibody, Immune Therapy

TRION Pharma develops a new class of trifunctional antibodies (triomab®) for highly effective cancer treatments. A state-of-the-art production plant allows cost-effective large-scale manufacture according to international GMP standards. The efficacy of the triomab® antibodies in terms of tumour elimination and induction of a polyclonal humoral and cellular anti-tumour immunity has been proven in animal models and in in vivo applications. Catumaxomab and ertumaxomab are currently being developed in a clinical programme featuring several clinical trials together with our cooperation partner Fresenius Biotech. Market entry for the first antibody is expected in 2008.



Contact:
Brigitte Stempfer

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 700766 0
Fax: +49 (0) 89 700766 11
E-Mail: mail@trionresearch.de
Internet: www.trionresearch.com

TRION Research GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Drug Development, Antibody Production Service, Immune Therapy

TRION Research develops a new class of intact trifunctional antibodies (triomab®) which are specifically targeted at characteristic antigens of tumours, such as B-cell-lymphoma and malignant melanoma. The advantage of these trifunctional antibodies over conventional therapeutic approaches is the fact that they simultaneously activate two immunological cascades and are thus particularly effective in destroying tumour cells. TRION Research is further active in the development of pharmaceutical diagnostics, focussing on pharmacodynamic and pharmacokinetic analyses in immunotherapeutic clinical studies.

Tripos GmbH

BIOTECH BIOINFORMATICS

Tripos (Nasdaq: TRPS) integrates leading-edge technology and innovative science to deliver consistently superior research products and services for the biotechnology, pharmaceutical and other life sciences enterprises.

Tripos partners with clients to accelerate and improve the creation of life-enhancing products. Within Tripos' Discovery Informatics (DI) business, the company provides software products and consulting services to develop, manage, analyze and share critical drug discovery information. Within Tripos' Discovery Research (DR) business, Tripos' medicinal chemists and research scientists partner directly with clients in their research initiatives, leveraging Tripos' state-of-the-art information technologies and research facilities. Tripos spans the globe, with headquarters in St. Louis, research operations overseas and an international client base.

The New



Contact:
Andreas Löffler

Martin-Kollar-Str. 17
D-81829 München
Phone: +49 (0) 89 451030-0
Fax: +49 (0) 89 451030-30
E-Mail: eu_support@tripos.com
Internet: www.tripos.com

U3 Pharma AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Antibody

U3 Pharma AG is a biopharmaceutical company focused on the creation of novel therapeutic products that specifically target key components of cellular signal transduction systems that are involved in major important human diseases such as cancer. The company has licensed a portfolio of validated drug targets from the Max Planck Society based on pioneering research by Prof. Axel Ullrich. These drug targets have been used to discover a portfolio of therapeutic antibodies that U3 Pharma is advancing towards clinical development. U3 Pharma is privately held and based in Martinsried, Munich, Germany.



Contact:
Erika von der Decken

Bunsenstr. 1
D-82152 Martinsried
Phone: +49 (0) 89 8103-9100
Fax: +49 (0) 89 8103-9199
E-Mail: information@u3pharma.com
Internet: www.u3pharma.com

Vaecgene Biotech GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, Proteomics, Drug Development, Immune Therapy, Infectious Diseases, Oncology

Vaecgene focuses on the research and development of novel therapeutics and in vitro diagnostics. Core competence and proprietary technology are the development of viral vectors that helped Vaecgene to establish a broad portfolio including individual drugs for immunological treatment of tumors and infectious diseases. Recently, Vaecgene has developed a new intelligent technology, AMIDA, for functional proteomics for fast and efficient identification and validation of tumor markers for early detection of cancer. In addition, the company offers services related to Epstein-Barr Virus. The company has also extensive experience in monitoring and quantitating the immune competence in patients and non-human primates.



Contact:
Dr. Reinhard Zeidler

Marchioninistr. 25
D-81377 München
Phone: +49 (0) 89 709 92 96
Fax: +49 (0) 89 709 92 25
E-Mail: info@vaecgene.de
Internet: www.vaecgene.de



Contact:
Martina Frauscher

Emmy-Noether-Str. 2
D-80992 München
Phone: +49 (0) 89 1 58 82-0
Fax: +49 (0) 89 1 58 82-100
E-Mail: info@vermicon.com
Internet: www.vermicon.com



Contact:
PD Dr. Fritz Thümmler

Lise-Meitner-Str. 30
D-85354 Freising-Weihenstephan
Phone: +49 (0) 8161 1411211
Fax: +49 (0) 8161 1411212
E-Mail: info@vertis-biotech.com
Internet: www.vertis-biotech.com

vermicon AG

BIOTECH AGRO, FOOD, ENVIRONMENT

vermicon AG develops and distributes products for the detection and analysis of micro organisms in food, drinks and water. The microbial analyses are based on vermicon identification technology (VIT). This gene probe technology allows the extraordinarily fast and reliable identification, quantification and even visualisation of micro organisms. The VIT-tests are very easy to perform and do not require any molecular biological knowledge. For the food industry VIT-kits are available to detect *Salmonella*, *Listeria* and *Staphylococcus*. Breweries profit from the VIT-Bier products which enable the rapid detection of beer-spoiling bacteria. VIT-Alicyclobacillus is of benefit in fruit-juice production. VIT-Legionella allows the fast and specific detection of *Legionella* and *L. pneumophila* in water samples. ScanVIT-Legionella even allows the quantification of these bacteria. VIT-kits are also available for the detection of *E. coli* and *Pseudomonas aeruginosa*. For wastewater VIT-kits are available for the detection of both nitrifying and filamentous bacteria.

vertis Biotechnologie AG

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Chip / Array Technology, Genomics, PCR, Analysis

VERTIS was established in 2000 as a spin off from Technical University Munich-Weihenstephan, Germany. The company offers highest quality and fast turn-around molecular biology services in the field of functional genomics. VERTIS has developed an innovative technology platform which significantly accelerates gene discovery projects.

VERTIS products and services can be broadly grouped into the following categories:

- cDNA synthesis ■ Full-length cDNA cloning ■ cDNA library construction
- Cloning and analysis of small non-coding RNA (sncRNA, the prototype of which is microRNA) ■ Profiling of gene expression using novel ultra high throughput MPSS DNA sequencing technology.

VERUM.de GmbH

CRO

Keywords: Cardiovascular Diseases, Clinical Research, CNS, Dermatology, Diabetics, Oncology, Respiratory Diseases

VERUM is a CRO highly specialised in monitoring in Central and Eastern Europe, with experienced and well established monitoring units in the Czech Republic (since 1992), Hungary, Romania and in the Ukraine (all since 1996).

VERUM also cover Slovakia and Kazakhstan. All 26 CRAs are highly educated (23 MDs), well trained and permanently employed. A long tradition combined with an excellent relationship to authorities and a broad experience from some 50 international projects guarantee the smooth conduct of a trial and high quality of the data. Client related key functions like reporting, contracting or invoicing as well as project and quality management are provided by the German head offices. The 40 Europe wide employees of VERUM have handled trials with up to 1200 patients per study. In addition to its core business, monitoring in CEE and performing of audits, VERUM offers a full CRO service to the client via an established network (PSN), including monitoring in Western Europe and all data management and statistics services.



Contact:

Dipl.-Inform. med. Christian Sacher

Sembdnerstr. 5

D-82110 Germering

Phone: +49 (0) 89 800 777-60

Fax: +49 (0) 89 800 777-88

E-Mail: verum@verum.de

Internet: www.verum.de

viametrix Gmbh Analytical Devices

BIOTECH DEVICES & REAGENTS

Keywords: Clinical Diagnostics, Devices, Automation, Analytical Chemistry, Proteomics

viametrix develops devices for protein analysis based on electrophoresis for pharmaceutical, clinical and biotech laboratories. Our portfolio ranges from improved manual equipment for SDS-PAGE and Westernblot to devices, performing electrophoresis and staining or blotting and membrane processing as well as detection in a single automated system.

viametrix
Analytical Devices

Contact:

Dr. rer. nat. Hartmut Schlichting

Tonwerkstr. 9

D-82205 Gilching

Phone: +49 (0) 8105 779380

Fax: +49 (0) 8105 779389

E-Mail: info@viametrix.de

Internet: www.viametrix.de

Viramed Biotech AG

BIOTECH DEVICES & REAGENTS

Keywords: Clinical Diagnostics, ELISA / EIA, Infectious Diseases

Based on 20 successful years on the German IVD-Market, Viramed Biotech AG produces and markets IVD-Products, based on its proprietary research and development. The company focuses on Westernblot-, Stripe- and Elisa-test kits for serological screening and confirmation of infectious and autoimmune diseases. The major products are Westernblot tests for Borrelia sp., Yersinia, Helicobacter p., Epstein-Barr-Virus, Bordetella pertussis, ENA and autoimmune liver diseases. New analytics based on purified and recombinant antigens are under development. The development of antigens and test kits for specific analytics are offered as service. The company aims to intensify export of existing products worldwide and appreciates further distribution contacts.



Contact:

Dr. Ludwig Furtmayr

Behringstr. 11

D-82152 Planegg-Steinkirchen

Phone: +49 (0) 89 899336

Fax: +49 (0) 89 8599949

E-Mail: viramed@viramed.de

Internet: www.viramed.de



Contact:
Rachela Mohr

Hanns-Seidel-Platz 4
D-81737 München
Phone: +49 (0) 89 6279-0
Fax: +49 (0) 89 6279-1770
E-Mail: info@wacker.com
Internet: www.wacker.com

Wacker Chemie AG

PHARMA & CHEMICAL INDUSTRY

WACKER is a globally active chemical company headquartered in Munich, Germany. With a wide range of state-of-the-art specialty products, WACKER is a leader in numerous industrial sectors. Its products are required in countless high-growth end-user sectors such as photovoltaics, electronics, pharmaceuticals and household/personal care products.

WACKER's operations are divided among following business divisions: WACKER SILICONES, WACKER POLYMERS, WACKER FINE CHEMICALS, WACKER POLYSILICON and SILTRONIC. The Group operates 22 production sites worldwide, supplying over 3,500 products to more than 3,500 customers in over 100 nations. The company is represented by subsidiaries and sales offices in over 28 countries across Europe, the Americas and Asia – including a strong foothold in China.



Contact:
Juliane Giese

Grillparzerstr. 10
D-81675 München
Phone: +49 (0) 89 41 31 38-0
Fax: +49 (0) 89 41 31 38-99
E-Mail: info@wilex.com
Internet: www.wilex.com

Wilex AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Antibody, Small Molecules

WILEX is a biopharmaceutical Company based in Munich founded in 1997 by a team of physicians and oncologists from the Technical University of Munich. WILEX is focused on the development of new cancer therapies based on antibodies and small molecules. The therapeutic approach of WILEX targets the prevention of growth, spread and the metastasis of malignant tumours and the destruction of malignant tumours in the body. The late stage multi-product portfolio includes both, drug and medicinal product candidates as well as research candidates. Currently the following compounds are in clinical development: WX-G250 (development name: RENCAREX®), WX-671, WX-UK1 and CA9-SCAN. The company's strategy is to develop WILEX into a commercially successful biopharmaceutical company with a broad portfolio of new drugs and medical products for the treatment of cancer. WILEX AG has been listed in the Official Market Segment (Amtlicher Markt) / Prime Standard of the Frankfurt Stock Exchange since 13 November 2006.

X-Pert Med GmbH

CRO

Keywords: Clinical Research

X-pert Med GmbH is a site management organization (SMO) founded in 2004 by a physicians with different board certifications and experiences in the conduct of clinical studies as investigator as well as in the pharmaceutical industry. Studies are currently being conducted at three locations: Munich, Jena and Berlin/Brandenburg. At present we cover the following treatment areas: General internal medicine, Diabetology, Endocrinology, Neurology, Psychiatry, Pain, Orthopedics, Surgery, Physical therapy and Rehabilitation, Cardiology, Dermatology and Urology. Work is based on an investigator focused SOP system. This allows us to perform high quality GCP compliant trials (fast enrolment, timely response to queries, professional SAE management, experience with eCRF etc.) as investigators.



Contact:
Ilka Rother

Lärchenstr. 3-3a
D-82166 Gräfelfing
Phone: +49 (0) 89 89665425
Fax: +49 (0) 89 82084607
E-Mail: muenchen@x-pert-med.de
Internet: www.x-pert-med.de

Xvir Therapeutics GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Xvir Therapeutics GmbH was founded in 2004 and is focusing on the clinical development of novel cancer therapies for the treatment of various solid tumors, and in particular of drug-resistant or radiation-resistant tumors. Such cancer therapies are based on the use of oncolytic adenoviruses restoring drug sensitivity and radiation-sensitivity, respectively, of the tumors. Experimental evidence for the efficacy of Xvir's therapeutic approach has been provided in several animal studies. Xvir's therapeutic approach is covered by proprietary patents and patent applications, respectively.



Contact:
Dr. Per Sonne Holm

Nymphenburger Str. 1
D-80335 München
Phone: +49 (0) 89 99317446
Fax: +49 (0) 89 51556413
E-Mail: info@xvir.com
Internet: www.xvir.com

Zentrum für Humangenetik und Laboratoriumsmedizin Dr. Klein und Dr. Rost GbR

MEDTECH

Keywords: Oncology, Pharmacogenetics

Full range of quality genetic diagnostics for more than 200 diseases and the most comprehensive services in the diagnosis, prevention and management of hereditary disorders and birth defects affecting the fetus, the newborn, as well as children, adolescents and adults.

DNA- and RNA- based testing in molecular genetics (mutation scanning, genotyping), classic and molecular cytogenetics, immunogenetics (HLA high resolution typing, immunoprofiling), pharmacogenetics, molecular oncology and paternity testing.

Continuing development of new tests and implementation of state-of-the-art technologies such as array-CGH, microchips and single cell analyses.

The laboratory is accredited according to the international standards DIN EN ISO/IEC 17025 und DIN EN ISO 15189.

ZENTRUM FÜR HUMANGENETIK
UND LABORATORIUMSMEDIZIN
Dr. Klein und Dr. Rost



Contact:
Dr. med. Hanns-Georg Klein

Lochhamer Str. 29
D-82152 Martinsried
Phone: +49 (0) 89 895578-0
Fax: +49 (0) 89 895578-78
E-Mail: info@medizinische-genetik.de
Internet: www.medizinische-genetik.de



Your business
contact to Bavaria

www.invest-in-bavaria.com

www.bayern-international.com

